var title_f3_14_3296="PDR traction retinal detachment 1";
var content_f3_14_3296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe traction retinal detachment in proliferative diabetic retinopathy: Appearance on fundus photograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 298px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEqAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5cooooAKKKKACiilA3EADJNACorOwVQWYnAAHJr0Lwj4ejsdt1eqGuzyqnkR//XqjoOiNp6x3VwubphlV6+WP8f5V1tnKjxAsMSDiuDFV242hsdNGld6l2ELli3X1qUqQCD8wNNt1Yng7lHPSrQ5UDt2rxpzszsjCz1M+YMAMHGakgGV/pUhgO/DHA7GrNrbF2A6CiVVKOocrchkcQdTuAA9RUjQeZtSPGR/EeorSFsqoc8CiCJH+4efUdq8+WI3aPQpwGWqFgUkULMOue4rSs4IwBkjnqc1B9nIcSdXXn61dtlZ4t4Hynngda4qtXmWjNZU+XVFhoQqfLyvelYs0OAMj6VIATGDzkjp6UkjCONVLnJ5rhu2x2tuQGJArIyKc8HNUrGH7NemFh8rLuWtKKMyo0gzjPQjrTry3KwLKmdyHPTtVqpa8W9y6dipLAJHbB4xxUEkG1QMDI5rQI8zYYxwRUggVTjOcjH0p+1shWfMZi7UG4Dt0qG7zI8RQ4/DpVi6jMQDdRnrTIgJWUDjceKuL+0aqHYiW0Z2BI4B6jmrEkZ4U8Lit2z0ndB8rnceuTVW6tDHIAx5xyax+sqTtfYFCyKNvCsUqk4ZG74rRms4nhaYN8vTaP6VDEpBwTx71PLA3lHDAionNt7mcoNHG66FChVzsDY5PSkijwqnAIP60/XYDsIzyXwMVpRWDLDGD2Ar1HVUaUdS7aK5lT25Cl8DjnmsK9jad846e1dvPax+Tsl4OcVkXsSrLtiCntkCtcNirMOVGDp0DRSMwOCRgD1rXDYQKxBPemR2fksWk5kPTHapBCU+93HFbVaynK9yJJMgkaKMZxk1WnlULxgZrWihXkvGHIqpqCIV4TAFKnVTlYhUzL8svAzEjIpxg+QfN1FMhU7lT+92q66bFJ3cV2Oo4uyZUoaGcLbqo6VILTykyxGOtWYgrjJNMuPnJTOAO1Wqkm7XOSpGxl3QDMApyT6dMVj694fj1CLfDhLtRwezex/xrpbG38yR3bBROB71Ykjj3kuoLe3auiOIdOVo9Dmq0VJWZ4lPC8ErxTKUkQ4KntUdej+J9DTUoTLEFS5UfKem4eh/pXncsbRSMkilXU4II6Gvbo1lVjdbnlVKbg7DKKKK1MwooooAKKKKACiiigAooooAUV13hbRD5a6hcgZ6xIf8A0I/0rN8MaT9vuDNMP9GjPOf429P8a7pDIMjywQeOBXJia1lyROvDUeb3mWYoHkcNuAJPIP8AOrEUIiOMg881FbyhF/eAqfXFXImSblSCPavJqzkvQ9KnRRZt85ABAQ/hVtTGCQcg+9Frbq0QZjyp6GpkhV3bdn0FeZOqrs29nfch3rznpV21XnOPriopIGjjPAYfSrOnRMr/ADkEVz1aicbo0jSsiccphgSD+lSW1vskyFwp/WtOO3R4gfWr0drucEYxivMnibXR0QSWhnC180gHoOtSWKKsskXYHitJrZlGU6e1U7aA/bH5684rm9pzJ6msYXJY4sOSOnepo7PzGyyhk6gGrsVsVfG2mXEqxYj34kJ/KsPaNu0RezuwmhxtRVUQ+4xVRo/ODBBmMEjGOta9uEmg2Md+Dk4q/b20SqeMEjgAVi6/JuUoKJyWmQfZpjFOPlbJTP8AKrhtPNZmUcD0rS1a18yJjGpMifMvFVoS8lscssb45VRzmtHVc1zo1dPmXMjn9QAjYxoCSfWobaI7gWPIPArQubYg7x1zyTyaZHBk7trcDsK7FNctjDVTsjT0+ZWX7xz0xVa8VyrNjKVLZWm85BIP1rWSwjeB0ZtwHvXFKcYSudKSW5y8KtJKQeDirsihIwgG7PWrdlpwLyAHGDgCpJ7dYslm69a0lWTlZA4LZHD67DtZTGp2hsmuj0+KN7aORSCzc+uKzdchK27Anp0PqKu6NdRwWcauhYbfvCuyrJyoq3QjkurkWtMGtnRSA5PBxWVZ2YSMSyZIArXMX2qSQnoOM1Rvmff5af6teKdKTUeRCcU1oZ12EEpbPOOlUXndzkrxnir7xZOO9HlrGmARmuyM0kZqFiGM9yMcVTvMHcznjHWn3MpRsBuKz7ufdGQxODW9KDbuaRpla25kZjnn2qaaUYIHTHenxXkcY+7gY9Kq3F1G6MCPmPeu2PNKWxMoO5mNNIsmVY4z2q7axvdOPNbC5qmifez2q/piYkLnHSuurK0W1uZ1IaGm6pbRgIRgVlSyNuYhiQe9XLuUkYPas+VsDjvWVBdWcU4aELBmY85z+lY+seHrbUZFlLtFKOGZR94e9bMbfvCTjFSTugUcgE13RqShL3TllSU1aSOG1DwoYoi1pOZHHOxhgn6GuXZSrFWBBBwQe1erMobvXn3iqNY9amCADIDEe5Felhq0p+7I8/E0VT1iZFFFFdZyBRRRQAUUUUAFWtNs5L+8jt4R8znk9gO5NVq77wlpn2Ky+0SofPnAP+6vYf1rKtV9nG5pSp88rG1p1vDaWSW8S4VBwe5PrU9tOA+1tpAORUEsh87amQD1pogLPnnI9K8l63b6npQSiaySJISu0Ee3NPWzi3A4ZG9uKpwQkKH5BHcd60rNZHmBLMW9+hriqyUNmdtOD3uPijmCnZL8vo1W7UXQx8quB69aQgoxDY/DirltcKE3MeBxnFefVqNrRXN0mtWSpKVXdLDIFPB74q1FdW6R4HJPAUrmnWrLKcA8VoR2qK3KgD1xXm1ZpO0kawnFj7K7tGChyVOelblq0Um0xspHsaoR2ELgblUmrFrZxIW2KQemRXm1ZQe1zdQTNy1tIWz0yad/ZkaSMy9T0zWfaMbJCRISzHgE5rYsL9nbZcxgEd+xrgnzptp6FOEoq6KkttJFHuLZx04qnLA0gVnibf64zXTzNDtXOPUCl2Rkp5eCp4NZRxDWtiFWstUY1pHCqjbGQzHmr8IWM8Ebverj2KnlDUctoxTB6+tYyqqT3JdaM+pC6mZiV6dDWZf2gJORtcdCK0baN4Mqx4qSaNZVKsvFVGbg9C4z5JabHMmAsrI+fMHT396btaG3IdBluBWw8JVSFGSv3c1EsTzzgyptGOa61Vv6G9ot8xStbZ4zv3decVYyBvI4LcVY2BN3PTpVd0yQycnvU83M7stNMZGhQbhnIpjxCYKpzjOMVP5jDjbUijHIOPpT5mtSm7HMeLrQx25UnOMYqPTYGksUiOCcdhWprED3WfMOVB4zUemR+R8zfKO1dsatqKXUfLeITW629tx8vHSuekQtIdveuovFaZTkjaBWEwWNm9c1eHk7PuRGnYpSQjzUUE5/iNVru1MTNsb5T2NanBG716iq9zKoXbgetdUJu5Lpe9qYUsS4+ZT6VjzrtbO3PbmuguHVh6gVRECzHDLjJ5Ir0aVTlV2UkkYnkyOcJnb3qGW34xnkDrXW28NtbQNnBwM9M1jSxh0LkAKea6aWJu9NiZXZiIjKeDx/OteyhEagnqetRRxb5NwGFHSrhBxWtarzKxk4XK1yo3nniqzRh+D0q1LlmIHX6U0R9AM5FOE+VGMorYptCoFVHg3vwTWrLA3eoQix8tkt2rphW0OaVNyehRkPk/w5x+tedeJ4JotVlknyRKd6n29Pwr0mTh8v+VZWv6empWLxBR5y/NGfRvT8a78LWUJa9TixeFc4XW6PNKKdIpRirAhgcEHtTa9g8IKKKKACiilFAGp4dsPt2oLvGYYvnf39B+NejKdygcgH0rD8N2Qs9OQONssnzvxz7CuggKMMdHFeXiqnNL0PRw8El5irF+9+c5q5FFtbgYDcc1HHEcgjkdTmpXbMoHOAK8+cm9DuirEv91Ac/StCyfy3BBBIrOby22FTyKsRsFUAA+ua46qvGxtTvcvXiNcJ+7yWB5xUlujx2h3bSPQimWr7XJVyCRTWkdmK4O0GuLX4eiOlv3bMv2Bw4BPWuhhnYOAw3Dv6VyAaSNwVJxW5ZSSTqrqzYA5rkxUL+8VRo2epvlmlAKERqOPl5NTO3kqo8wncccHmq2lzQBcXJYnOT2rQvLa3ZRJDks33Sq9K8qdoyszvhTswjEexXlkHnDhSe1XoXjcBPNJfrlTWaIBEE/ebyxy2fX61oIICi4MZcjt2rnqJGrSLMcuJhHEfMb88Vp20LQgySZA9VbNZmnRpa8u6nPpVt5JJnJiDLCvr3rlqK7stjlqq7stjVgvkUhQQyt09RU8rq2AhIPsawEtZmPmKxGTk1Yhu/Kby5MhvU1zSpLeJzTw6veGprvEjoNw5Heqb2kivujPFNjulLHc2R9amW4iLlTIfbBqFGUTNKcDNmE4Y7l9qp7ZFblsA9q287gVB3DtVV7UM2WreFS250wqpaMpsARkU2ziYzliPl7VfFuNm3A9qbzEcD6U+dWsivaXTSKsyDdjHNMjADgE4/GprtXJzgke1MS08xFzncD1q01bVlqS5dWPe1RyGPQc1i68REimPgA1szSuiFcZ7VzGsyzTEKqcD17mtsNFuau9DbDxk5XZYnucW3ygciuduWZWyOT6VOrTswE0g4/hWlEGXJJ/OvSpxVM6nFIyZLh1LZBCYzxTtKgk1C5YA4jHrW5bW0TECZQF9CKlu4lgH7gBF9u9auuvhitTIwbyyS3nKD5gO/aq2xFiA3YY84rZDI+fNyMdDWPdWU0km8Z2dR6mtqc76SZjN2ehk6hLuIt4+SetRfZXIHmMSAegpY0P9qkNkY45rSlC9BXc5clkhylpYzigA+UYAqCT1ydx6CrTjkg8U2OHfJnmqjK2rMbN6jEhBUnvilWPGOOverwgUKMZBqvcNtICZL0lUcmR7NvRFK4bblR8xqg4w2Scmr8ihSe7d6qzDaC2MmuqlLoU4KKuU2QHk1BKVQ96shSxxnBolt1CZIya7oSUXqclbVe6eeeMbER3Yu4h8kp+fHZv/AK9c5Xp2p2iXVpNA4ADjgkdD2P515pKjRyMjjDKcEe9e7hanPC3Y+bxdH2c79xlFFFdJyBWr4bsft2pxqwzHH87/AEHb86y67fwdbCDTmlZf3k5yP90dP61lWnyQbNqFP2k0jalJ4wCfUVNbqxYHBFPjZhyE6+tSZbb1wPavIlLSx60aNnctRSDoc4BqVCGfJHXtWcXCHqeKtxYdMgk81y1I21O2EUy0I1L56D61Yl2wxLuOc9BUFvGCQWH51DqCbW+XOK5vikotm0KaTLcTjJIPFWLebDEN09qzLJwVbd29qu2s6KDgE4NZVae5vFLYuiUs+1V5961tJLRt1A9qybcmVy0a9e9acIZWBwc4rzqy05Tpir7G7boxnLAAjr9a6K0vEa38tFKqeORg/QVy1rIQVPJIHrXQaaxuWRSdu3OSa8fER01NG1a0i8TujwsXKjqxqrchzgGNQ7f3BzVotFCGMjZGcDBogAlmLAjgdK5E+XUcZcupZ024t7aEMsY3dOetatpL9r3OxwhPQDrXPmL99IA2VX8quWN15T43cKOlY1Kd9Vuc9aipJyjudN9njKgRnFUbmzZnY4BFVo9SDyYTp3ofUvlbPSuRQqJ6HFGlViyvFaTpIwVcH0qcW0jMTOCpX0rOudUIIO/BHTmrEGoNKAWbORW8oVLXOqUKtuZl2KBkcPE+VPY1e2hkyRgmsyK5BbgHNWhIZOM4rnnF31OapGV9RzYBANOjtt7g5BzRDHubmrSoUYYHFRKVtEZSlbREc8cC/Ixw5HSomjWKIsTj2qxfW63Cb+jgcGq4tnnjTDZYDkUoNNasUGrJtmJPL50pQcVnX1tg8/lWi8bRzMwXkHFVb+5Hlt8nzYr0qbaa5T1qTaaUTGmt0UEgHPWokA6jnPpVG41N/MKPE31U1GmrQAgAlO2GGK9NUZ2PQcH1NqMF2BK/hTL6J5JflIAFQw3aOuEcFvY1M7nBOSRjNZWcZGElZmc8OH2E9euKZMX3LGOQgwGFWnYPwFOT3xVQkZO5iGroi29zCqtTl7lCussCec9auSIFX39fWq1yA+pnnvVibgBVyQeOa9KW0fQJq7RWWPzGwOg6mpBKi5UDntTCyq+OQB6VWkLSSBIwQB3qlHm3JlorEkkrsxEed54OOgoiwnHJbuaeiCFSFPzetNVdxJ5JNPToCVl5FS4UgmqzKSRmtCbggNwxOB7mo12Kx3Zz6VvCTSuZzknoURAN/fNRTDaCD2rUk2hcr+VZk+DIxcmuqlJyZyOyMu9wE46muF8XWJguY7lR8sww3swru2TzJCcnaKzvEFoL3S5o1H7xRvT6ivYw1T2ckjz8bT9rBpbnmtFKaSvYPniW2iae4jiT7zsFH416jBbrBHHFGPkRQo/CuI8GWn2jVxIRlYFL/j0H869EiAwRggevrXnY2pZqJ6OCjZORGke48mlKkcKDUgIDYAOKcwwSa85yPTjuVzHkHIJep7HIBXafxqW3A3c1aihw+7jmsalVJWZvTHRg9smnzwBoiXb5sdKcwCHj73bFKWUjJyWrhcm3dHTGNjJhLJMF52k1rwWoYZOar20SvOS3NbkIQx4AAxSxFZrY1cb7BYII2IxV5ZVMgC9utQRhUjJI5PU1C8mG2qcGvOkud3OmlDua9rIvnYY4rbRyF/dsAR79q5m1G7blckd637JGOOy4rirxSOlxTWhcLea6oCT3qW4mMcapG2COpFMij2sXJ5qrM6mXANciSbHGBKLjYuAWZj1zUlvdojbFyWPXNZ067DkEnPeooruOOXBHPcmtfZKS0NeRM6WOXYM+tZmpaiI1IB+YDpWZqGsCNMRnn1rDuLs3J3c1VHBtvmkKnQ1uzUi1AyzZYnANdFbXIWNSp7ZrgllMT8g1vabdPIoDngVtiMOrXRtOlzKx1UepbOo/GtS3v1dRkj1rkZH3naKtW0+wYJrzamHi0cdXCRaudrb3cbfdJrQSVWXO7tXFWl0BkE9a01us8hu1efVw1meXWwdnodCXUKc81AkjRzbl4BrOgui3BNWdxdTg9Kx9ny6M53S5dGSyRrKegDnvjrVG801WjO9ea0YXDIok4I71bULIpQ456GkqkoPQSqypvQ8s1qxW0kLDgdjVObTYry3Ux/KTzkV32vaMtzEVbiuOurG6sIytuCRnODXu4bFe0irPU9/D4mNaC11M+20mGyJk8xzjrzV+K53qQsRCepqK0dJ0IO5Zc8qaufZhxn5j7mtpyu/f3NZJPczla6a6P3Y4scA8mql3byF2dNwxz7Gt/wAgkjoCO9VLlHeZoYeSR8x9KqFXXQylTUjkTZysUmLHdI56dqtT2/lBUDGSQ/pW7dWiiGOFF+bNBs44h0y3rXS8VewnSW5zaacd+ZCcHmpZAqfLEorSugMFVFZjnySSBuJ6VrGbnuRKNlqVpoWcdeB1qW3t2iA3Hn0rWt4B9n3OVXcM1ga3ePAAEHTjIrSnJ1XyIwkuawXsyxSfORtHvWVLeoXwp4psRS4bdIxJ9KlW2hJ5Fd0Ixp6SMpU0iFr5fL2qCazZZGk65ArYlhhTAVAaqzpkcAYrro1IrZGE0uxn71VcdKjLqD1FWHQdxVeSIEn5a7INM5po841+1FnqtxGowhbcv0PNZ1dV41tcC2uUXjmNj+o/rXK17lGXPBM+ZxEOSo0jufAdsEsJ7gj5pH2g+w/+ua6iLJNZPh2BoNGtUxwU3n8ef61rxgb8eteTiJc05M76C5YpE6IGBpzIWx705ECnuSelF1uSMeorhbd7HpRVlcdFC2MjtVgNsGWpLVsIMjr3qO4YyT4XoOKwleUrMqnJjg5ds05gcEnpSqoQc44qFpC5IwcVle70PSpwvqXLJABkZNXUbZwAAKp2pKoMfdqdjgGuWpqzdRsWDMTxnNV3c+YCeOetAYY6dKjmctjAxUxjY2gupuWchGOa37aZUTk8Ac1yVo+E56gVeFwdijcSMc1xVqPMzoRu3d8NmIjjNUg2CGY5NUGkLAUolcEc/L61nGlyqyNIouXskhiJU1z80spYgZFbLSO0BzgKazrgA5wM1vR93SxokV40llIEh4rUtLdAoxzxVSAgqA1XEfZgCqqNvRGiQ17dDG5xyOlS2xCkIAQT3pyj5GG3k9TVhIMoHUVhKWlmPYtRtgdakLYP3uapqdifvM81Xnvkj3Y5wfWsVTcnoTymxHIQwK9RWjDOxIrE025hmXOfm7gmtmN0XnI6VzVoWdmjmrJdjUtmwevNXEm2nGaxEnG7ParkUw28jJ7CuGdM8+pSNtXVouvNOjuNp25/Ws2EuRyT9BUqqEk571zOmtjjdJbM6CMC6iySN4rD1Sz354q7azeSVOfl6GrN9EXTzF5U1hBunM5qbdGemxxNzo8N0MLmOQdCDg1kSfbNLn2z/v4P7wHIrtJISHLKtQywRz5BGSexr1KeKa0lqj1qeKf2tUYKy+ZGJF6EZqGAiCGWZ/426mpVtriGeWCQYUH5cc5FQXcX+lW8OCIxzz610xtsjrVnoh0C/P5kg+Y9Paqd6Tg9M1oOCQccYrLvWEYL8YHUk8VdPWRN7mXLu5znFVpZIlQ7yC2eBUF/qYlcpBuc9OOlZ7wXMgORtB7161Ok7XloZyj3NK81K1WEKgY4HWufu7/zRs2D65qZtNckeY55oWwSJietdVKNKn1uQ0kVba1bBYcZp/lyZ5YgGrjDC7R17U5U+UZAq3Vb1M5SM6SM5+81MMBYdSa0blBt4H41T3mIkGt6c3JaHHVlroU5oGUcN1qnOGQcmtOVty5x9Kz54nlccYArtpSu9TmqOSiYWvwtdaNcgclB5g/D/wCtmuAr16K0Xy3RgCGUqfxrySWMxyujcMrFSPpXsYKopJxXQ8PHQaak+p6vCVRFQLwoA/Kps5TIwKoxvweR+dWFYccjFefKOp3QSktC0kjuyjoR39KdLvlYAHPrUaHgkEcirNvCzASbCB61zTajqdUNFYuInlx/N1xwKpXExiY4XLH9KtZaTrwBUc0YYZ44rmjo7yNYNJkSys8YyOtSwpkc80IgwKnixnpxWU5dj1aVrDowQuPSjdUoCFT2PaoJWIx7elYLU0ZMswxgCnZyO/1qqvXrU6ZpNWKiQyeapyCT7VLBduAAetWCN/HQ0xbYE5OKOZNWZunZalmG8+XDA1YhnWZwA/4VTaHbEWUZxVAyIj7gSGHvWapqexaZ1EvMRUGqoAPFUrPUDJhW5I/WrquDyBk1g4OGjNENaLZtYZJzzUyzKso3D6U1sHuSe9Ocoy/dG4dDSeu5rfQvR3WThUG0jGTV62kRoguelZcVtIYRIeOOKhFw0D4OOe1YSpqWkSXI25kV/lGASKzZNHaZyUODu9aYty7sGHA7Vp212Qozj61Hv0vhJ57bGZcaZPZ4ZDu47dafZ6s4YwyqQ4OOa3CUZCxyW6/Sue8S2UoaO6h4x6VVOoqz5KgRlfc3oZJSRngVsWBCEbjnNcZpussgVLteexrobXUrSRwFnTd0xnFcmIoTWljKvFtWOphkCkHt61X1CY5Vh0z2qGKZWUAOpOPWq+oSMLdimMgZFedGn7x50KXvmpbXCk4bOCK1LO5Jj8stlTxXJaLeLd26s33hwa1Y5WgcMSME9KitQs3F7mVfDpto3ZIiCwyCpGc1lsfImyeQavW9yJgeeB1FVNS8uRAYxhutc9NNPlZzUrqXLIoa9NHEsFyvRXAbHoag1G2SaNJgMbeR9Kin3TW8ybTn+GluJmSzAfhsYrujFxSS3PRhBxUUt0Yet3c9rEjQplD94kZrAuPN1WUdUhXnaK6HUJv9DZHxyKyoCYUACjBr1aD5YXS1NmnFtkAso4lxGoDDr71DLGWwW4x2FaYfYM7etV7lwe2K1jOTepEnoZ0kOVzVV0UZyOaulzzg571VuVxyf510wb2MeYrIqvJ057VM9uE+9xVeJwG5qaeUpDluprVp3sjGSb1KV0SoyOlUZiG+8KdJMWkOTxSOBgd674Q5bXMnqQk54xxUTSgNgDntTicMeeKrsh3bh3rrhFX1MaidtBTIc15p4lj8rXbwDoX3D8ef616U0ZwDxXA+MoWGs7gPvxqePy/pXpYFpTaXY8jMIPkT8zrVCg9BipYpB5gAAIqrMSBwBzU9sm1Acc1LsldipSknZGgz+W6MUHByRXU6rrkN7bW0drBHGiIAQoxXJKC33jVy1jAYFu1cFelCdpS3R2xvsaMYDKWHT0qJhk8EEnsKSeRVGE4FQq2fm9DXKovc6qUb6knseBTwQoFRO7OxJGM9qUZA5rOSuelT2Jy3HtTJCcgClhXP3jx7UEZ61CVmXcRAQeamR8nAqFsrgGpkB4JXg+lTI0iXAdq7u9AkJYZqENuBH86kh681i1Y23LysHgKAD1rH1GBUbJwM1prIACE6nisvU1JPzdKKKakaRIrEfvQARW+iAR4HWuatJNko5xXRW8m5KeJTua3HqMHB5A6VZ05RLeBWx9DUB+UA8VNafLKJOmD1rknsxNm5dQlWUL0HYVjapEizqRg+1X5tRYghcc8c1kyMZXLuefWsaMZJ3ZncWDkdMjtVqN9h6DFUUYIMjkmnxuTyeR9a2lG5DbubtizO+0nitK7h3QbcAgDnNYlhKoYEHHpW6lxHtI6jFcNX3XewKTOHvh5l4ygYZTjFUpneKbA4NbfiCxY3H2iH5VPJqglot7D8jASjqCa9OnUi4qXQ2fvDor2QKTuIx70z+17ve0aSsVbjBOaU6RdpFkocDHSobKF01ABoydhzTSpNNqzJUbHY+EkeFGRic7s810VznPPIrmdGuJEmPHeum+1KwUspBrwcUpe05jlqp810Nsp5o7gnouMGtO42PHGyMDkdCazhKjSqOAG4q1HFGpaPdnceBnpXJUWtznqpXUtitcSGEEInzVjXVywJ8zBkBwErcuFKyAOMdqx7iET3zOAAF4B9a6KDXU6cO47soGzeUFpDk9cVSuEkjU4X8TXUW8BPBIqtqVqpgYZya6IYj3rM0lUU3Y5H7RKzbBtB96c0MspG+UY7jFVp8pIQcbgakW6YR4wpzXpcr3ic09NCtJEFJG4nmq8xBBFSSSO0jHj0pHjzHuZfyreOm5ik2Uineq0pJ71O8wAK8Z9arD5iT2rrgnuwk1ayITwTxTuNpz0pz4GT1NV3kAPA+ldKTkc5FckLnbiqxmGOevpTpSWJqB4iea7acUlqcsnLoPd2PSsDX7fz7uNtucRgdPc1u4IXgVE/J6Cumi+WV0ctaCmrMj6nPBqZSAuKrxH5OaUbtwIPy02jCEbK6NBABHliB9TRBc7XOTkdOKzJixYc5FImQ3pU+zTWp0Ri31NxpN5B9e1TxhSnpxWTbznOGIHvWlHICByOlcdWm4nZC9tCwgAXmlUF+FAqKMs2cnC+9Oj3huvArjktTug7InCMAMdutLGPmyRwanjc7SNoGaeAAucD6ZrNPe5pzFcnc3QCpG46HFRk/OccU0vlh6Vm1c0gyWM7jg9anVsZAxk1Vbl8jGKnhB3g+tTJHSpKxOgwD61UvQX461ZlbHSq7N6jPvUw3uS5FBFAbGOa1bZyEPNU9gL5qxF8o9a0qPmRqpFpXOME81MlzsUjPWqAchhTnPFYuCe4SZZF1h8ZyKc1wCBg9azXPykZxkUq5I5NP2a3M7lszg8YqW3nG7AAFUV6c9qiluRCc8FvSn7Pm0Q73NoXSwksWGK0tHvkuFO44HQVylipvZwrHAJrofsq2REaSZI5yK569OKXK9wvY6e78trEqQCcY6VxCW08Tu6fKVPGO9dPBJ5kIQHLe9Z2qsbWRWixnoy4rlwzcG4LqUtjW0e4a5tFEuFkXqPWp7mKGO3d1QKwznjrWFDqRWRC0a8c5XirEOufabsxMgWI8ClUws4vmitDN1Y3tc09Cj3QhzjJrcC5PHSs+zAjgGxRVxHIPHPPSvOrNyk2TPXYuQWO8k5HAzVi6jEPlOOuARj1qTT3POQMlcUTnEgViMIvSuJyk5anC5yc7MYwe6jLbOBzmsqSBvO4wMnmtlZCkDY4FZsLeaHkPJzxV0m1fsaUZON+xZt4ACAPmpmqxBYshQKmspGEmWUbT0NN1gxqu1ABnLEe5pJvnRMW/apHmmqq32l2CgDNVMHaOxrS1iQfaWIxg1lG4UZGc19NSu4ous7yY1Y3BLMeKbLOY1woPNSR5YMcZXtTZ4wEDEYrVWvZnPzvYoSbXGeM9aqkhD7VYL8kYFVblecr1rupx6D9oROSx+9ULg57UjOQCaiLnNdcYNbEyaYr8Hmm7qRm/Oo2bHWt4xMJaD+3FMHutN346VFJdrGwDnnGa3gnc4qzSK4Y4x0FIWJ78Uu8YqSOMMBitbpGcGrChcoB044qSOI8HNTQxfNkAECrccakY71hKpYuOjM8goxAGSRUsMhUeoqWePDHjFRKrA44xU8ykjspGlFLuRQMFalDhG2nHrWdBIY35wB6Vdba4yDzXFUhZnXAsLOSdp+761OJDnrWeh6YxxVlSG+6elYSjY2RJJkc4pisGPvVh2AhANQqOcr1PeskaJ2JQm51C/jVyRVj2kVCAxZSMA0y7zt+Y/lWT95ornuSO+UPPFVmkGTQTiLOarSMDzVxiO5KJOe1P84qOTWfLPsIxVeS4Zh1wK3VFyNYmsbkYxkUfaFIxkZrCLH1NG4jndV/VkW2bavuPJqdWVV5IrDS5dcfNTjO7febNS6DJNa6vF8vYhG71qgoMhLGq6kswq9CuBS5VTWg27GlpGFnQlSQD0FdBMN8zSKu1T2rC0qfyLhG4ArpIHWcOyEYJ4rzMS2pXM2TacolkC5G4cCmanbut0DKueccVPbIIZwyjr3rcmjWbYwAORzXnTq8k79AVSxx+uQmFInCgblwcVi2kbNOrZxhhXZavBvgCEcBu9ZcOn7ZgQPlzXdRxKVOzOepDmnzI6IMywRheTir9uhZRRBbK0aEYIxV6GLYvGOK8SpUXQtzsS2eY1JY9Krzys84I5FOuJtx8pOw5xUMTjz4R0Hf61hGP2mRGP2mWr98QIhOM1VsoSlyYmYgMMj0NLcuJb1YzyF4q5fhImglB5UgH6UL3Uo9xJ8sVDuK/wDo6/O6hP7orn9V1EBHJOfTmtLVJk2FgQK4HVL4ZcngAnFdeDw/tHdmlJKMeZ7mbqt3vkbJ4qjFzzVS5uPMlJ96s2xDAd6+mVPkgZT2NGFG2DaxANJfMFRUByR1pIyQApI+lV7xgWPUVlFXkYOCauRYUfNkVUlOScHildjyCagyQa7qcbGRXnPOMVA9Tz8CqynJ6V2wWgKVwAyeaSQZXinsccjFNDZGDWq7mUpdCuQcdvpWLrNx5FyigjlAf1Nbsg2jIrifFc5/tXaD92NR/M/1rrw8eeVjzca+SFzpInEiIwPDAMPxFXImIQKvLGsHSZjJpkDKfmUbfyrTspGlkBLENnkU6kLXOeNXS5txYRMDk1JE58w56VEilU5OfSkVH3bhwPeuJpM6FUZoEo/HU1BJEAwI5xzRADnk81ZI44AyeM1zS9x6HbRndXKMpVmPH5UsTYTHpUskWCfeq5zGee9WrSVjsjIsIwHTqasRSAcmszzsMDU8U/ByKiVJ2NlI087xnOakgwHA/U1Tt5gy1aSZWUEA+ma5Jwa0K5jR3xqcg5xVKf77EYC+lNMgB4P4VUklLcVnCk7jj3C4nCrjdn2qjJKzd6WZSWyelREe1dsKaSNoyGsxxyaZmnmmnmtS7iA0Z/Kg03PODTSuFxwPzdqlFQjrUqfpUyHF3LMH3ulX0AwPWqlupz7VbUY6jFcdTcbJk6cetdDpBwhyeMdKwIuMHtWvpcodyp9K4cQrxE+xsozFh8wIzzXWadEDaKeuRXKWkYZ15G0muytsC3QLx8vTFeHjHZJIynoZurW6kbienQVnIVB8vHA54rbvEBQMzZHpXPrP5l2VCj0AFKi3KNuxcNUbulgiDbnqTirpyqqA3PcHvVKyDoAZMAe1Q6nqageTGpLeorncHOdkTyOUtB5mETNjl2OAB2qaVfLtfMc4bGRVPSoDuaS5I39celR3c7Xt6IoiQo446VpyXlZdNzR/FZFnSm80mVyNxNWNVuQsLKaqReVayhFYkCqurOoO4tkY6UKClUTInrLmKU9w9xGcMNoHNcXrbEMQOldA05hLAD5G61lazGJ1HljNe1hEqc12Im22cxyWzmtC0JQfWoTaSrkkYp0ZK9a9abU1ZGczRWUMeozUV6QR1BOKrM/GRSM5ZQCKyjSs7nOnrYhY9ajc4HOCcVKACcE1HLH1wa6ISV7FShpdFKU02LnOcVK6ZPPaoT8h4NdsXdWRjblFcDPaoS2DwakZsjNVJWKt1rSCvoYVXbUnLEgA4xXnniGQS6zdEHID7R+AxXevIBEXJ4UZP4V5pM5kldz1Zix/GvQwcdWzycyn7sYnXeBYEu7W6jLEPEwYD2I/xFdAtoIvnxjFcV4P1A2GsJ821JQY2/p+td7Pd7uvIbsBWOJU41NNmY4Z80bMfFMuzB5PrirVqFkAycVmI5z0wK1rWWMqAwz+FcVVNLQ7VYnKoGyuGFSKATx9acvlEHHHFPhKjB3A/WuCTdjohKyI5LfPOc1Wnsy65x0rT3g4B6D0FRsCVYDoTms41JJnTCTMN7R9wx+dOWHaK24kPcZNRtCN5DDI9q1+st6M6Itsz0j3YxxU2wqq/NxnmrsQTJGwZpTAGGOAKzlW1LKy4IJOcCoQMksauOcKUBqq2FUjPJqou5WpWkG4Y7VHs4JPSrGzGCetIcVopJG0XoU5FxUdWnTjAqu3HStIu5qhhHFR1KckVEy85rWNgYqnGKniXJGDVcN271btevBGamotBxdjYtYQqDucZp8yrtJJ4A6VXiuQnBFVL2+YsVTGK4/Zubsgu9yw84iBNWNK1HBbdxnvXPyTO5+Zqu6RCbibG7Cjk1dXDxjTbkR7RPQ9M0BVkCyMc+ldI02wfLxxiuW0DzVMe04jA6etdBIxY8ZOO1fJYmN6gr8ws037sDPA61i2iMNQDY4Jzz2rQuD0VWAY1FFui3Fh26miHuxdupcDSuJDJEYozz1LCqlvZSCQuSCw55qeAKsCyMexwPWrsZ2RZ79TWLk4KyLcuVWRkSTSxmQBuTxzT9OVYYmdj85qGRvOumKHIBq1MvlwgAjdjtWj2t3B6bmXPcNFeEHoaq390hwN3Xn8anvyrDDYVx+tYVxJiUbtpHtXbRpqVmRJ3LSzRFSGIII5qCR/skm8ASRemOlVnRGXeveq000oG0nKiuyNNPYzSaZcu3jmTehU/hWBdsqMalknMRIB+U1mXM5L8kfhXdhqLT8hVC0JAVwKczDHBFUo3JHWpMnBrocLMySRIDjJJqKRzyc0xnODTQc1pGFtWZOWoZz9PSq847jpVljkVE/StoOzJb7kAYAY7VTulYn5auSZANVmJPBrqho7mFZKSsZmszG30i4J4LLsH48VwtdP4wuCEgtwepLkfoP61zGa9TDxtC/c+dx0r1OXsKjFHVlOGByK7uxvS6RTfeVgDXBV1PhOUTQSW7fejO4fQ/8A16MRFON+xnhp8srHXIyTANnB7VMqvEcqcrWWBJC3yZK1et7kHqSp715co22PVir7GmkyvHywBFTREBCcn6VmqpzlXBz6VctkkaPLHj9a5KkEkdEY2LsTFh/KrUYB6tz6Cs3BQbi+DUttcpnGTz1Ncc6baujoizUjUAHd0pBbedgK2BSwBXUHdx6VLGVR2Yk8VwybV7bm0WyF7fYw9R3pJCOORVhp0xzz6VUlKu+QDinG73Oi6K02QWP5VQcjecmr84JPtWfcqEYYHWu2lZqwDiR0Bz70xzgZHXNRjI5oUl35HArRxNqYMfl+aohH83NWCRvGaNvJ9KFKxqRFBjiqspAOKnkYh8c4pk8YYZBPStIOz1G1oVmPvUkEpXjNQtnmiPNdTimjK9jQ88eXyeaqO24k00A85NNbgVEaaTFKTsLjNdd4esljszKxBB5rjwcGuj8P3zFhDIf3eOnSufHxk6fumcVc7TR7spuwg244rYW/VICzAg1ztvdwRHG4YxzitFZ47qMJGQw6dOlfL1qV3drQtLU0IJFuV8zsDT7zHkDHJPpTLWIQRCNSTk0amQsIjUHrywrmsudJGkVdklqxl2jP7tOtS3lw2MRH24rPtAxwsYKr13Gr8ECozGRic/pUzSTuaNpO4yGAQWxZjhmOcmonuVWMb+vX61HrVzGFRUkBIOSM1SuXDwqy8ntWkIOXvS6jvzIpXwld/MOdp6is2WPcxxnFaF9Kyop3+xFZ43F9oPNejSukRNJK5Sy1vIepj7imy3KH7o61q+QrKxdgPY1iahAYHLwnK55FdVOUZuz3CNrFS7DEHBrN8lmzgc1qCZZFOOo7VXU4LYFehSk4qxjIrKhXvUoY4pkhOc1GHOe9bNcyMk7MlYe9JjPSk8wHrT0ZSOvNF2kTKGowrjn1qOQ46VJIw9agY5HPWtYK+phOVnYaeTionVQfenOSTWZrN2bXT55c/MBtX6niumnBydkYVJqKbfQ47xDc/atUmdTlFOxfoP8A69ZtKaSvaiuVWR8rObnJyfUKu6Rd/Yr+KXnZnDY7g9apUooaurMSdndHqFvNHgfLnPvV2JYpeoAx7Vx/hy9MtqEYkvFx+HaujtrkBs9/SvIrUnFtI9ijPmSaNBoEUgjgVKJ3SLYCCvfNV0mD/e6VIx6ba5Gr6M6lNk0dzEVYPGV9CDmkt9j7mjzu74poUyjb0+lQRhopiocg1PKmnY3hrqjXhaZFOxyPZqmW68yPD5DDg+1ZoNzsOHDrSLI2QTwwrmlST1Z0wehp+aNuFOT270+EHIJzn3qmJHdQTsRvpip7GUnPmkA56VjKFkynKxcMe5Sc1TuLUOwOMfWtNUOM9qilJKkdvWuaE2noVGZlSQDbxwRUKptBq5KAvvVCWUA8V1wUpG8aiBgGalqBpOcrTo5N3rmtHBpGqmmOIyeKilyM8HFTgjPvUdxIAMUK9zRMzjnJHNOUYHepPvyAKOtWvsbleATXS5paMhook4+tIBkVZltyhwafHGAORk0varoUo6FJl281e0+3ablXI+lV5hlsVoaArNc7R0qa037K5HLZnTabpy+UWbIUdc961rFTGV8sfITjFPtrR2WNFU7SOtX4bNo2ViRk9K+YrVua92Vp1Ni0jCR7mOWrP1VtxCnjvSTTzLjzMn39ai3ebLvZiQK4YQafMyopLUuQcIqKMcdao61eeUgijJBxy1WRcBMAEGsvWYHlZWjBKkc1pSinP3h2ucxc3D3NyYrfJx95qv21xKE2A8KOp71U0YLFqE6OCwz2rXmgSSPdHkAcmvUqyimo20NYx6GbNIWwW6ioFfMm7JqSZkB255qBSGOM1cVoZz10L0jl4RsP1qq0e6M5BOat2iqDtelu1aJSYyMEdKhSs7Iy5HYxLjT+C6HBrLlLxMd2ea3RMQeOaoX6h0LY+au+hUd7SMZuxmLIHNLkCq8gOdw49acH3D3r0eTsYSk0TttxnGaaBk1EHpQ5U5zQoW0RLm3qJMuM4JFQFiD7U9mJbluKbN8qbga2iraGUpX1I5XHXmuQ8XXvmTR2yHhPmf6np+n866G8vUhtpJJPuoM/X0Fef3ErTTPK5yznJr0cLS15meRmFdcvJHqMpKKK7jxgooooAt6ZdG0u0k52Hhh7V2kMgIDKcg85rgRXReHr3fH9mkPzJyvuKwrwuuZHXhalnyM6mOXjiplmIPWqMR4HNToBXnyij1Iq5ejnbOc9KcCsrZyciqYkUKQBz9adFMMfKc59KycOqN4aGihQYCu1XYlVMB2+9WREuWBYkc9q1bYKcYOT71y1kkbRbQ/ZtUgZYHoajCywjKHOavlSM56DtUKqu8jnB7VyqZqpXJEvXMKB/lI9KtwSowBzw3AI9apGEE7o+fY1LHbP5B2j3FYz5Guw1F9Ce7tSY8gVjXMJBzg1vrKyRxhxuzwx7ioriEMfmGVPcUqVVwdmJ8yOZkUr1BpAW7ZrYlsTjKncKri0wO+fSu1VotFQqNPUphmHZs1FPvbBPetExOh+7mntACu7vU+0UXex2RmpIo20RDqcHNdXZ2iSQZbuK5/ARVIPNaFvqRSMqaxqc09jRvQrapD5beuKzt4Xknir17ObgH3qkISTgBjW0YqK94zVV7JFVvnb5Qa6bwvp7s284BqhY2qM3zjArq7AxwRqI8g461zYutePJEpX3Z00ZS1gQyOOOwqva3iSsBIpxnPFYGp6jvxDD17tSW8zRR7upxjrXiSwtlfqy/I6rV7uB4Y47dQCo5OOtc/PdlOASPWgyyG3ORnPessSs7nzFI+lFCgoqxO2hfiujvHJ+lbVnOksTbya522TcSzHFXrW58mYDGcjpmnVpp7G0JLdmZDEYrq8IGSGz+FPhkdpMZIU9Qaj1lxFemRD8j/eA9afF+9AC4PFdL1jzPqbpq9ytewiOXIOT61UVxk1ev0MaZ6cVjLJtfFb0lzRMKsrSNa2ZnYAfrSX8hDbVzwKr2lwivh+ntTLi4XcwXOPWkoPn2J5uWJXaX5jVaWXzCRk7R1p0nzHiqrKRnBPB5rupwRhKpcbdNGV+Xjis4j+7kGrzgHr1quy+g5rvpe6rHNJ8zuQeYy5yKcX3Dg1FI3PPWmEHgrXTy3MFLWxLu9ajnY7DkkimZz9aqateLZ2bysct0Qepq4Qu0kZ1JqMW2c54jvN8otoz8qHL+59Kw6dIzO5ZiSxOST3NNr1Yx5VY+Yq1HUk5MKKKKozCiiigAp8MjRSrIhwynINMooA7TTLkXUCyqfYj0NaIY9ulcTpF8bK5BbmJuHH9a7WJlkVWQgqwyCO4rhrQ5X5Hs4Wt7SNupIoLHmpEAU+lKhCrTVyz+1c17ndpEtxud3tVuGQxyBhniqakKcYqdSc9K5pq5pT1NhboOnvUIlG7g81nYz6+1CoysCCT+NczoxR0RSNhZQFyOoqWG8AwBms6Ns8EGrsEAYD+Vcs4xj8RsoGin7xs561YntFaAfMVYc8VDbRhQDnp61c37lwBXnzk09AasUSjZGCNwHUd6bFGWjcy8N2q2zGN8bBU8eHUhgD7U3UaQadTI3pnaykZ70wwb+Ihx3J6VqGyjY9T7CoZk8pSqgjFaKsnsVFJPQoNaIifMcmq0skUQ2hRn1pbp3zkniqMjbj0Jrqpwb1bN00y1burscgZrQih3r8o61kRfK2a1LO424JFVON1oN+RcgtVj69aW4lEYwpPHpUctx0IqtM5Y5xx6VypPdivqOhl2uTj61be5d2CIAUxknvmsp32nA71p2BjFvhsg96VSFlzNE8yuXLW4f5VkPy5ouCVlJAG0+lUJ5FU5U5HanR3igFWz0rD2b+JIpPmLcbiMEkHBq5ZeRwHb5j0ya5u51IKCgBPueKrHUBINoJ39q0+qzmjRRsdTrmk3At2bAC9RzVDQ7hOY3IEi8ZNXre7YacEky7FeSTmuWmLLdu0fHNTRhKcXTl0BPlOj1SRHDLnkVz8owCQOaV7l2GSeagaQlWzXTRpOCsZzktxwY9uoFRmQknNQFyrdDilZ88muz2djn5ubQsnAj3d/rVSVjgmjcT3wKjeRQCDV04NMzlJCF/lquW70LKpJBpGxg11KNjHR7EDrufOaTOBg05+h9aqvuzXRFXMW+XoE7bcseAOpPauK1m/N9c5BPlJwg/rWn4l1LObSE9P9Yw/lXOV6FCnyrmZ42OxHO/Zx2QUUUV0HnBRRRQAUUUUAFFFFABW3oGp/Z3EEzfumPyk/wn/CsSlFTKKkrMunUdOXMj0NJNxNTRuAABXJ6JqWCtvcN7IxP6Guji3FhXBUpcrsz2KVb2quasPzEE1MMn+GqUL7asQyZfLDiuKcWelCxZHHGOKSRgi8VFJMrHAqJpAy4zUKDe5fXQsRXI6d61rCYHkiuZ3YbFallNhMVniKCcdClJnQLOOmeKmjuACBmsMz4Hy0sU+05z+tcDwl0KVZp2R0EjBxyeaRX2jkkisUXwGetONyXHB4rP6pJaMr2qN6K7jHBbPpRPPHIPlG4muYe42vjPNXNN1Aq5DDKmqeA6oj22pel09pPm2EKelQ/2UV7ZrUg1GEDDkY9Kb/aUbOQgGKznGtT9DohUbMaW0MZIx1piKVOD0rXlZZQfQ1TmCAfIvI60o1W9GbqVyIA445pjPnjpSo/OMUbc7mUZI7Vez1C9yORSVyRzT4csuM7RVWedugQj1BNRxTuvVe/rWvJJxJcU0X5fmIGRj1p0RCkZ5qorFucqKnUfKSe1ZyhZWYouxakEM527Bz3qhPp6CUNDwRT7d8Tb1zkdqnMmSXJIz2qVzU3ozZSbWg6zaQE+a3QVSvn8m8yOVcVI05Dcoce1VtSCvEHRgSO1aU4e/d9QuloyST5lHHNV3Vk+lPtZw6KWAzii5fJzjitopxlymMtSAtzgj8aYFAB28c+tIT8wHQUp+6xroSMb2IyxGapXGRznNWWOAeM1BJ84I21001ZmNV8ysV4vmPIqwT8tQKmw4pWOOtbNXZhH3VZg74FY2u6oLSExxHNw44x/CPWn6zqaWUWBhpm+6v8AU1x0sjyyNJIxZ2OSTXXQo396R52LxnKuSO4wkkknknvSUUV2njhRRRQAUUUUAFFFFABRRRQAUUUUALmt/RNWxtgum9lc/wAjWBRUyipKzNKdSVN3ieipKPxqQyY6Vg6MzNYRlmJOSOTWkCcda8+VNJn0FKo5QuWDMFzyKrm4PJB71BJ1NQ9zVxgh+0aLsc3zc1owXAQdsVix1bt/uioqQTKjNmvHOX6UpLbsd6TTgDtyBVpAPtPQd64ptRdki467kcbDdg81r2dquNzjGfesu8AEgwAK07UnagycYrjrtuKa0OhpWuLd20KZ38Gs9pFRcRj8an1EnzBVR/u/hRRj7qbdxJK9xqykHk1cglKjIrLf/WfhVmHpWtSCaNtjVS6JXrg0z7UOQc+9VIvvGmSfermVGLdg5mW1m5zjjtVhHyuelZkfSrcf3ampBI0jIWaPdyOT9arscEinyE7vxqA/eNVBF9Ljom/eAdqtmULgZ/Cs6L/Xmragbug6iqqRVzPbVFiGTZyBgmlYlhuHBomA29B0qFCfWue3U2g+gtyrbASwAPQZ61Rf7hFWrr734VTm6D6V1UFojGpoxlnJyw7VLISap2v3zVsfd/CuicUpXMr3ZBJn8KQscYp8oGBUf8Bq1sQ97ET5PFB+UYNLN94fSopfvGtVqYzdnca74rG1rU1sxtXDTEcL6e5rVf7orz66YtcyliSdx5NdmHpqTuzzcbXlCNl1GzSvNI0krFnbqTUdKaSu88W99QooooAKKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color fundus photograph of severe proliferative diabetic retinopathy with extensive traction retinal detachment of the macula due to fibrovascular proliferation along the arcades and across the macula with associated hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3296=[""].join("\n");
var outline_f3_14_3296=null;
var title_f3_14_3297="Tofisopam: International drug information";
var content_f3_14_3297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tofisopam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Grandaxin (HU, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2529484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2529485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of anxiety; premedication for sleep induction",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2529487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 50-300 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2529488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10485 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-4F267068D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3297=[""].join("\n");
var outline_f3_14_3297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369827\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529484\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529485\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529487\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821158\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529488\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10485\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10485|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_14_3298="Inward rotation exercise PI";
var content_f3_14_3298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Inward rotation exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hold your elbow at 90 degrees, close to your side. Hook the rubber band onto a door handle and grasp with only one hand. Rotate your forearm towards the body two or three inches and hold for five seconds. The forearm swings like a door.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3298=[""].join("\n");
var outline_f3_14_3298=null;
var title_f3_14_3299="Robiscek sternal closure";
var content_f3_14_3299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Robiscek sternal closure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 455px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3299=[""].join("\n");
var outline_f3_14_3299=null;
var title_f3_14_3300="Sevoflurane: Patient drug information";
var content_f3_14_3300=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sevoflurane: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     see \"Sevoflurane: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sojourn&trade;;",
"     </li>",
"     <li>",
"      Ultane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sevorane&reg; AF;",
"     </li>",
"     <li>",
"      Sojourn Sevoflurane",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put you to sleep for surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702919",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sevoflurane or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703757",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you or a family member have had malignant hyperthermia after getting an anesthetic. Signs of this health problem include a very high fever, a fast heartbeat, muscle stiffness, and trouble breathing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a heart problem called congenital QT syndrome, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698063",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Good mouth care may help. Ask the doctor for a drug to help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698330",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shivering.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a liquid for breathing into the lungs by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11863 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-42AE1A7C96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3300=[""].join("\n");
var outline_f3_14_3300=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220831\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220832\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030570\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030572\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030571\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030575\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030576\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030578\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030574\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030580\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=related_link\">",
"      Sevoflurane: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_14_3301="Seborrheic dermatitis ear";
var content_f3_14_3301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 330px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFKAVoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD548PQq0pYA4HpXY7CbY5Ofauf8Px7ArDqPWulPMRBBGetbz7EU9Vcw7mMwMkm1GKncuT0PrXP3dxIqKs3lzopIBmiDH/voYNdNqCEICxyvAVj/I+9c9fRDJ43Hdnk4Hvx1NSOW9yzA0Yhghs9PguLqVljm2GQLhgT5fXPU/MRgcAVMtrb3Nir2smms8SyPNb+XJmFV27pCemDkAYYk+mSKfoEU0l1PFayhXe3eNcqMZZS/H12gHHODWRct5Si1gdlt2KB1+7uI+6G985P4juKHsQtwM7fbRLO/wBrugFEYZcon90bT+GF6DvVyzgEkqPI7bg8ktycZIVQC2PXOCvFXNJ0snTLi9ceTDaq8rkEZbK8cdSN21c/71TaZaj/AEaMyRy25ikknaNSuYlIeQ/NztKrt7cnAqGy0XblswHTryRorlrbzppt+9RJ8s0WRjoinyyf7z46CsGz232r26QoY4mdVRO4UfxH1Y9T9a0r29tL8M8c7QxXN0Z7lPshVi5bgMdx+VA3ygcDr1qz4DsFl8TgqxkSBDIrBSucnGcfn7UbK5dNXkke3eHYR/ZsPlAooADYGPxzXY2DzMVjYBVQf6xv4xXOeHo1SFFDg9QExx9a6d2wgxzIOQR90D1NStj3ktLGvpN7tsgFJX5tsgK+mc5J+gNalsFkkmIzPcTO0zGQ4JBx8vsoA6Hn6VyGn38zm4WFAx372I+XAI5zntx1rRtb2byRHYSxNJwxUnaA38Oc9ep57VG5nUoPU3LqzC3EtzEIYrqQBZWj+YHBwNw6Fu2apMSkKpIpgDHkH+E/5H61o25IuIfm852iKqYFG1QAck569hknAxx1NR3cTqdzI6llEjM+BkY9+2evf6CpsYxlbRmOVR3COCqcnI6Cud17SUnWSQBnGcvk5+mK6yRVVgVXiQDIzgj39qo3KB8KwVY2BUDr+ZoibJ21R5LeaQ135ltIixrLlo2YgAuvKnP8JHP1rh76wlaVDIvnqA2A2d20HlefvAH/AMd2+le5a3plvcxnCtuUqirnjg9cdyPfiuF13Tpk1Rp4XjilQoEcjhNwOH9lPzKR23Y7Ck9CK1JTV0cNpWjyX2o2sSRW1zJFE1xFGqlvtBJTzoMjncF/e7eo+fB7GTSrFLDVLa2kLxWtxeRRyOGEamN5MEkE4zhhyf0qxcTXVozXmmyJFeW7RXUXaQFZdo9yPm2kZ4BJ5FW9Yht9XsdVl0aCSJfMa8t/O5cRu3II6ABsfMOOOOtXGV1dHmThZu5wuv6LHDZRz7fmRpIsxY6IFDFhjgg9frWTYO8D2+Qk9su6NVkUgANyyHuBznI+6SGFeh+I7SK5M9urKthJeM6/OFC+fBHIRu9flxk8Vh6toY/s6zuYFlAVJdzHadroUj3EDkEZQejdeKtSIcbGHc6pcaY7Qndd6ZO25Le755HUEg5Vwc8jg5z3rU0WZP38OkTTQxMC1rbzHcUdsAKcdQG+nWufDvLbS2xRLlHTccjDcDIZT1yPT0yKjsmWDSLiWKV2vZJ41tiDjCqC7kjvztxVruQ3bQ62LXm1CxlTUba3uIV/eTBo8nKcEOQQeAT+XWlt9TTynsb2K2iVyFW6QlgVA+UMWyQcYwe44Nc/f6kjalFqCKts8ieYGiXOCfvow7jOeDzz1p96VuIV8gR/brYA4XGHT+EjsR27Gh+Yl5G/Y3MnkXmm6lHHcqW81YuQzEDiRPfA/GmWcMBdrvR5GljQFlDDB+bs2eeDkfjWJFPFuQywuVRsI6NiSA9flJ6fToRWleG2lBuY5ftenz7VvEjBieOQ/ex6Z646ZqN1qV6GbfRLp1z59lCfIukIurVjlUbPQenPQ0JKtwUeIL/rBLEwbDRMnUH8M80+J5LNZIpikzGQSRmU7S647465GOR3qG4byo5lVBFJcKBKhAJVc5wD/P2oT6iaNfW0tG1e4ZZ28m8IaQDgq7LkN9DxWalxqlsYna+nZ7dxEuW4OVzjnrRqBWbT9PnKYk8swSup6sn3f0NTWXmXll5oI82H5XOfTof6U5Np6CS01NGPVor1kkDtbXqj5poR/GP4SPSoL+81CwUeaY7u3LH5wgJOfU9sUk1k0OnWOpqE2ST4KbcfJkDr69acI/7P1GdbplFuzs6EE9DyCD6jpSb6MduqItHv7eW8EV+PsqoHlWYL3AzyeuKvLr184hW6jin5xG+QGx7Hv+NXYbWE3kn2pBAJ/wDVkkEgEVRgsla/so4kRwjBpFPC+WrfMfrj86L7Idt2Vr+WWS4WTFwiOocFwAc+xq80Uc8YvYVUKYy7KOSOOcZ7k1btLIhJbJ3E/lzSRAMcHgkqB7YqlZ+fDvSRDjcJItuD/vIaXkx+aLnhCwm1rVYbCC3EV7OVjGGwcnpVqyF5Z3LRxtFNNbysC0gzggnjnjqKZp9/LY+fe2Ts0rgsj8KyEEc/lkCrnki8u75gkjmSL7RHJuCgHr0796SaG0Z1/FcDULKe8M6rMomZlQoOGwcY4Nb8ljqbSOY57xoySVb1HY1Br2rahqPgbRbVIyp0mWZFY45SQhv6VatfEapbRK1y24IAfriqa6Ji8zzjRAWVPl+YgDiumkULEBkMcZ46fSsjRYlWBhnk/KQPStiTaFIY7VUcsTWk9xU17pnXUazWpyO2DXKalFgxxM2Gdgg9ef6e9a+p6ykSslqQRzmQ9B9K5/5o5jcSMfOCNJ83VRg469Cev0pktm1pt3+/iWyiRpI3luTJuA8t9jKgGeDtUbqxWeJrhZYkZ1lfznMjbyvTd25OSTuPYj3q9D5cekTrBHxb2W+aVxhhNI6rxz2GF/E+tVdNh8zUooi2I4T50vH3I1+Y9O/AH1YCl5ErubWrrM+lRwhSplYNJ8/Us3yqx5424OemX9sVXRZjDcw2yfaAkJgIRhkjJU7SD935Qff8aq6hdC8vdUuw7szycuAVUFjlc9ehyB9KfZRLNpX2cj51jdmaQDYBvTPI5ONxpMaWhELeeMgyI0UhTH3hk47EA5/Gu++FtqfNf5cybtrEnpznHtXKaRZRQ2c0sKuoUZMxwM4ID4UfdwGU45PWvTPAFuVslnCM0k7tI7g+wGf5VMnodWGjeZ6PpyRwt8zFZBkkkcH8a0QytGqHKso2gg8e/X0xWdZwkoQWkBIHGNysPQj34q2rJ5Z3HeVHCjknjj/9dTc9uERwtEkufmYeWw5bqfxqysKqj5m2RhjtZumf5d/pVIPOISLYGMY5VgOn402KTzXjE7y5P8LZKkjoSPSp2NbSfU6Gwkkizbxy7XyCCo5I6guD+HJ4wOlbKSeUJgojubjeBIxJGWAHJbPzE5PJx7CuN0+GMW84fy0R2yzMcZ/DuOBx1rRsZk8yPygVZydrOpOW6ZIPfj6/rTWpy1aV22jpvJdYnu7gkyzHJQjLKD1XP5cnms57RnaYnbgkgYHGPQVbtr1JIyk10FSRyG8wfK7cD5T/AAg85POTVhVieEsZhJhsMEGSR3yeePpiho5lJx3ObltHct8qGPbtUMc49Tnv9a5rxRoXnxAW0beZtJ+UgEdcj6HGa9AuYzDdHJDqoJAAxgY/rVe6sg+ZTGVyAVweev8AMVErPQ2VW1mfOut2nlQmYZkjGSvljggfeUDqPl5q74LWCXfbvJb2qhZLdrqTecgl5Fk+Xthgu3Bzwa6HxlaPZXtxG5B23u5SONuVGS3H3W3DpyCp7GuO0iSbTb28e0LJcRxie2XafnVTh154+Vc81lB8rsRiaSkuZFTbIuni3kSNpkuI3VpOimMmNsgdFO489gK0Bp4bTvD8STkwJqUsbgrgxmQqVyw5IK4IzVLUViS7mSOSWSFwZIZGAUSRyKWwR2+ZWB55zVu2uri2jkUsgu4tSRkkDdJEQyIcc9cFfxArVOxwNaHI6XYRTa9bR3T+VFM5AljKqI3IIX5jxg9fpxVG20meW8gSQRCVUEsbY+UBCQwYdhjn1966l7KKC6igJSAvawSt5a7ghDiMnHRcExkg8jORTZfLaa4lYGNljMWX5kXOGBx0bG0/gRWl7aGFr6nH6rp/2aKNfKKwyq7PtIGHXJ2j1Xocex61kyJJA8KLjz4pPJOw8EN/Cfz4Nej6vb+faT286bfLb7b5QT5Ui8sO2zBPUFuB6D6Vx81ojXRhKmR7OeLIB2maHIIYH+8B+hz2qkxNWMzzbmSPzI4g6hjHJG+STg9jUyXhilLYYcmGRQcEjP3W9/etdISftccn7tPtDqVJy0bEfKT+K/zpnizSpzqsTR+Uk0yyPJDGM7WDsSGPfqMH3pKzB3RHDcRxq1tcqsumN+8VyMPEw/hz2/lVe6tWkl8pZlEw5MUnyNjtjsR7iqcsroqRvHtkmG6RAeDjgfSn4E6hJiJIFbIDdUI7A9vpT9RehatiUtZ7G5VGVyJkO/O2QccfhTrYXkN4sjiRwV2ezLWfFblpAYlcgjIDjHIB4zWlDbXJs45NwfzGaEqrY2kYOT7YPFJjRriEXVo0YfyIICCN7FuSefl7HmtS6ji8hWWEz3jD7zjgLjhgPQVgwFRZOY/3fkIchskvtbkE+w5zWvDKbfTLeeCWWSWzyhikO5WR+Qo/OkMivLcx3tjJG5KqdkjZzzjt+OK2PDBgksrpZo4luZCglLj5owpz8p7ZOKdqxhMXm2sGVjKlWT1YYzj2IrHhW4j1EbT5fIjG7qcjp+NK9nqPlutDrNTtIlvEaWMyNlbiaaI5LhgVbH04qlqdnBdlZbRvKdVXIcfM49R9SMGrUVw8N+G1FXkks2CyIQB5URxww69Rn8afqtx9msLx9JKrg7GdQWym8suPQ9j7VUnZsIq6OYufMhWzYQ4RYgXJ6AuenvW3JcW8unWpkQRz2rlSyHmSM+o9j3p+t227S1vrYhYn8pZIScmNgOSPYk5qlPo2oWHiMaNcxlb4yC2eJiDiQ4KgY4wcipaalYas1c2LcwtpevWm6eOVY1u7I7sqzKRuDD3UmuXOmoxLCGI5561rwmSx177BqEUgmsXKzoxwCpBVl98dapS2uopK6xjKBiFPlDkUpS1uOK6HPQ3sdlG8jrkL0VfWsfUtSuL9vnyIx0jX7o+vrVbY3keZdNtj+9g96qXd75hEFpHgHoB95j/Sulo503aw6dkjZV8xWlzk5+6v1+laPhyMy63Zs2X3PvJkwdwBGeDwSf5VlpZgbDL8zsMhB0BzVy1n+xahay+aFkWReAcbQflOT2OCee1AMSMPL50yKzvcP8sY+dnbzOAB356fSpbhjZWs+nW7xvMSHuJovmzID8sSt3AJYnHBb2ANSW/+gyyW8OY7gzSW0kzthlUcsFx0z3PXHTGar2UhsIFvYypuJCVt4242KeDJjHTG5R7kntSDcZH8vmQwsvyAMZGGQ77xk47gHA56fjV7TImuh5ez9+z3ES/LyWMYZV/NcY96hsLOKW+EeGEEySLGN2Cu5G28+zAL7/jV+FljieSJU3C8SdGGcgGPK8emQOv51LKLcF2n2CIRoxkdCVQjA+bpz9Mc1634CsxbWVshLNLtIcA/dbnP4V5ZqMltbR3EVnAXnuJFnWY9Ioz/AAAdNykFWb2/Gva/BFkJrCJkDLEQAOeduPX+VRd9juw1k7s6IJH5NuRK6+Y2VMa5IwM5IPPTnAz1qFmiKqUdzEPuPyM+uefXmtODTYCwE0TybvkC5wAc9c/w845pt9G1rdEi0c5ZnXgjj3z3Bqdz1aVRbIy/naU/w/KcgeuODTUtyoDb0YEEEjI5749K0bi1MoMy7PNGBsTv06885/pSS2qwwiR1WNcEbsk7j6Hnj+tKxv7RdCK3Xa7ZZhhvl9zjt61qRQqoEgcK0oBY5OfoPf8AWsmOaSPKq8gBTDDbg+3Hp71oxzZtozvb5eSD1B/wp2sZ1Ll61cLIYtp4/hZuc9a3tNadZCocsBnA6bARyOOvX+tcqt0iSgEAAnacDvXSQTAvGVG5MAMn+P8AhTvY460TR+zgQoxYqg4VWGcZzgAZzileMYLKvbpjp7VfsV3ZzuDt8oOMg84/D6+ntSXCqjEfejxuPzH/ADmsmupx8+tjzXxfpkd3b6uSu9ftLr5Wfn2iNCzAdeOD9VrxrXFmgNvNExMkBw6scKCcgnI/hdSen49K92vEkj/fFEZzM8rq5H8Z+77/AMP5GvN/EekCBrl5ogjGT5UmGBEr/MAp+oPt81Q1fU74aw5Web695YhV0UMUjVPNUYJ8uRlYlegJJDYHr71LbF7vVdStyHV7wptVjvBkAwGzxjPy49vXFVJQXgeGckxOpdFXCgOwyQPy/So7C6IIeTLOnlLvzhWw2z5vocYPvSb0OJxszTmMcrWlwgIhNuRKVbqskYUkjnOHQc+2aoSSyzCSNEzMlw8bxAccA7h685LD2+lW7W8S1e3jf5UlaaIhj8pV8lQfqXZT9BWNe3b6dqsijZFuk8u4jIJ8t0JAdc9RgkH/AGWx2rRttaGCVnqTLdRmG3dxugTZA8a/I3G4jB78GRT9KqXUslvd372zbZlaCdMrk5ibjrz0OD7VCkybpredShuFCl2+4p42v+DdT0w5qvqly93KZeLZ38yMRg5C8AY9Tg4I/wB0+tOPcmS6GzrUn2uIXduEW31BpLghH3NGzNlgf169qZr88k+rW90ZGdL22ikLR8AtswQfxQ1nwXAhMdvIj+TL5dxHGXyuGUq/P45q9Zymfw7bxuBmNJI3bsSj+Yo9R99x7031sJdDF8UW0Z1LzEBCNEivDt+ZCBjHtgjNZ5z9niVORKy7m44NdfbW8cGo25lWQKrhJFb7yswAGf7y4yfYVkavpps7i9+zsk1iV3bozlTsfaWU/Ug/Q1d7q5FrMypPMjcIwOR8wOchgD6V0/hKKH7c1lcq7ROXZVDBSHZMKcnjrWHfQrttJLaPLKnzkcjjjn61Ih8wIygloVAXacH1B/Amle6sO2p2Cw5txeJGHg8k25KrkeYydMdzwaZpybrVLK3hjf7R+9G45YhBlfp3q14eup7HQ57YFpCkkN7HJjG3kgE+3JFZt+l3a2wFvhJIHUAjqodv4vYe1D0BalzSokmiks0JCyQeZEpPWTd0/ME1RDBrogwl2BwB6HIzz6iroVGvVYny/OkMQx/C45A+hP8AOkvfMh1iPKLHDMEyVPO3rx74/lSa6lJ9Cxq0cmnak06P5l7ESznGWkTuH9SKu3MEoh8gSEQ6jCZ4ZF4WQgZ257EelZ+r3wme4aAtHBdIAhZep6EE+pxir2j3cF5YQ6bcSzrFGSYWX5lgcAbGwe2eDVNK9iVe1ylFcXEN05hZJeEDrIMKoZcbWB9egNPffLZf2pZQTGSZQJI5XLzW7ocbge4BAIPpWrr+mLb/AGe4yZUv7RVuBjBjmDHOfbjj0rn7W7mtsy2lwSLWRZAhODtz8y/Q1XVpgtk0db4iNprPhPSNWDSpr9vK8U5dSUukxkOG6ZUkZFWrHx54KisbeO/0PdeLGqzHz2GXA+b9c1LbyQa1FeR6dalILoLd2MBIb7PcDgg9irjIP0FcpcaxpSXEq3eihbhWIkGRw2eR+dUpqOtr37icHLQ8ZZ7i9YbziMHGewH0q/DbJEm2FQAD80pHJqEwpBbRyyM6oVxt/wBodR/I/jUXnT3jqkZwnYAdPrVmS8iae8+YxWmS/dz1/CpLDSjMJJLzKpjOO5zwKnsLSK3kZ7g7iOenBJ6Afj2rZvFWxJXUbdZr3b8tgzECP0M5HQ/9Mxz6kdKV7jtYqakguYINWyD9oYpKm0/NMi4Zh/ssoVs55O4DoayUjfc5fOWGeT27D8K1BdMt9cR387SW1yFjuGA+4V+46KOAUPQD+EsO9VLOKSeOKJV6nnaOc+oz2+tIaRPp8zW0iSoCZI2EiqOuQQf6Vdi3QT3kluxEiGJ0JYHI2tt+oww47YqoYYo43Ct5pLbF28hj3JPoP1rXsNOS8mis7XCEOkLZHzErk7yPUgn8QBSZVtSvEot7FvKc+ZKyruZN27nn6gc5Hf8ACve/AMs0mlW6GNpYggZWT5Ub1H/6uMVl/D74dRQtFe6uFmul+aNGGUg64A9Tg9T3JxXsdvaWtjAss5VIx0yOv0FZ8xtFOJRt4LuWMqscMKhd2Tycc8fjVQ3EryFkVSm75fMUMw49fSpb66k1GWRYw0duMtsHf6/l0pbG3dHREUsH5KY7Hrn0FZczb0OhOUVcSBHRFW4WZogCAI2/P3/KkufJkt2W3EkrDgFn+ZMHAyD2Oc+1dF/ZQgUNC6EjAe2QZVf909jz0qjfWKOATlSMgN0ZT6H3/Sq5mtyoYi71OX1BmE5VIMsR8pjTcWHUE44GOgAqFb2NZIULGUuCNpI5IPOR2NbGw20hjuJcKcYYggN7ZHf8O9ZepQ7JMNpaxRP91yowQexdepz61V9rHoU5xnZFUyLLdb4izKSCoPJHotdTpt4kkSzODuyFbHTPT/61c3FaBJ7aREYRu+ZEDY6dee1dRBb/AGaAYOFbp7ZpNWFXcWkjqLOdTwfl7nPJ46Y9afdsJCqGQrKTtCKMEnn8B6596z7WVYwExkEfLznj+Lj1x0NSaq0zQkQyoTxKEeQqZO+GYj5e35c0t0eY4+8Zk9pHczuse5nhQlGjUMHXHzq/Ye2fqK83+JKvK6WYjWG1VftMkbPuKIMhYg3fcxyfYcV6OJ2WB3W3u0LjYWEXykAg8EHOMjFchrOlz6lcT3LRyIG37EdgiquONxOSWPXAHFQ9rI6qXxe9seK6wjxA7AhEUscgDKCGJweR6HJGPeucQ/vJI2VpEkJDgZLbWORge20H/gNdz4r02a1NqJlwJQOi437BuPufrXGxwBUnDEeY20rIDgLz/n86hOxdald3Q0tE08b3GHjgkhedR/dRlJIx2Kbh9cVN4tsozIxt3M1r9ouVaRmJIz5OOTychxycZ59KoHDAyxfK4wu1iAWHt26dRWleXwu7N1mSdWaYP5m1mDqAFx+G3H0IHarizhnCzucrcgvGVZmbb757cj6EVFsMttOqvl4iJAWOMAL29cgcD1Wug1CyAC+WNwK7lXjcT3+gHBrAvbaaKS6gLLHNDh9rcg4IJGfoaszkroneUXdhoggbdPCj28w6eWwYsuG9CrfmKu+ErmTUYb7TVCj7XF9shB6+dGCWUH/aUnjviqXh1mnu7GzjkWES3scke9sBd4KNnHbO0/hVTSJJoryBouJonE8e3hlA+8K0fcxTex2Uk81/q9reSM00l1tmOFCKPlwRx04HGPWqunWjSXkdnGrIknmQkMcAAjcQR6naPrmoJLl1tLO5ijQWjyebDg42sOXT8Cenoat68YI9ZDWSNtmuElQbsZVxng+gOP5VlHR6mktUYMiTQzPPErGBuQG44yQMj8OlS6c8aTQyIiGNyVkic/K4I5Ge3qK3tStLaWXdtHkXoM6bONrYxIuO2CD+lcwbRoQVUhXUDc4OQ3ODj1qlpuTudlocloyxtHu2ok1pgnI8s8pn/dP86k1m4FtfxG8G21vrSLcw+bOBhif+BLXLWd01o4uBGoQnEuDg4xhuPfg/hXT+LpbGawsjbSIwgQIhBw5DgNyOnByKp6xuJaSIJ4XeHzVYJIsixj5seYcZB9uO9X7W8hmktmvY1DCULkNkJ82cj8ap6Uv2q1UB1a5QhwOCX5xgGqA8y1Fushi+0LI3zg8qdxAB7dqzXYtms0qXmniOOKPzbORnyQSJEc4zj2P86qWCQyeIZbZt9kj7odxOUJI4A/HvU0WoQ2uoQXTxshw0c0aj76nhvoec1SuPJV51uJG3QOJLeVOMj0b9Pxp7+obeh1Npc3a2OLny55LOVoZFlBAmA6c9m4rJ8hLmWO4skPksGzC4y65GGx2b+Ypt9CJPPJldWuUE+7dk+YOQcfgQaDcpBJC8M42v+8ZQcAcc/Q1fN3JsthmmWk+muLCIzi5DAw+WcbTnO3nrkfrWh/wmksfyTWNo8q8O0mNzHuTx1pbi9u47azuUnPkgkCU4yGzlMjseozVf/hLNEf5ri1tjM3Llo8Et3z+NJXT90e+546JHuY5ldiVYhwP9pfT8CauWKMskaxxszuwEcca7mcnsAOSTWVCzZAGa1ree4jLCCV4nkUo5T5SR3GRzj2rcwOhRxp04wUfWVOEKkMlj7kjhpv0T3bpGsCWcyxsqyM3z5ZiPfLHv9e9UNPAtwARtAHHGK1zGslsJc5duozySelO2g0zFNsxZDIy4Y8sTjk96uW0CMSr5EaDdM3cqD0HuegqaeMlVUgLgfM5GAf8A61dN4U8IXerbZLovBbNgtgEM4HTGen1qdi0m9jG06zutX1P/AIl9tGrBhhVGI4AOgP0/MmvY/AnhCDSlaYAy3T/6ydxlnP8A+vtWjoWiW+n2kcNlCsKLwCB/nn3rr9JhSNkVkAQEZBHbp+tZt3OynSUFzM17aCHT7B7mXEmw4wDhFb0J9f8AIrMWW51WVWlc7QcqMYH5U7UHfUbtMqBbQkpAq8g84Le5OPyAFaen2ojTLghR/D3/ABqGru3Qu3KrvcktbPCBYxgd2x/nmpXUQnbGMf3j1J+pq2pxHggBAOOcAfWq0gDjJJSMH8W/z60NErXcns2laMx24JIOXdjwvpkntV65gVI/OLGeCb5ZHx91uxHt/wDWqtYxLDtku8R2w/5Z9z9avzz/ANsxTWYAitnUBFAO7PYtj7oyBx19hTtoYVNHdHLapANskbkE9j/X+VZc8n2jTXEhiUxMVcE4B75x1BOc8fyrXvydqh/vxgxtxycMR/OudeVk1PasccjToRsZc8rzx74yKiDtKx2UW0x+j+WZWXBdkO5DtxxW9G4kiTeQDkkMedueK522meS5nYhvL6BTycdiT/LFayBzG0bFfMwOO+DVTOmoru5uQxxuyLLI20ghh7HtUkm14ogrAMnAyucjsD+lZMF4bdE859wU/MM9cdOalmuJQsRQpulJHyjcQPpWbZz8juXLhQ9uke7ZIo+U43F2J5Y+n0rQi0+GOIg8zBfmbOT6Z9sD86y0lBcNuLAAZY4B/L0rStC0rMCX+XG0DGevT3Pf/wDVUp3eplNNLQ8O+I9nJHJYsxaSSOJ4c9lP3QAOgGQfc9c1x40uL7PcymfYy25Yr6tuVgvuMB/xFezfEPTz5ccjBEj8x2jVSSEXPDH1JyfpjisTTorG00Zrm2RGt3s2tbmRT96RBuV2JB2lkZl2jnscGly63PXpSi6CstWeOXOnbrqWEKVO0w7McnnIzjvzWXZF/LeJTIsQyNu/G0ZBPGcetejahZNLNDOEIu5YGeYsNp3g7mB/Mr9cVxMGLaYMqN/rQGweShByPyx+NPbQ5K9KzM+0Qm5ktJEKoCSOMlVHTntxVLW7FLSeHzExA4PB/u85/wAa7zxL4cMtk93Ybz5GJA44ODyPl/2eMj0IrjtRuRfWMXnRkTxlldO+SQc/TqBWvkzhlG2py0cU1lqCxjeJwflJXgsMOpA98D861NYt1sNa1FoMFR++hGPvLKodSP8AgDH8jVS8DSzq5YiaArtkLfeAIwCfUCluZrm7hMpXetlatH5gPKjd8u72UkjPoQKtao5JKzNHRrmFI5rS8ikl0+4KSSImN/H8cZ7Ovp3HFSRuYjbtNILi0jc+VMF+V0ySM56MD2rGml8gwkEbEZckHgKQDj/D3FaSq1tHNJbSTeS7kScDABxtz2OefyqXqiloadu7zWZaeUrESi5Y8L8uCfowAB+lJ5NxYNDHPsSWM+YC4zkgnHHpgjHrWbDd+Zbm3niXyxLuEkfbg/L+ddJ4fv4tUu9MsdRY9fKScYwEC5CNn0xwacY30Jba1MbyHmmkuNkhs7cAF3ORnoy/kTW1a+QPDrWV7bO82nnKS4wzxt/q2OO3B59RUXimz/sbVbQ8G3uIxdSOhBSSUEqdpHGAc07QdQTTF0e+u5I5/LgFlJABk+R5jA7h6jIINUtHyi6XKNjHcx2X2q2ISe1lHy5++G75/CpdTt2ea4ujLHI0ww0S8MjLzTrnSzp2ujTb+ZLe2eUSQXYBZWiPzLn8OKffKGmMsbHdcKJoyRjBHGcj1AxWdrPUu/VC3YSWW3v7Vg07xrL5XH7zb8r49/anvdR6np8ZSGN/srFS4G0vGeQGHqKyFLPvjjjKXDsJoWQYOR1A/wAK19OuIL+4mZiVIj8ufjYCezfXP507X1W4XtoXlCXcFncWatL5AaKUNgEd1+vpVW/hS22G8USwyfOFAwyA9Cf5U2zX7OY1mZo4JifLKHksOOn1q/PK06yKkImMKlmYnqo5bj1zQtQZnQXZkbbCxeFcKI3HOfT/AOvVCb+yDNIZLCQOWO4FMnPerU2yBYpVgIWQAkKOqHv9auD7ERnzHOe7Hn8fep5b9S1LlPIYOHBxke9dRodgJSrPnFc7CuZl6HBrtrL5LaNlyNvpxXWzmSvoPv7BVjO1cnHQcVS09bi6mht7VWeZ/wCBF+6PX2HvXQ21tcX7COIBUxlnI4PTj3PP6V2/hbw1b2CFY4ijOcu5G5mPuah1LG1Oi5vQoeEfB0VoEmvG+0XBAzx8qewH9a9Hs7AQxDIKjHUjkVa0uySMAtnHuOPrWqIUJIYhj64rJyO6nSUdClDtiTcihieAxHSrejoJZJk3ZbZuGRkH2ouYAUjXP1+lQ2QaykS42seTvQDlh0I9eh4HepvqdPKnF2Osls0GHUtkDAXPA+ntTYWLMBgtJ6d/xq7b5a2icYCPhVcEEE4znPpjH54pslqsErCMYRhnLH7x9P8A61as4E+jHrFuIP38enT8PX61XugsbgsRvY8AnoaumRVgIXt39axtQYoGd/mA5w3f2/8ArVLKpq7LKP50EjvxtO7zC2Np/wBkevufwq5puoxIdsQUFVzvzwOc8+v+c1x12zLtaclEJORtLeUQf7o69utMgviGWFImEUhHB4Zvc/4Vk6iiXUo8y0NS9mWS9vAMfO4wxOOvNctcyK2uWUbNJtYsT5bFWC4OTkdfpW1cKIhNJkhJVPl543YyDj2rn7CQzeKIGjRylrE0rFDynRQwx3yalO80XRVl8jpitssDPHOyuR8vmfMCfUEdfSpIZuH5JcKQQB1A/wAis6WdIf3i4O7hxIoYj149D69c96im1CS3iHlp/rBj0bgngfj6962lqbqDaNKSdUYgKMjkArkH2xSB2R0YOAzHd97njoazGllS9MG9JvkVjtU5XIzg+hHenXGoSwNLGYf3hjXcQeBk5BHr07etQ9EWoPodLBM8TfdRxnn5Rkj8at2TRBwrOUXkK7HkDPf079PSsaO8UHfFEWbgBQcj861rWBWO+U7QTgkjJFZryOacbbmV4/CTWE0iD92+DtAwE6f/AK64nSCyxzQSmSKydhucLw0h42uo6l8Dn2NeleIrZ/sDNMRIWO1lJ5Azgn3OCD1rmtD0u3l054rtricTSY8uMkxwKM5kfHDdhgnJPpVpXZ24atGFCz7nK31rZxW14E33fziZz1T5iFbceRgNzgn0wO9eZ6va/Zb5lMZzDPs2Djdg9M/hXuOpWsU2lPFdPBb3McfkpFBxHcR55kif7qkrgEEFsgj0ryvxLBaC4e6hliczapJHHGgYp5YB59uWAGe5qJp30E5qaZ3ejTC5sbeaTckBj8p2VeJQCAFHYLgpubttOK8p+I/h0afdfbISrRyZJCnG3k5B+nb2rv8ARUkg0AWqy3C24u5oBHv2hHJw0bAjGOR3HPtVPxR9qGhXYv3sYRHCVZJIWDuQOpzxzwcitm7o5JQ5U7ng2o5LRlSNuOfamqGXzxjfuiI+bqMjp7itPVNOWPUhbzP50CbXkYcBlHJA/AY/GswedPNIzr+/cl2wcgZOTj6dKaehwTWoRL5sMQXdiRRGT2B6r/UVdtLhhbNHMhkSQrDKFOSGHv8AlUcLD7MIoxxIgjk29Rg8Ee4OD+dJbhopZoovmDMGHlnq45LDHtQRsSiKaNryO4QLKFRyV6MM8H9adpcjCZiYsxjKBh1DYyOfWq1gXa9dWYlNhdj2IJ+X8614I2d7WyuEWFlYSiSI/Nl+FyOhH+NLyEXZb+/k0kWcbKY4FkVI5AGjUM26Q8+/QdqZqaLdWtg0dvmE25aSRpNiKjfeU59Dgj3piqLOC6s9SjkaZd8JjifAYqeQW9+BgU2+Z5tGs7ifColmJUixwpDkYx9QBV3e7Jstkavkx6tpseli433cChrR+vnZ5wv1GfxrPgfzbNYpskQuYyACpwc9fT5uPrUxgaCGGFH8sWuPKcsAyPwxx7Fv5Ukl811NPN5bpcyH/S4j9xunzD6mlKw47GYEb7Pbyh5FmyUB3c7vX61atJ/Mt2muRuVH/eSR/fVuzH1HamTIba9ngwPKfHDfw554/GorQvaSK8OGZCcA/dI/un1qE7F2ujpbG3gvojaST75pBmHcoVjN2GfcVSmt7iwWRAkoUjepUZAJ4PP6Go4IpLvyRDmJA+5yQSU5zkD2q5cvJcwSyRzNvjG14W4EjZ6j6jmqeuokraFVpVuYTGybX6Aq3IrLe4jDsBI5wfQ1ehhjRU88yW8bnAk67W9R7VpLqjKoU2ETEDBbjn3qNy1oeVQqBIpPTPHH6D3r1Lwx4cubmKN7xWhQ4JQ8MR6n0/nWx4M8AQaYq3d8RcXo6Pj5U9Qg/r1+leiWeljZu2hVHX/Gtp1Ow6NC+sjE0fTIYcKqbVBxgCursrYgKu3cM926/Sm/Y9kibMAE4zitu2tiFJHOff8ATmsNWeilGK0IYgYjjaQ3v/KtW1xKMY+bHAHfFZzI/loSSVyRtPUD1FX7Z0lC+UfX3II9B+NCCa0HSwI7l1dgUyemMCo3jkNtPHgSRt829W2lQCOQOhOfx5rShUFW84BZDkA4yrH6+9F9GWikRAQVUFg4+YZ46/4VSIU9bFTwzdrCXsnYoGfCOeBvySP6102oDzY2Y5Lj7wzznviuW1i2a7Sdy0bz5aQufkbcMANj3HUeuataJqYuIVgnmCXGPLIcZWVR0BPZvQ/WqTtoZ1Yc37yPzLckzrCT945xk8Bfr6VkXF8NjOpZV/hHXJ989OOlW7x3nMoRgofBVc4+bvkDr04IqG10l5mBlkAUgDcuQMnrj8KiTfQUHFK7MFnmknCR71kY/P8AvMtI2TyT1x+laltpv2bMlyxJH3gDgk+gP8zXQrZWlkD5UaoBxnHzH15/z1rG1bUoo0ZsqigcDpWLjbVj9o56RRga7ebInLbcDoM9/UnvVHwFDLMmo6oFJilYQKSCFIGejZ9c+3Sue1a7l1vUFsLEnMjYZh/AueT9a9W0Gyh03SEs4lRcBQZIyW+TuMe/BH0qqW/Mbzapw5erM9rfzZCsqh3GHXPcgc5I6r696zDp+wylmJYysWwcfKeeB7ZPc9q3ZJMPKzN245IK7Rjv7HJHvxWbfMkVvcebLiRCGWIYOSwG09yT1BxzWzZUJSWhQ0hWjaa5jVABIQx3ZyWHJPrxWja2izOpZCufuOeM474/rVDQrm38wrIpC+Y2JIQCVHp/tZ/TrXR6cAqBnyMDPXBB61DHWm4tkdtbvHIECbArZIA7Vv28SuckLg88jP41iPdhrxdjZDKCepAJJHU1tW0uE5yPb+tTsctRt6sffRRmzkR2jjRhuZ9vzjHTA6msuNYUsY40Ysiny40cr8pySQAQdzAkZLAgGta+8trJyzNyGDLCAHUepY5wPcVXu7uSO1W33JEEJBjXGXGRwR17nJJ5wPetE1YmEnay7nMa7fRrbSpcC3nyCZAiqUhGMAMCPmUlvujHIyK8nm8t7NrWYjMN6Jnjdt6vFIqqcEchtwJ69F7d/Utdl2oi72E7qWQIA5CjkuQM8AH068CuT8VaDCmmWlzpqyTs0iuY3IEi7ifusOvucfKcZ4qJrqd0FFRSKegpcQaM8QheeSbErNG+ZMNk5ZWHzIRg9PxrC1nUb+LSJLAl1tJAYyjR8pzyqt2H09a2rG/1HS7AyRyyXNsg2RbHCSxOfvAbRw3Hb5T19a5jxKokNveNdJdXFwhZY5JWIjIOBvJwQfYUXutCZ9VI4fWZpL29mi+TcxyQqhEQZ7/1qrewxWtsEiP+kyneWI6J0GPTPXnmupstLjtLqF9QjE0as08y7h88ajewGPug4x+NYesJLNNFbDatxcM08iquAjEZY+wH9KpHFNdzBiT7IhYK29j8jHoR0ampMEij2ow8pPMGDg/LwcH6VPdqogstgADK3zg/fXJA/AbT+tRaTHJdSPCgG7lmbqVUrg4HsQp/GrRyMktoGEtvbStkxuGfHDKpHyZ/4C2alt5Jk+25Jlfy5YMt1JXv+GM03T1Mwtb9ZolWV9kiIxZ43UgcjsCpyD7U63d4p4rsY/0gEszfwsCVLflSYkdTr6TappMesokMQkWO0uRHj93cqmUYjsJFwc9yDWa9yLjQ/tM0JZIIfKJxgAMdy8emcnFaemasuheKbiF7ODWLO/tRaXVuCCZIsDa8ZPAlQjIb3q9rmmTeFjBHJJDqNvqUayWt9C2+2cDg5xxvUDBU47kVfxLm7/mTs7HKSW63FtcF5GSJ4Q23+ORlIBIHp70ii5U23mDF4lsH8s8lkzgq3uK0I5Wt54Ll/LZp0CuByV4wSvoOOtZlxuWASKzb4pXBfjJUnOT/AN9fkKiRaHSQuYEuUJlAXEmTkp7fTHSpInjmdcsHKrzt/iPvRaOYLqdZlyEysiqchkPRh6461cfR/tVpc3GnPGXg27oSeZQe49fpUuzKSFtpJo7xJlIKMRlDkFSPQ1Jod4Y7wrKgeCTMbh/vKSfvfge9GjtM80Kthn3hDGRyBjH4GrUNlbiaVgrlXRicn5kwcYPrTTsFhuv2XkFxvZo1k2Yb+E+31qusku0YVyMd1q9aStOrw3cgK424b+MD37MK6JbNSoMdxHsI+XJ5xQo31Q720Z6HFaoZgq7jjkccAf8A660YI+fLVcofQc1eSIZOMcD5cdvQU+C35Jc4OOM8YpHbdWKEyKsUkTff6ZxyO35YzVqCeJoo42ymAFIzuwBxyPfg1JLtO12xGwyGB4IGMH/IqCZVwGiI3Ku7g8kD/DrQaXTJFZRKXhHmCMHHyk55qfySJVubQEOrFh0+dcfz6jFGlwR3kSLkFgc7s5wO/FNSY2dwUbM1u7Fj/Eyt6j39u9DQXu7I1LeWK6hjeEFY5vkZV7HsACOOaned1SRbnAnhXy3LjBdfU+vbmseCQQPewKUaCYK4Y8HPXI79eKla6M22U4YkDdjnoTz6ii5m4a+RYvGbbMUP7qPczZ57j+Wf1rOgiSe4M0pRIyvmbmHXHt/KpNyO+bld8GWYpnG49APp/OoZbje7b25ZcnI6Y7n2/wDrUMtaKxrxTwhFkkJVVOGY9fwHrjFCapGSQq7M9B2HGM/XrXK6hqC48uNj5cX6msmfW1toWYsdzcADkk+gHepcrEexVrnVa3rSQRkZzjqegzXmWvajqmrytbaRayTEf624PCKM9Ezwx9xxWzaaZd6tMJtRDJEOUt16/wDAvf2ruLa3mW2jjYhkUbVXuoqLc2rBNUtjn/hnocNnB5twyG6JywJ+Zf8APrXpMtujxMed4XAK+hrmlW2eRUcbZiN6lQc4Hoe/860otQNoAtyAUx8snPb1rVNJWOeTlKXMUr2N0M8gAcpF5ZVsHepOQDkYPPQ9f0rJvY2027Z4Fka5a3HkvECGBbILnOeRnqOxB611iQR3Cq7qGWRSIyf4wByMfdOeo96xtTghhNkIr143RmVp0XDlCMFW7L6Bvx71R006l3Y4G1u2gnAfKMSPMOMAnOTjHSu1glnmtzxhSuNuRznp79utcibdHvd64A4/eFdu5DnDH3yec12NtughCqFYADnPvzU3sdeJadmkYkFzcx6u0MjHbkZ3HG9eoHtz6V2mn3C7GkaPcigDO04Lf3a5W5TytSj+UEOpGD95QD3rpdPbyo22KAzDhuCV/CoZhiLNJpGnFJmJnj2hl77toXrwfaobryjHt80IE4bA4+vHPpVm2DHeY8vEccY/ix9KZO5UPGi7GwQBj+R7j3o1ORPXQ4rWbq3gnlWYhhIoQbSFJ57nj61YujDc6c8LJDFHAvlmaRicfLjBb0bOCPXmpdVCifzEXbLtYKWlAJ+XjGQcEHnPNWFiNzbKXMs0CKsnmbRMSexYnBIyOuKo7JtcqZ5lqltaab8nk3MVzwInjGGA6CIA/wAecHd3GCO9c++mExy3txAt1cyD5pEkIaEA52jGct6k9TXTeMY2F8ZbkETFHAcgY25wVI7A8YJrlLm7+1TJFHE05Cb3S4lKEsODlhjOBjrxmo6mklonIy4jJBHeqLzzG8ho1kdQ4QEgtzgFuMAk9M1y0kpNrcTeYwluWMeerrGOdp/3jjPsK6bUTHDDBbSw+VPcrOjKQG2gj5cEHnle3rXJTbpVaVE8uNvmCbs4z/kVaujhqWbsilfNI1raocbVVhHzwihiT+pNV9PlFo090+TEwEJA4wrH5m+oqefe6MkYDOCVUdMkgd/rmq9yPIiVc5QI4IIHIX5WJ+vOKtdjmmh+kyLZ6nIpLRxXBIkUcdOD+B4P41cW2VLScLJxbzKcseVQkq2APrWaW3ravKe64IJyccYPtitKMyxrbyIpmMyOGCjgMrfcPrkc0yC9dXDi0FoqeSm7l9o3OvUq59DWhomqyQaZPYpma2n5ntX/ANU6KeHX0YZIyPaiexhu765trdsM6edAzN/rRjJRs9DjOPUisiOcKrHylVozsaLGC0Y+9g+vT9KLtBZM7DUPDenarbve+D7uS/tYjlLa4QR31uOuxk/5apyeV/KucgjU3QhnjMYLESDbgn5cEAHvgn8qimURTAFyN4WeCZDgshGAcjoR0PuKtW2oXkt00uosbsLtKST/ADMCP9rueevvUtpjSaKuourWNosEcaz6aptmkjGGmTcdrt79qSynYTArnLoRjnr7VeuiINba4lhT7NODFKATznqMevQ025slgv0ghhleLO5CuMshHYj3o31RXkaWkwQz3ccgcrA2Az/xhsc/r3q+umXlrrQs4B5u+UovG1+4O7PTHeq13YQ2ktvcw/vrWVM5XnPs3vV6K8umtrm5LlpJJvL/AHr7nReOAf0qklsydSnqUcA228VvIohOyVu8hz1Ht/hUTvFG7Il9NtU4GR2rWllW4s9OaKNY0R3BJ6u2fXtUI0iAgF4Ji56kZ5NZu6ZqrM9+ERdIyrMMgEcd+xqQcSs2CDtII7ZqWBQsMikYjTHI6r/k8GnKB5vlSsiFwGRmPBB6HPv6+/NUbXKs6FFaeMM8Z+WQYwQOORVFSbG4i2sWiLZjlUY3A9Ac1qi5WOV1deVXYynqR2I9aqK0b288TBth6IzYDEHqB64PBHvR6Fx8yq9mS6z6e0fzMfkk5yfYfj/kUXV5I3mW9zEY0P8ACxDEMOG5HYkA4qKQfZs7XMkRAYZzlPr7g96zLmXczZ6+p6k9Kls6Iq+5cWdZI22n94vRgO3cU+EqEwBkZyAvHNZYnEMhwQXB7ciphNhNitj+dQOehblui77UGcHAWoLiRYIgCcucFiDnHt+dQSXARfk+Zuw9a5rVdXle5+x2AE99LyE7IP7zeg/nTuYOV9h2saskH7kFpJHbiKPlicdhW54X8PSNILi/CtcdgvKxj0X39TTvCHhoW0huZm868f70zck89vQe1d9a2yxoBxn+dNRe7MZ1eiKkdlHCmAQOze1ITjP5HJ6fWtFkCk+o4x1A9/c1QvF2xh2wImfCAt80h9fp2z+VOwQ13IZ0BgypwCwxIRnafbHf2pqu5g8q6wGDEK2RwR6+1aFhCxeCSeJpnnby4o0GD77RwFRR1PU5pniKCyFrcR+aDcIBvKnKpgcj8/Shx0JulNIyrS9ni/4l1wkTxBw0cU46gHld3YdxnpU1/AzQSRxoGhck7AOgVs7QP4gM9R+FZGuj7Nd/aBt89GUvtORleDj6/wBa2NMvU3J9pX93IEGCMbVzldrdep6ep9KqDuteh0axXMjlbyMo4hZS2z5y5JHPGRj6gfjXQae+62i3gHC4xnqPSh7HdrlxIVV8oVKhwCT0UAHoA3U8jB7mm2YPm7zuJb73PPXrjjFEjec1OKRUvWk+1I64+VsNu+8a6DT9rMPNaSNdxAIxjOMjOf6daoalbtMmdgwuD8xwCPrWhpMjR2xTeHXgfKMcZ4OexzWbWupnUleCsb6SxwWxWeOVo8YyU2sO+B6nk/mKp3kipbsCXVN20sBjPt3x/WkjvpZAYpJJDuIJL8DcCOnHFMupmlfZOog6AsAAc+4ye/emcsYtPU5/V0DoJ5EiMSMoGzKtwRxgfezV2NhHLNKkSSI5zII18ntxnBOMetZ+pSRqUuLaZZiepJ42np+B5xVy1KxwIsa2yu6gIynYVz/CRjoe/X61R1z+BHOeJLVT9qWW4E02QSXk+aNcD5eR8w54PrXm13pwtrm6+1MsEu4FopBlXGRnPsc9fce9ew6paf6SA9u3mJtIDR43DOdpYZwPc/TpXHeIoGyf3LuLeMzIswDugPTkAfIB69eB61Mo9S4VPdseV620qNDc2bxwmCYSKg6xgHgn3JArC1WJba7dFG2B1SWLsAjDK/XGcfUGtbXY/K3WsfIicsCCPnIAyx7dWP0A9qx9SkW5H2UFTJF++iboHRlBZM9u7D33DvRHU5amjuZkRxdMGwoUqxJGR1O7PtyKiljXfaRspLiJUdQejNknP1yOKs26o9xHI2wrKzW7FhwCVwre3Y/gagvPnn8woxBwGB+Vvl4I9iCDVo5WrlJo2W3XLEsoOQe4J/xFaunShtNltHZt0rLJE3/PJlzk/iSPzqvNAV3MrCSN2Khl7HGRn06keh7U/S1/eMORujIPt6j8Qf0p3JsbNjcBtStYpo+JoDCTn5kIHT6jip7izkd1jl8ob1ZIygwVb0z39azYXd7dJAo+0xzrvA7P/eH1GAfrWkrTLO6RFZFL5KOeT3UqfXtkdelPTYVjPtppI4xaXi7oRIfLycGNm4bB9PUVZ2NCJLfIlWQ42Y6EDt+VOvktZ5GL5R5cNGzg7ZF/u5HQg5GetaMekNNYJPZ3Ucy3CYdQQSsi/KR6g4xU2fQpNdS3NBDqNvbASFJrmLc3y8RuowfzAFJpkr20VvHcF0FuQ0chHO3dww9R1/lVa0MkNm0c3kqgQbXEmdre3erY1EW+iyW95/pduTtjPR7fJySjehJzg8U1YGi3YXUSF4pGT5XdlbbgSDJwfqc4puoWUIt1mbMQckbUPbPcfWs6yaONIJHEbRK43jrgE8nHoeD+FO1R2tImDs2FbksOG5xz+Hek5X3BLU3Y0ktLRYpI4wZiB+8HynjKn25qxFZK0SNK5WQqCwD8A9+9Y11fSzDDEhliwmeQORinNqRjYpIELrw3Hf8AKquhqLPom3kNrIr58q1dipkK7vKLdAx/r61ca3zZg4jZM5kZsloiR14HzLjt+IrOE5jDxOiyxvwU5XB7gj/OPpSo89uBHHIwhYEKS27J9MDp19fTpUnS431RcmjSYxQXLrE4ztf7y9uhH8Pc+lY7W1wCxj/eBTgqG/UGtNrkGHyZFXyWIbBHRufxBqiZlVhks4wcEn9DUsqF0U7m4AjIcYcHj2z/AErHnfDbs5P3gAMVcvp927B3qP0rEvJgi8MvXB9Pf3NS2bx0QySULgjrwev+eaa12EDbm+UcnHUex96xL/U44lZ3cADoT2/z6U/TdMutZVJbkNbWI+YRHh5PdvQe3WkKWo6TUZ9SnMOnEKhbZJckfLEM44Hcjriuk8JeF47SwjmclryUkzCTO8MCepPUHqMdKbHYRWojWFUAXAQbeB68V0Og3CyRBefPjwm3OQydvyq4pdTKrBqN4mrp8XkHaV6AYPXP/wCqtbBC5HB7+3/16Za/MvPDdQe6+31okmHClR0Pynp+Pt/OtLaHHuyN2UbS+wqMsE5AIHc+386ryQSSq11c7pJZD+4jA2lz6n0QD17VdREIDSDfz9xu/ufaszVriONUeVpJZR8qZbG4c8H6f/qpbG8NXZE1xqr2dmY0IN1LlS+eVUfwrg8KeueprnHZpEm3HhlwAOlV5rh5ZGlncFyf4FCj2VQKvW1izRm8u/kVVJiTs3sPXrgmsZScmbOCgVPEkIDuygbnJJYnkqBgfh3qzoFzJLZ20mfmjQIob+Ef1J9ay9fu/MuJTuBJPQenoPQAVf8AC0QXSbYiXP7vkY28Z9e9VS1bNLe5qWdiyI0NzblkidpIucvGWz8oPpk7seo4qfTfLMah3IlEeQcE7+On17GhsK8Y2sdr53IcHGO4/wA4qO7eaN/NWQNIT14yxxyT79PxrVoe+hposjiWNDGwC5+9jHvzWXBcyKQhCnsHb5Qee9a1xcef+/RVkD4Vmz5bghQSuO46HPrWRezW6XXmMZ0gIO44/iwOnr/9aoaJpq+jRtRykwASHbglm+boc/Tv1p0twzO6LiTKnJMY27SOhOeevT3rHtJQwZGVrmLBDLt6HHGf8BVq7LOrpmBU++WKZ2r7Adjxz2GaRLgk7Es6W9vok22DyjDH5aecFVTLnGfTAU4zwB9aXSUjuNASa3IlUOFBEjOAM46kZ9iORWJJqSx2UsKyLuYfuNuGPPG0KflAz/Ee1a1xc3Wn+TZmI+TK6CY5LOp2gEx7SAQSvT1J96bCUJJW63LgieJo7gxtJGylZAyhiSR0PPTjv+Ncb45to5r4vArQbVRpA0ir5bDOCuD90jHXuPQ13Yl82JnXHUvGuQcP6Ejt/wDq5rPv7gQBpbmITQSZgMjRKQAM5XDdT6cgUbmcJtSufPnibTZJLho2QYQq6lGyu5hk4z3PORXFT27yWybE37U2OB/CUOAT7YIxXveqaPZXR+xWdirFwHt5WYIVVhnecnnnJBznqOOleXPpT2mry2roZGuZDEIyuH3E/IwzwcnK49Tj0qdjaolLVHDwBMMJ8/ZpFAYr1Azww/3Tz78jvTz51pdNuZWlU5Yo3yuCOSp6jcOc9ea0JLExTY+bY2SDjp9R14KkEYqo8J2ECNRg4PoCfT607nK4issflyCEyCBiBHuOWiI7MQOQQf0zxUdtE80kwijzJsB+TgKMgE/lkk1Pa2hnO2POedpXkj2x69sVJYA263TKWjk8sqHjOTlhwP1oTIaJo4YjCt/G4+zzDbPF3UKcKx9uoP1FWrWS2tLn7Pd7/wCz5m2KXAZduOxHI7GsSwlktXM0fzqoKsAe2PT/ADnFatvCrp9lDkpMo2Z42v8AwsM9skqfY/SquQ42Ne3hkgtpLW4k8+zRg8cy4JT+7JjuD0OPY1HeaZjUZbiQpHLJH55EfAlIONye5HJ9x71SsLlrbbZMpdAxRInz+7OfmQjtyDj0q4nmNZgQSEor7kDt9w5zj+n40XQWZVtrgWGr+e0fmw4LBl5EgxjdjseelOvZBGqSRphzt+992Qc//Wq3Mg+2XcIi/dtGJAAcKwPJAB6EH86rXYiH2WEELtlCs44DKT94VHkUtiOSMLnYFCoOYz94IeuPWnR3xuIvLuGVjEBGrse3YmjWLYwzF43JKHyyQ3TP9KqytmNWZFUkBWA4H1/OmDRbhLGWFYztcqxG8/Kx9BTZbfzJHdV+ViSMjHB/GqbXbxxxxyoBJFJkNnkDP8qsNI2TiBiOx3df1pBex9O3AAdXEec4+bGfYj61GH2xhcFh2yOPypvnnaIX+XPBY5x9arTzsAT1xj8aGdS7FqWQnG12IPXJzke9Zl1J5YbLFj6nnNE955aYyMkc+1Yd1qCsG3SfJ3+lIqKY2/umRQ24BB1IbrXGavqzy3At7dGknfjYnYepPYe5qxqOoT6reiy09j8v35DysY9/f0FdL4c8PQWFuTEpeQkl2Y5Z/qaW5pzaGb4d8OYmjutSbzpwcjP3E/3R6+9d7a2vlwvtXIA7d/8A69VVtzGsJB+Ug+4HrxWvahm4OMnjPQZ/p9apES7lRrXdaMXQ5wACo5Xmqpgmt5kkgYBiN21uN2OufTj+tbQUspjCklhhQOoxzj2pZ4XnVWjDYQqwYc4+np6UWKjPoySz1WO6jULhJg2xvmwPxrTuQU/fOvHf/Aj0HasD+zd0UtxG32e5jl8oMrDYzHOFI9GHf1p0d7cbmilLHPynAJx9c/0NaJ2MJ0le8C/c3u3G072bAAFYc7NdyszMNhHHuM9h3rYj06K4bdtJIyS7HaAOxIFWkggtgsgwhx8vOCPQ+3U8VLTkRGahsZml6Mok+03ykIrYAPr3A/zzUet34mbaCFjQfKByG+ntUutauNixwARxKoRFXoPU/jmuN1C9YcocbeRj1/ziodlojanCU3zSK+qPI6KqxgNIwjCjnLMcf1/SuysIha28caElEVRntwO1cd4ZMmp68rycw2i7yMcFz938hk/lXfFAyA5AGfugcYqqSsrm0nZ8pEm1yT91TxnPAp5iEqKDyS6bSzABMnr/AD/ECo9m2PJwQCAM+lX7QLHIrSweY+7emRleBzxnB4I/IVqTJ21RBFFJazSsZYvLO6PeuCCeobH8Q7f1pL6F1SXEm0DLbcHefZeevX+VXbq0n+yxT2jQRxpGW2ICQvzdPcZ9OmKpzTG5g2mZ4pNzbmY/KwA3KRgZUk5BxigiMnJ3RDbSXDzlZBa/aZIxKzLktGTjA54PABx65xQ0wMiMoMkeMmSFQJlznIPUYzntxVDS7lUniYtI0DLmdmxkgZC4bGAyknn8KWaFWZIUXG8lQWPlggZ4Ldvr71Jo4WlZkGrS2Q+03Nx+9tcfZgjoA+SANzYIwQfz+taa3VtqdtpdxdxNDI67Xlc5DBAR8mD6kcn19a4fWIbidCbWVpI3A4CnC56ZOeec49eta2nXwOgaWiS77qKILLDnHllfv7h6kkVLfc2nRXLFp/1Y61XZ7YyJEoVBtVo1GF2qCufY+vPOfasjUJWcwl3ZmmBbaPuDcOfoTznI6A1egYSWLK6bgvzDaflz2JA7D045rMuDEg+ceZJIFYORgxnnn8QeKTMIJXK9zuuYwrxxCGIgKwi3E4Ocew7471gaxpsGopc20qJKjgGNmXB4/iHcDA7+1dnFCCi5BYsQUdTkLjtnP1x3HPpzmXMSxT7nKFNzKcZ5HqO+Oc1ViebseRalYSJeN9sBbZzJMRxyeXPsQQSfx9ayrnSnSaRZYA4Gd4UY3qe4I454IP4167q2mvcNbTwhQ/AYMmFZSCH+oIxz7VlRadDFKytERkkBccFCOw7AHHHTuOtQ0To9UeWm0S3y6SM21j8wUqx7ZYdVPt6iql1zAAY5Wk3KZAxB2tnkgjHB68969F1fw4zQG6g2xzxEqA5+WYdNpJ/Qn0INc19ijuYpUa2kEsIw/lj50PoynqPpU3E4JnLSW8cSebDIzKJCoZhgH2OeQfUHirULCS3eBxtVBmM7uUOOgb+6eme3Q+tXktp4JdtvISWGQGXIYe+eq/XNV7iNGVSYvs8iHHyDaEJ6jnqKaZk4FCEvG0p8yWXzW3EPkOknUBj61P8AbfKndLkfJICCJBk4IyMr169wasqm0Swzr1XapIwGH8/6jt6UxkjmXyplDZ4UTN82Txjd2+vejmJcChb3k7OHikZJ0AYLKS271XHf1zWi18lyJpWLtsw7cZx67fb61SuIJ7SVZFQ/uxyjnIHPUEc1KJPPLyLtjeXJ5IAYDrk9/pTvcTjYttJDcM4kI8soRkcZPr/XFVZoH8gKzKWU7FI5BBPWr9u0F1KJpYRuwAcjAII4wPb9apurWqBSAUL4zu+ZSOmPw7UmCKl6S6odoGw7WGM7eP5UguYsD/R0Pv5nWpJUdZN8kLOM/OQeoPt7VkPbTb22gbc8c9qEw5UfVFy2OFJ49ewqlPPjGTS3V0mz5sgjrzWBqeorGjMzDGPX+VB1xF1O92Ix3cDpXJ+bca5eyWtg7JEn+tmAyE9gO5/lVaae68Q3j2tm7pbI2JZwM/8AAV9/U9q9G8OaFHaWaRQxiIIAMY7DnH5880JX3CUraIh8N6NDaWohhUAIckdSx9T6muptIhu8tQu0HOSOnHp3NNggWE7xgEjYwJ6nFThha3aOmwxsmSSDjcP4c+vFWibkXklZIgzYQngjqvsf51NghBEHU56uB096junGAR1HHAwcU6EGdSzMMKueuMUh+ZcUSLvYOxZQCGyBn0PHepo2PkyCORN4YMY88c/+y1XKmCaBJVzlgN3UNn+o9O/Wp7k26pHkZkVyCpGN2Tjr/npTRI6CNPs4wEjaQMpkAJK4bufrjgfWobiaNy27aZSCWzyE/wBrA6+w9TUX2goX2vhW9fXkBvp2PqKzSdxYRNh2OWIHOOw9gOTQNR6s2PtixQYwBGp3Bd2Sx9WPc/pnp0rK1DUmKszHAP3celUru6K85PHPB/pWTdXXysQcjkYPehslU1e5Dql+0jYyRnjg9K53WNR8mDozs5CqO5PZR71T1rW4rWOSWd1XbwMnj61y/hXW49X8UFpARHCuYge56FiP5VCi5HQpqLSPXvB0DWNosUjA3DMXdgflJPXj26fhXUxzOVwnHGRmuWsGRJwRv8wrztOc/hXQRSlVBGSTgDIx/nmtkaOPU0oHZn25BOPlXp8x559BVzy4THc7JCDs2qiqG57cenUHpyap2SNICXIjJYYJjLZ4PYfrV+VRJsldMXABAJUs3A4BIOW9sj+VM5572JYVY6eR5ksNzGzSsAPlK7ecL/Fgd/auVu55f3RRUwoACGMbSeMnI654xWsl3M3npEnDgnhtnljHzY9QRjNY2o3DXV35xi2Ix4SP5QPdR6Z7Umy6MGpO4pLQgHITfIxERl3EDOChHTnjnFJM8s8Z3M7LGPLdMYC57Y44/kKouZVQLefu3T5ETbscjJPzH6nr+FagNxLCXia6e1Cje5IAQkYIBHU8dD+NSay93UxdScIy/u3j86JWZfN2q3OegHA7YrG0i7eSQsCRIHIUAE8Zyata6PLjKSAI/wB4xhTn0Cr1yP5VmwWtxaTziX5ShCOgI3L8uc+/XmoZtdKJ3dtcb7dPLIG7IIJAGOvXvzxU5hWR/M6sP4lHX3x+lc/p42E/vSjDjG0HrgcZ98V1FoE2bGwTg8Z6GmtTjl7uqGIVy2Nn4nqenP8AnjHvVSaHcVVWQFFOVxyAODye/Oe9XYI905AC8NsHsf8ADPT2qBsb4PmKFgVZlXOBzx+tWYt6lYxyCR/NdpHBCmSQliwHTntxkenFRRqkgYiMyscjLgZXrkj37VejLxu0XJTJzz1bHA/z61UjDq7OSDEn3D/ePUgj0xx+FIEitfW8a2Yikj6PtBIBEidTjPUj+lY0+lRwSxTxwhnBGHjX5gh/h9CO4z6VuXMSzssMrNHt2yxqeShxkEH2bt3BIqyhkLMuGM/Qso65547Zxn69qQ9kcdc6DHJJuigWSMyDcQnyFvUr1U46ke9c/rHhs+bDKsUkNvMSvzbmVMdc9wBjBB5Gc16yq74mjYIS3RZBwcDHA9O+feqn2ZZZ2Jm27WIkTlskgFgR3GBjI5/Wk4oSk+p5NJ4fuMsl6TMdhEUnmBsbenXrwMYrO1PQJre1kM8Je3i6SLyDn17jrXt9xpcUkG0RxFnIj3EbivU898qOcjt15rOv/Dtn9ltbeOGbYHJKt1KAZ/HJ4zxzS5SeZHiU8Za2VFklKr8uWAOAfQ+nsazzAUkVreOMkcncMFSD6dvzr1jVPCP2FfMilEjOvmCEjHAwSOnbIwfeuB1bSmsws0ayPFJu5ZMHy93OR+f+TUu6Hyp7GXaAxXCpcr+6IyvOcf489qlvLVFd44JdyI6hSw28dc/nVpNP85VaCRFkBwhPTPUAjvkVNqcDI24EFHAIZSMdSu0j+8vQ/SjoTYw9jjCSgeaG2dzuHODmqhUgkDdgewroL61ZbYzxglk7khuRUK6XJKokCkhhuGMY5pWGkeh6tfiHeWY9cn2rl4IrvxHPmMvHpythpBwZfZfQe/5U6wtLjxPfGV9y6YGwB087/wCx/nXpOmaYlvGsYQKABhR29BVGt+hD4b0OC0hSKONEjUAYA4ArsLe3CYzgYPJqCxhZRtb7uMfjWiImMfoQvDevqP8A69UjKT1sVJVCEk48tjjGOlFyu+2EDhnT7x2EEr7j+dTEsYNzDfAflcf3Oeme3/16ZCrJO0PQBsLu/u9OaY13MmKRo5tkowy4B9vf6Yq3cIY4vMty5i3EsAuQPUg/lkdqdfWolgjkXaJuQw3c55IJqKB5V3LLtBOMjp+OM4/Lika3vqWPtoaBopQHjfDFMHBI7/r+YqtIzyKyu7M3bJ6++aqM4WQpGDgcqc5x7Upk2khyWBGOOc+n5mlcdrbA7OZSVGSRjJOOP8KVDshzkgclc9T7n+lNLgDcxycdR3OOg9h3+gFUpZ0Qbj9wdOeTjv8Aj0/OqREpX0KupXJjJ4APv2rl9b1NLSxZt4DBcsSeM9Sc+2al16/KyurOM4y3oP8A69eU+NdaN7KbGB8oCDMe2ey/1NLcHLlRh65qc2rXjOSRbgnyk9s9T7n9Kk8MXZ07XbWds+WzbHx6Nx/PFT6JpEuoThUU7AevrXS654Shs9PeRSyS4yuckVqttDneju9z1zRWO0fxbhyAOfwroYFKNjDBe35+n9a8++H2qC80i3kJ/fKmxx1weh/xrvrGQYVRkbOcEcgetI9OMrq50+nIPKlAVy33ckZx7dfTPbPNUNRvJI7URsVmkf5c7/n4BKgkHngHHfHrVhmMdgF53sQ3HBBB4JJ4xz1659KxLtXll8mdmCKcqhAByOmCO5HGO/FDZlTgpSbY5b0SuHjVVkDj5IwSjDv1JPYfX2pbx0nea5JJaRwANoXPTPGagtbB7eYreL9oQrt+Xu54BAB5xjPbJ7Uag0TR/Z5VmhfzuXkT7gI5Bx0wMHp1NRc2ajze6V3W41K7maNDyDKWZgqIucDB7H5e/enRX5S0eGaN9k52liwGxyMls+47e1I0gtJ5Vjc3VvNH87xZVsdQASMY7kDqD7VRsokFgzhomEke9SitIEGTjJzyeCNvB55NMmTVtduhlam85QO8kiow8vzd3AOQWUHpngflRbGS5knubiYSNM+S3XJGOBx7VZ1u8jltLa20yNzE5k33W0nc7KFZVBGAcbieCFA65pbZh9qiWT7sSKg2HBIQAA9xnAFK3UmU+a2het5JbSbzXkXymRoRk4YMSOfxHat+wuE+zvcH5BCx5AHzk9wfqMe2a5iVAk5mkbq3CkZ3cjGT684zWy6KLNJY4liCKOP73J644PX8sGpJkk0aunTtJM0y+WGD42tyORjA74HHPrSXA2FnI2AxhyM42nOBn8DzSwM0Ui24EaBCTsH8LMwOPQ8459KrXk7GPfBGpaElQB0wRnAz9Onsavoc28tCaQ4lkD5YOw3beCPm5I/OqVzbNIrHc5YAbiowGYN6evzfqasuv2iL92P30a5QjBJAJHI+mMj3FJcoTBwdzqilO2/jp+pz9KGUnYpQwmK+hV1kaK2T5yF+73A/+t7VKzmJJopnzGc+XxjuPl6de456inO/mW0rzytG0kZCox6AjqPpjv70v2lbbyYchmD7cKDypGenXAA9qnYerJy3m26xxSRo7KArMCVPI+b1OQcY/wAKdF86F0ilURNhncZznr9T2/GmupeOVm+VVJBLNjOTk7QfuhuuB19anIZmJhIBcYUOCowV5AB4Jx0/+uKe5BZ0sO8ruYlEsB8qEJIXBJ+8QT1B4/I1AhU6jNGkjKiR5BD55btn6nP86sxMiWmUOyKL5EYN8oyeF57+/XrWfHcoNQvWiViHRGYxDHl/MuTjPJAA5HBz04oIte5JqJM2rSJ5nyRRKitjIUnJ6HoOlcV4x0fzr8yqdiKAJAXLEAn/AMdXPOPau2t7/wA8r5/lrLNcF3WU4ESjpkY+9tHQ9Kw9UmgmiuDAZGe9YxxHORtLFMMTxwvOal6oqCaZ5XFDLY6iFmAIy2EkGwE45AP45H4it6504TvJ5AaGM2iusUihTLg7UZs8Zxk/T3pfFsE0V9G7+WDpxUR7hnfGCDubsxOSCe4AOOa63w/bLdySMiF4ooUUJI2Sw52qD6BTz7Cpj2LnpqcFHpsElnIGkcMkpU7RujAYBuSOnGa59rC+VisM7LEDhFIxgdhXr0toNKnS3AKteFPNkGD8yuCX46AqcD2xWLdJBcXM00do4jkcuo+boTkUS02HHU6PSNNjt440jUDbzwOmO1bH2cBdzHGD1A6VPBEo65VhnknpViMbj935gCCuM8dxVJGXMR26YAK4DKcj0JxVoOfOZ2BRQAXA52ns/wBO3FMjQRLC5IaJ85wc4Q9cn0HWnwymKQlnzuBVT2I7Z/wqidwkEn7x4wMqBu2nKsOoyO44qjc27xbZFQ7dobC84HXgf0raVTbSAxnehGeDynt9O4qk2C5Mbsox9zPHXt/hQ0VCRnrIsoUpvZc525xx7H/OKqzkruRThc5RSefbp0/CtC4ROWQBZB98dMn1H+FZt6mYio+90688/wA6k1TRQbIZvl2s3Jyck98e+OKinbHy7mGegxjJ/wA9KJZNmTIRj1Of1/8ArVkXWo+XIqxnc+dx5wBjue2AKC3cvSyhVYyHqdoAPYdT15rB1PUdpaTIyoJ/E+3piorrVBMpYNsQjaPmxxjv9eT+NcJ4r1+OwtGZmDu3yogPJan5Izfuq7KHjDxCYi8ceTcTZ25/hHTJ+lcnpFobm5jQ87m+Ynvn+tZqSS3l08s7l5XO5j/T6V6P4C0vL73RSZAMZHQVoo20MYy5nzHWeFtMht7fKhcovOe+OuPfI/KtXxJbpPATHgh1Izk8ZGf55q9aWYtVSMudh7lQRj/HNNnDjTiEBcCTAfuowf8AGqbtoaOC3PNvB1//AGL4lltXK+XcHfHnpuxyP8+le2WEnmKrqQxcZ4bH4k14d420wxXUM8IMbqdwwCSCOeMV6X4B1ddS06JpQFuAdsiKcfN+PY8EVKZrRlpY9MtGJtN0b4TGN24qfmAyOvTgZz1/Os/UIyzOEUjbnA7qf6Yq7p6F7NnZjtGNyNzuHXr26elVrldnMY78sDwfSky4O0nYzLjeJPOLKspzuYDrkc/ryPQ1nySXMUiocsu/c2DgZz93PbPJ98VpXLgJ8+MdAMf0rLvdxgbe4whDHJ+X0zn8hUtHTF9xJbkxabJfWsmyYXA2bUYjeM4kZSTwBkMV+7+VZmq6hJai4eS4SKC7CMFiCsk5xnqMbmJ/nzU8cLgGOeGR2DF2xMCgjKfOMjoGC9j2rE06znnijuFYRQOzloeMEDDLz1UkYHGDwR0ppGE2lItaZBttzei3cG4AgIkLEpEx/wCWZJxuPAJIxmtjS0bEsh2rnCMVbbs9Bj+IY4pUhY26oxYDKsoyBjnB4P3ucHHbrV20hZ90K7XVAXdYwPlbufTHOBTl5ErrcqXqeVNDuWNVbnOSzZ/9lB649jWlbyrcSwxeaRGgycAA4AOOR1+v4VV1i3EYh+XLRDcw3jgHIGO5+n1zUWnjaA5UEDIA6ZGD17nk1HUb1jc3huTzGJJzFkZUADMecZ9SV+lRzTqJ5rcMxdwJlwCe3zcD05/Dmo4kTzo9w5EeAD7g8AHsCecU1yxAODGxB5PRSpxnp0Yf1quhzFq2DpbtJbxncMYMsmCM4Bxjk4+T+frSRyeVK0eVyHwCi8ncMYPp64pbUkboroswdd+UA44z1PvUUbTJJGLjGZMsXQAgdy2PQEL9OR6UAJJDbs8PDtuAKhgclTxyfrkevANUblobaBw9xKIMIF2DG7rtyfc4IH0Bqf53nJmVooS25mA/1akYyhJ9RnvTGO1JI5YokVH8q7CjIbYeGUHqG+U4H4YxSZotA3qLSSYyxG2LK0UkmNoHACOM8Kc5BHIP0NX/ALQrRgQMq5AUq2fMVsYZdvUE9NxxyMjrWMYvOt9txuMDHzowcNtDH5ii9PvZyT03dqtx2W1Wddwm2/MwJDf3cFjncDjPfBHFIJJdTR0jdcWySXEvmNbny23cswHIYY6HBBGBzk1TjlWeS6itXTyZHHmEdGUHO1T0PTOBz1rI1SS9SeFw0vk3GY5Y1i5ZQSVcYPBGT6dx3FT2N21hbRWyYnjkHyPHJhTzklflyPb05FK6FydTd1WXy3hlBPlpIu47iTzlfMBPXrz379Ky4pVudWYkExW6vDEMnqHx+BPPI6DHtWdq5up5IbO2uporZW3uColZQcqF3AA45OTwMGtXQ7G30v7QqRgzIAiqCTsbGQyP168857ijdi5bRK0uiw3zatFcxMVxnOeNjLge4XggdzWlcWEdhORBI4toQN5AwpAXBwe3A5HqahhMwtpbsKoDAKsYlyzAMMLjGQO/uT71Vvr+51K4WwhS2ihdjvG5m8xxyQTjgDA49jmjRCs2/IbrOp2wsmlt2VGuYvJjLDjZn73X0yfxAqpDJq5hQwi58oqNmCF47cY4+lR2sMcurSpm2ngt18qIEHMzZzIB04BwM+nStpodYZiYtVhgjJysWxDsHZfw6VO+rNFFJf5m1GyThgrYcfxHjn3qUy8xg/JMCE56D2Pt6VEYg6eZE2HwNw9fT8aWGVZE2uvI4I5HHcH3HUVqkcovnSxI7Iy5JberLzk9eP8AOetKjkwr8gKjktnke5qOESx3aysfMBAAyMFyOhz6ipApEnmoAFYZPPT2xSLVidZERR5nQAD/AHT+NQyhX4VmBJ5JGBVedwx3gjGSWBHPPcGq5uHQnBO0jkgAj/8AXSLUexJdHBJY4J6kdazLu4KuEUr5mMg9wP8APFPurrzMlj8oGcH9KwLq9Ls23cQrbScfyNI0jHuSXkhwwA46j/CuX1bI8xyVbPy5z1AI449z+la13diJWkzgDjJ5rznxp4lSwtiFw0rAiOPIyf8A61O1xOfLqxfEOvxafbEuxPUKoOSx9AP84ryy/vZ9RunuLlsvjCqOir6Co768lvbo3F0xZzwMDhR6AdqdaRF8ttzt5raMeU4alV1HZbGxo1nlwGTdISCF6ZOcDn8etex+GLf7MZ0DRusblFmUZ8zB5K5/hyOPzrgPDUDQ6VJKwiEc8nkjBzKdoDYA7LyPqeK9L0eNI4UEhKSOu35juPYD/wDVSvqb0kaiMYwkYyVLbD82D1yM1OsO3cSyhy4VcNu2sPWqkkSMHcGQYzliPT/I5qbDSRZ5Vgw+fOMk8E/UEg1J1SWhheMLJZLLzCV3+Yp2r+uPyqW1s5dJe21K3yYQqpcpjqo/5acd17+1WfELLLpe1icPIgJ7k7ufr0/nXR6SRIkkb5IY565HPHTsPar3RlT91tnWaK6T2ErliQVGAP4vfPpVG+mVHwueR3PXp/8AWqjowfShNA+94Ezs287V7D3APTviqV9esQZGQI+Bhc5weuPr6VDZrTi+Z9gubpTOYwzE9Dn1qrclhwDyTjaBkfQ/TrWbHLH5m5n+UgnIyAP8RSX2oOXBgk2zSKx3CTGB90n6Y3VJ1PTRFEzi71CDTmI8p+J94JBi3ZwADyT0A966jTIgFkEnmcqdoPzNIwbjJA+8evGOmOa57wrpryX8F9E3+ixN5cUrtyj4+Yjv8pGB9K7G0jZLQzcmQgxxr2DHGCT2xkn6iqjojmqNOVyLyZUv5ImGXhWT92HwQQDjtg47455qTTpESZtj5iYJlFPzNgfMp9QDketVYpTHLHMFKhmfJbJ2A4GQfUnP0qHzRbSskRYQsQ231OP/ANfNS5GkYXRb1CeKS+kk8p9iYjBZ/wDWHByqgdhuUH6+1RQbFCrg/wCrVhwMgkZI/DiqNoEcLIytlpCS2Txg8EfX+tWGnIc/MiiPChVXovP549TzQu5nNW0RqSKqfI65c+WzkjOUP3vyySPcVGrny3QkGZpCyfOSpHTLfgO3vUE8uy8LBiDGhAbG4HgbT9MjH406Rsscqj7lzySSV54BHfv74pmVjRuZzEjmJsqsfC55OPu7s/QjPr2qGKcbo0WTGF3BlI747npnp9cetUpjEkMR8oy7CRuKl9ygYYY98r196ZZPHcB4oUVoiucEk7hxnGfUAHHbFJvUEtC3ME2zbZkLb/3MYJAc9WQdtoHJ98GobUmW8inWTZHD8jHBJAUEHPZuOCeOnrS26wxobckqkZ/d+YMqydMn34HPYj3q5DGqMiqB5jkA7c5k7ZGfQjP6Uh3sMRooYzaJEQ8RHlmMk44zn2BUnd+tWFUqJVkJjOQwIypAPfPbg4J9uOahZJhcF4yFkYsHby+EyOqnu2RnB4HP4yNIU8uOZgZnQlYlIJmJyMnHT1APQ59hTJepBBafZ0w7+TEoOQwP7xtx25YnOcHjmqSQtGkzW1uVt3ziOY/6wKfmKt/DycAHjNK9wb6WWUxn+zocmGTOfMHHIHoOOfXpTrKaaPUrmGYRrHDcHylIxzjKlT0I5YY/E1BVmiikiWLXSyxzSPOo3rMjLKrMMjHY9F9AcHHNSrcQm08q2W4nnYCMhAGG4/6zJ7HPOOxNbqhFj3urTNKwCKBjGR8v4cMfYmqdzpdvHC91bkRPsViqMVdsdCHXnOTjBz70WDmRSnE90giz9ntdoIRSAwwcDJ6kZ6cADFOksY76CS2iCHe371UB2wxKODnqT3680txfyoAUKiRxgtJbKxQ9lBGPc49ia0bBHjtSHuZo2QDefKjDOv1546jIotcHdD7a0SwtYol8iRI3BUyrtJP+0emGHepk2FFJTTskfxt8348daSJT9pa9uiXQISBOwPl8enQDp9cVjM+jyMXl0fUp5GOWlFxIN57tjPfrVWElfc3YHktJxbNyh/1Z7kf3fqP1qzdKsuJQqo69G3ZVvY/jU2rWvmKASC4+ZWH6VHZyJ5O51GCctx0PT8qu3Q5lLqJZzo0DRFSSWwcnkHsM0T+ah2lVAJ3Bt3T3+tI8IMiS54PXB6ehqaQpnadoZe/TP40mUnqUZ0IBOfnwSOOP/wBdZ80u0ncACRz2/SrlxMELKwGCc8jGKwrq5+djwADxnjA/rUM6Iai3jgIx3EDsoxx9KwL+62gscbW6Y5zUl5eEDggY6A9Ae9cdr2sRWkcsksqgIDyxwB70DcuUr+KtdjsbSSWV8KoztHfPQD3NeNanfTahetdXGBI3AUfwjsKs+INYl1a781yRCp/dof8A0LHqazAGPHU+p610Qhy6s8+rV53ZbEkKmR8Lgk+tddounvLDthgZxtJLEYyemfoPSsPSLRnlX5QST8oI4r07RLMWqxvjcSACA3CDuT/hTepMdDJ0W18ueKERSOhXzFDjBVhjcPpnp3rutLeNppZHlSN0YRqJTtYhc8fmT+QqjLD5EzsqqCMtu75PQe1WrOGJLaGLyzMxTLO2Cfr+JzWTR2UnZnSpcKrZRMvtDMC/fpkVHlo0YSFZo3UZx3zkg/jjr7UqsgQSDaUZMKR3Xjp6dqYk/mG0RoZCmPLIDAEDOR/M0upu9jA8UXax3WnqgwFmEuFORwMgc/71dVoF0hkWTIOUXHfPfj3/AFzXAeKZpDfQudyiIlFDYJ2gY59DxW1o1+YFT7zLjhgSSR2q7mVPdo7++mDM8kLck8HqPU5HX9KxL+RpH2kFs8Me2fY1ALsu5wgAY5JHHbvTp5lERb5jkYY+3+RWb1Z1U/dKk6OqsIiZG2gbQcYPXPPbqffNPbS5G0Oa5nVRDcP5EVwxMQLYzgY5GSDgDqe+DVjR7VLm/LTFtgIRW5G+UE7foM8Z6nPoK7HWtPjkj0oLMyWv2opHFzwQcKxVQd2W3KCeBjNUokVatmohoOhi3sI496SLGiRyQO5MiqP4jj35x61WvnjMqxrMzIocyYXgsT1I9MgADjp1rakNq9pdrc26NCgKom4swYnBLN2JOOc9qyWiLKg8x1WZ/wCMhgrDJLH6YC89c5pyM6erbZWljzO6AkMyqGYfKo4zz+J4NNuol+yybESNlTcCGALZwuAO/XPSpgPLJkJCtlSR93HHsOBx0HrVW8kRpYF2uABvwQM4UdsHPUn34rM3bewqoGQRhg+QVIA+VcHgY6+/0qnOokcoBgNGTkHHJJ5/X9Ktln8xQrDhhjadwG7t9RgVmXuAx2zeWJEZVkAHy+9UZNm7Hav9nlklCBgmQrYyCTnjH1yPpVCKV0nSOGRTDvEaEjK7lPBPocHGaSe6eayKrIS6xkohAAJHHHqPX61VtJWt7xijLvR1+ZcqoVvuse3X9D7UNkK7WpPMDFMsJZBJcAqY5k+VlyCW/wC+gvUc1YDwhJZJIYkUBpFAzyM/MpxzwSwJzzxj0qldSCSzSWORQwABCgnbnJLAHr0VffBq7bm3jlRU3RqXwoLfOex+uOOO9LdjEkFt5WbhTCkLPE74LNg9Gx6MCpH/ANajzp72JYbdWhLITluB1GQM8nBxnGOx61Wa8e5QRWqkQoB+5fkIN2Nwz19d2cDt1NW45JrneYog6rsUliPmJ4A29hjA49KRVurLLSR/ZHZSIc8eWQUZQOoBHO4kZx3xxUd1tG+NvlW5bYrhSSydXOfQhScgcHr60yGZAzPcZFxGG8yRuAzAhc+yk4wOxz71BG0o1KJ3shKoSQkg7Qpyoxn8+nqfSgVjeMULp+6kSXBGwY+/z6HhQcZz0zWJqBaO6lQx+d5vIIfZtO7ax5/iAC5/POKvvqWnvaNskkZlQFVWP5mXOQCR125PNVJ7iOcyFJWMh5BYhFUEYBB5Lg89qGKKYJeRWV1HJKXGdyrtQqVz12L0wDk8dmYelaMWoWE4ja3uYBH/AMtQrqQnGNoDcjODiubuRLGs2ZXWMyAgbioz0yMjGPp+VQ3d3PEhiuIoJHLMZJlfczH0DDrjAPv1FK9iuQ3rm+tmmUGRXjkkUpFxuOBy3rzwPf8ACq7ajH9oR2H2l4FZliizHHtJ5w3fP3gT0I6VTtZIxvAkOUXaHZDFtPU7WHLH0zirNtpESGPdOHcso+TnnHY/hxSdxcqRZnF3q90gmkm+z8DbFCQmOpx3JPPXFU1tkKgpHGFxxugAOPfnrUs8j/ZriW0Mk4lxF+9+Ta5O3PJ5B5zjJHOKjOn3pOWjlZjySspAJ9qGXFWR1qzb0Iz0HAyeKrxsBPKqnKuMjjjPpVCOYRnYGDHkipx85VwRlDux68c1qzgasa8e1UIzkD171TvpCiBsjOenf65qH7QVOCc55qne3YEZB+maTZUFqUrlnKEFgDnOPpXO6hdCNeG+bPWrd/qAXccg561xGt6ukLu7EYX2HHeoOq9hPEWqC1tnYso2rk5PT1rxvxDrUuq3OFLC1U5VTxuPqfzqfxTr8mrXDxRti1Bzgf8ALQ+v0rn85OODn0710U4W1ZwVq3M7IcTnr+dXdPt/OkHB61Wt4mkcY/PFdboFgQRI7IsY4y39BVSZjFG5oGmLGY2fJyCSMckD0FdbaTSq8K28MSy5B8yQZ2gei9CSO/asyNBHDG7Sj7uTtGNw9BWjG+brzbjKBgEAHRUH8P8Aie9RexqkWZw8puJZGAByATztBGCeO/NJalZdJaSNju8kjPAI2g9aZf5aRYov9Qyh3Y88kYApkQNrBIkSYeWJnVT7D7x9BUyN46G8kxex84bCGi+Yk4AGM8D1FOk8qOO2A3neyOvOc55H6H9Kp6S+2BYLhsEW/YY345G3HsfxpwmaZrY5CJG4XzOgDE8AH2/xqOp0xdzlvFztBqOYht2OGII+XkZ/xrU0OP7TCjWxJHUoT936e1SeIbGa6WSMREfIGDk9OTXI6DqVxpGo/ZJQ7bD93OGYe3vTT6MiSs7o9GWGXlnQAqASTjkZ9a0LbTLi5bdcsILY5BQD95IMj16A9Pas/SdStptpkChx0WTOcdz6ccV0MN15x2pHuYAc4+8Px/nTsjSMmaGjwxG+igtYTLsYHYpOMZwTn2OOvWuh1a6ENtZrLdxKtqI5zPGpbzWVWBXJ7ls4BHbisG0WKwgjjd/9MeTe7xtgqONvPcf4VE99PdNFHHNIjpcxB2QKAAm47zkYyQMY74Jp3FKHNK/Q6PVdkluLNZDHhcsIwBnAGwsfUZb25rPu444ZZo7dztbfjYMhk2AHjjnKk59+9V5dsonmeQASMTJgfMzHDEDHBIGTzimXAiMhjtZUmRS2yZ1KeZwDz3HJ49yO1SyqceXS4zfFbNmUZZiASwz2GeB654qipEk8gyzJtwVAIyCw70FmQuY0Cqm1y6gBu/yewz6U+3AMrguiH5UUAEmTOM8e361K1Lk7DdxtwLhlDFZCWLHbgg5x79/0rLmaC7t5HUk8k8dW78fXFaJYNC2QMyN27MMc4PY8H9DWdZj5JcRiKYRlwc8E4yfzwwPocVV+hA+1a2ktERdxdnxySSc88DvnPT6VHcJK9tLatcyIJEILgZYBWGw4PIBGangik8lJNuZVhLxnHIIBP4HP86rRPGpa7jKOnk8F/mMYOOQfQHafxNJ6B6FmGdZPI8+Y+cu6JmjHJK4UE9jwRk066hbzBJtURyOEAII3ZyQOfunKkcdwPUVWso7aP5dwjLSBUWNciJiDgDJzggYIPXirU+WvVjnudoiO5sMflKldo+ikZwfb1pdAWjJVlm84SJK7RquXLIAGdiCzKD0HIyOQNvHWrNuqxSOl5McMhBYcbQWxkj06c/8A1qithLFGLaGIJHKHjMYbJiOCMjn7rAjAPTGelWUjCf6zfJvQEhMckZOMjvtzz320CbBIR5qiV0VnTmPoznptB6EkHP4e9NvW8qSAnpudOpUDcOCf+Brn/gVRh0WKS5njdo42K5JAXJAx9Mj+RonS5mt8GcK0jqC4HDY5UY6j7o4Pf6Ug6l2EGW4hE6RsPKYbkOcrnqfbOMDqcDtWo9pG1wGlZX8gZ2xhORjjPHTJz+J9Kx5fPgjleIFpM7ZF4bdHySQcckcjPcEHtUV9ePb+XFBB5zocrv4VE6kFv7p796q6E03sXggu4poFLvMoZVUjkp3Bz/EoyPfIPvSLEfs7LiKNcRrJhQu4A/ISPXgA98impcIIWlWJklGC27G5GU46Z7fd98Ke9OmvbWKIm3uI22ScQ5zgHqzZ5HPrQIs2MKiBYook3AEiNwCzZGSwPqCTgnjHFRF7WSWVhF5dtGfmfaf3vsSv9Oaz5r8xFxiR7aT5nhC7wuem7H3Rntnj3qWX7detGbkxxxpHkNknK4xnPcnpkelK/YFHuVNaurBZIjEs8skSl5vLc46YClvXJGcdavC2lIzNqUSy/wAYW64B74+WopoHEMLy+UkdvIrLgHO0MCSeenQ81BK135r/AOnIvzH5Xl5Hsfl61N2apJqyLCuDx0U4wfbsKmW5EbYPJ6c9h/hSEbpMJ8ynIYH0pWiUk7X6DOSOh/wqzi3HmcEEEHYDkE1iajdhOA2R6561ZuXaFCrE7jjrXK65fLDHknJwc5PT2+tDNKaSMvXtS2QMFb5sd/51474q11r+V4IW/c5xI4PDHP3R7DHXvWn448RPNK9nbuc9ZGz0Hpn1riSegXHHGMVpSh1Zz4itd8qELe/0NOQEuB1HQ8VGcluoz2rR022LyZ2nj+VbM5VqX9Mtd23dwcdTXaaRaR/Zkcggx9Bjr7msnTLZchVAckAEeldPbkGN1hPzkc8VkzaKCSY/OkKlSoA3P93r2FaMLqgi8wZBIweuaqOuYYzMMk4Hy9QatadPJiJpFVXYgZA+63t71Jexdt7jzrdnCkM4JQPwQQatKkdxa5jdi5GFfPJHfHtVOFA9lMJkJx8pOcYGen1/nVqBg19JEMqvl8ydNo64x60GiJ5zJ9lPmorxIzKVBwFBGPwxwePWq9kjTWTQTPlM7ccAkg8Ee/erdwyBzCBtt5YWIHcMR938ulVtIAknkgm+SSICQOMZbd/k/iam12bwlY0bXMoimJ2xRAxysRy2TwPr71i+IfCM9+0bxgC4kyUfj5j2H6GrkVwTdSwRIxa2k4LchlJ+7/MitXywYkkVyX3glCM4VecemQQaV9Cnc4PS9em0yUW2rQLjOBLGmD/wLoPxr0Sw12F4EMZDFvlDdvpTb3RbXULWQzwxrI2GUBByDzjd/L61zUng1ba4nn0++mt4YgCwH8eTjGB79RVq6Ji0tzsZtRXiWQLiPGwOmenQEDt7mrPh27ZI5pcbYboF3Rz8rsDtDcdMAHA9ya5ey0hlthLc3l1PDuMWOFzwDyB0rXti9pAY9ryLwF/2VI4I/wAcVL01ZtpLQ6K9ug6gIYViUnlFOHzgk47jOKitruKbe6uFVZCElDsdnykYwMcjOB+VZ9jeSSQFVTcFGGYrjI/kfpWm0kUaTSlZGZgWYZH3uo/LrkVO+qK+FWK+55FMrJiRTnAGB8uTg+uSRUSXJjnNyGdd5bfIecjvkdh0ojuTHYlmRgyONpVsgknJYj3xVaK4juI4mKhArhCHbHy7gMYAGOM9fammDQ+GYRJC25lzsI3qR8u5Rhience2KqXchaELNyEBxIP4QONoxwQQc/l3FSMws7K1t5CTuVxEzc5O4HB56t/Me9VNQdbhQ4kdQ64AUZA3YHI46Ht1HvSuK2tyW3KyFfmJdpQFVf7vBz/OmJDCxYbV3PJlMniPjaCw7E5HseT2qMs73Lcg+VtAKHGcjOFx0OVP4nFWUkt/s5Z0YIoAk/2gCenpxj+VIRYmO6Z7eJArN1VR8z9Qd30IPPrg5qrZq4LW0scbThSzMqkpKc9SDyAVA6f3cVLM6oNsSl2Te4kVyOM5BH5EH61Cs06W0gMZWJZCsxZcMylsbsj+7kcepJoHFaGyyEo1yeIm8t5F4CpkYJPfg+lL589vC088bMXyEfH3GUhgP94YBz6c+tQ2soTMcbMuxGjDdRhhyCe+QBjHcA9adHLJKn+lRs0TRhomJyc4I5B68YIz6UybdyMvl8Dy4YSoLgt0yeB9RypP0qS3WOW4lSNUMWVEijk9On1+mORSW0kFpDcSkqZnYpsdN2A2Fx7ctnHPANRW8ccYght5ChD8/LgFmzhiOvJzyM46EdKkZrQt/wAfK3EQZipyATk5PHsr842985qR/LaLZOXEiHPnSDAUdMgDtz07ZOeBVNg5eKBVT5UKyyFSwRie/Xjk4PY5xVe6PkxbUU7lkP8ArFbqPlZQevzZHrTISLsoQvaw2sf7/AZyWyo4IOM8AdQT/DnvThBBLtO4S/xKknzArnlcnk49/wAKoXV7dhJFZPMlRgkaNHkyADjK8ZxjHB49Kgmu4r2YmaFz50SswhYFS2M7fm56kZFF0NRZrWqQLNJKuTZ5JjABC+nI74wRj2qXm0ie4gmSFV6LjcrN3wPftjr6Vl3F5dpYrDFYlBJMBhXy4cfN90eo6+hpRbvNCtzNPidS4KuQ3lsh5Cgduh98npQn2Hy9y68jXFvKSpiSXG3aAw246SemT27d80R6hbRxqi31wAoAA8pGx+Pf61Wt9QeTy8R+a27iBiQNxPzMx64B5yOamIZSVa3UkcElOfx5o07lJW0Zq/Z8MJAB6ZK1DM5SNuBuY9uBVS71LYhLOgwMKM5PtXP6n4kt4YG86QDHUg9KtHBZj9b1OOJZOgXBz/8AW968a8d+Kj5j2tqw87+Ijon/ANeoPG3jl7yeS30mRhHyGmP8l/xrz1mJJOSSeSSc5PrWkKbesjOrXUVyw3GO2SxJJySSe5JpnPXnn04pG5P/ANakXkjnr61schPbwtIflByOeeldTotoW8sHjPU1j6TD0ODjrXY6TATliDgjis5M1gi5ZwC1RXlwN/Ix6e9XHR94aOQgN0A4FSKEIRXBGFx060+dlljiCEAKOh7ms2dCQ6FQojXJU9Vz6+9S2+/eFMgG0mQ89Md/pSRyAwxkJvKjacimkI8kbhdjM4Ur+PApDZoxzI/nyKXMWcgP/Ee+Pyq3BLI8Dv2IPyj+IjpWWiskbFhmMEgBRksQeefStG0ysfyqAU5GTxg8dfWmxxL0UqyWgSWJ/ugKCPfg/nxWbbW7QahJMSzIQFidug54HsfeppbmTIdxJEsZZQEGBknPPt6VNE0l3bndzEk7o6qcbVXGB/XPvS3NEyOyvIGv7mWTasj+UhYknLctgge1bGl3zRxsgfBkXcVkHKkn5Sf1+orjNLuRC11I6CaaactIuOcYwp9Ofb0rpNICvbNPOGkuvOBkP3Qz9h7lQAKjc0i77nW27iSFdxJUgBlAGM5GCP5VVu0W4ISME7j8yjrnPSm6dIZNPgJPLcHtwe+Prio5cyXLSRnacAjOeoJ596tMpLULthCSyCJY2UKcrjPA79vX65qCC/DDa5O3O1RnnHXGOvSr2pjzbUMu0EkAj0PqR7etYsls2WKMUYMBlPu4Pr/Tv6UTbWxcbGzawqiEo3ljcGBbqB7fhV3fuiMKhQZBwVGW29eg+gqjaho4UVZcKABll3Ar2JHU4x9aWCeOSVFuXcxbgG8kfOVwenv9alJDuW/NMsaRwKkgMyuO4yE7n0Pp61lQyM+oWrSkQqQU4580A4O78OB7VPNLM9vbqkW0xS4KMp28gZOR1HHPvWaUjj8yXzgsv3WZSd+SSGHPQDA496TeuhcEbl5KrxRG2QIX/dyk/dAB+ZgfYgHjgjnrmsrUEWFiJppHJG9224wAQCOOh9/TmrYkw+2NVgt4uQWXIPJHTtx19evaqEsaPcCJnRQgIUgbizEHp+Hb2oYrWRNatFEq4jeZl27gcAMRyV/kQakW6Tfc5dRHGqklv4fmIxz/ABAZ4981VF1EXu5vvqPL2Aj72Bjn/Pai3QlIlvuPMdj935Y88kY79M569PSgVu5rRM9ubUKVMzKVLhcFQR1+nUimTSzWsbMysw3hQR8oLN7+hx37iqunXTXm0w78DehOMFSgPJOPTBA9DV+3jMhgmmPllQH2ghg+cY5Pccmj0FtuLJPNhf3O8yqE2ocFYwBgk9zjjP8AsirEqGGOEy5+TghwCpUHjPckZ/KqyXn75VX90u/BOMheuMY7dcexNR3kxklnlLlVhG4dGDA8kc/Tr9RSbBIdFIlyPOnfYYhsdsblEmCd3HbGBmrdtIjmGFYPNXBdmLEmMY+bDAdBjNZFhbyLukulnaRSpIYMFkY8kjtjBHPTIq5dSxRPcNB5iBBwVdv3bEcr9SMZHbApJ9Qa7F6Wb7K8sfliZnTmRG+ZPc47kD/x2pI0e3aE3SB7iSTAZsMq8fd/LgHvgVQsg0UbXEPmRs5AKyDcAp5Clu2T6+2KlC3OIjtgmuH6hdwG7P3c85z8vHHWmKxdn865u5EhebaZS6MzY7cn6kE5bocCmGKOGSDyCWlDDy2CAhgBznPQjkZ96rwn7PFIk1zB5wyTICSqFT09MAY6cfrVud5FhVYFEjTt8ysuBIRwScHgjII9uvagFoMmmiYNLCpywIgi3nIXII5HTdyc9uBVIyzSaiouwJXuOT2Leyt/DgHPvznmp7OVIPLER3vsz5gHBXGSMenrj1qvLKzEhQ2A+VV1+4wJwAByc9McD1pMcdC7ZJDYW0yqybxjcCNxPPpz69e+farAvlx8uqeWvZCG+UenFYInjWCeZiwjTCgrghc9ck++egPPeqZ1PxC53Q2sYiblAwYkDtnikpF8l9zlta1/aGEa4KjLFjk47k//AFzXlPiTxDLqEjxxylou7DgGq/iHXpdUYxp+7tBnC/3vrWHnJx0rrhTtqzxqtdvSIpfsB24qMkZ65460ZHTkc9+Kjz7tx39q1OcVuG6/jU9rFuYc9fyqsRyMYyK0dPTeQWPepGjd0mEFVduFHBOOK6u2cAKiZIIzmsXSIQEZJEwjdBW5b/6wAKMAdPWs5G8C+6EIkgbdG2dmOpx1qBkLEA8KOdw/hpWJMcQZW3YyMelKriSHdGWQ9SGHPX0rNm0WW13sFKk+Wq5Jx60wsDCF+YspyPr/AI0b2EZUDtxnvikj3MuGkGSScnoTjofSkMswXYVSsxBYx7Fi7L+P+eTUqyiK9cJG8jcNgngAev8AhWSC0cbSHCAHB575rRtDI0kkjMiyMOB+FMaNF5QscvLGYDg56E8foM/lVS6mfT5VCHMM2N4AwoYAAH8eM+4FW7eYSxqzHdlQDJjjPTGPSqNyWuFug7rttyVKyDgk85+mMD602VczVlSO78xJAxiUoFVjluuAB/tZ4P6V0OlTSW0thbvhQJRI65zufaQR9ea5ZZAXghjkIVHYRRtGCRzlnZRnDeme3ety0dJLy2iSQOgkRGONpYfMzfTOQKjqVBnVyv5MaWjnMLyhSScFo87vwOAR+VTLcBdpT+LJBJxgFsjj8/oayLu4WcBomLzApkNgKQSQM+nr+HvT7e7KyCV97N3Zx905zz2z14p31Nlqb91Kq2u7ICE43MejDp+JqsimY+YSQScAkjPoMg/oaEn225D+W/HyGM53HOMUjMpdg6q4UnO3uOCFpspE0vmpC5aPIbPJ+9n0P+NV42kKSIiErtJUhsY45H0zVpp1NsYz8zFhtdWwcdOB1P8AQZqKM+YiJy0S7gPL5Oe5PrU2KRLOGURfaixETqNh/jPPJHfpUL7kmMP2cNK0JzlgpTHQjswxilmCw7oY59064ZFbLK4I6E/TGe9VLl2BiEbxvLIuZCvGwjqq+wx27Gg0grmgPN3xpMo2kCVS2OhGdhx7Akd6zrplKlmUKiS7V+UAKp6N+G3/ADmpooykEikh1Y7EDDIGRkH/AHuetRBXurwBQHjQlc525Xb8y/jnFIHoLBco0hjaJXiihQY6FjgYYe3qfrzxVtXYy7sl432ImBhMjAxnucEZ9fxrNf5vOldABEjCBQOfuqeD16p9Dz61ZmMEcNysrsQqgoxcDrjAGOpCnn6UGbRYgMcZWKzkwGkwEA+9nofXpirXnebbOIUMphhy6AcEZyW/Dsazra7UG32yfdhyqcDY6scf48Z9KLR5pLacbBGm5yR0IUHGAfqSP0pXKt3L4KO0ktgowsXRxncpHykHqCf8D0olUiCU4UhwWBAxubH7w+3rj1NPtMW8rT3KB5SAysuMr8uQQBwQSen8PNRSLM32g4HybSpzg7C4BI9cHGPakJF64vpoAqRNvzujYopLMmMnk9OMe3B71UunS0tItyqoBVCqYzhzgruPLdgG64xQxlieRpdyqBuLqSSdpyNpHTP6VMYIhCksux4ydrea2cg9ASegH/6qYrJDkmQysYpDFbhmZQpbkHou0dsA9fSi2uJLiMlAFEqZKlfmRRySD2ySOKVreN4ncRJHDcYiAmGAq9Q/Ptk+xFWpdQUynLgiVzgvwofgEDHY46ng8GgNxt1CqWaSGb94pDxmPkEddreozkY9/rSxfvfKkdAFdNoRc7o2Xrx/Fx/KpJIECEjZJHJuV1HO0NyScdsjr602ffJMeV80MEOTmQk9GB9M/wAjTBbFGOZo7rESqZZN8kUSfLnAyQT2GM4PfkU+43PASJFMko2njBQ8YU+xyMHpx3zVl4ojCI1RFllwqkcqGB5Bz0P+Paqdxe3dlKkdxKcOVSJ9uF2oMRjceg6DPt7VOxW+xJdWsQuQ2VGwHeQ2FdhjPXp7dhWj9v1dPlSKF1XgMU5YevWq9tBEqOJUjlkfG+Q5/d5+8CO/rn6CtF7ydXZfs5fBxuDEBvfFO1hPXzPionJ7j1pmQTz1pD1/D+lIOrfSu4+fEz7gDBpD3zSP/T/Cj/lm34UgE6sMeta2kf6+sk9B9RWtp/8Arh9aQztLIRG3ADkgryfQ1owsEgOxdxUfKf71ZumAFUBAwV5q/bf6t/as5G8TRBy6HdjcM49KIAxdomx36HrTIvvkdqmtwDqDgjgcD8qhm0dhrbPLEm0kqAMe/rVgRo8LxIir8pP+9nvVOP8A1U/+9Vm1/wBbF/1y/rSLKbIQpjwSTlVTqdwq7b+cnlwKFLgDryT6nNRW/MpJ6/Mc1Jbki4yODgdKOgdSae6ECE22DK7bSzDKpg+nc+1O1S7jeCcKjwtKI4yMAsoLgcntnn8qrPzK5PJ80fzpNZ/48bw98xH8s076FWMt1ksL2y8kMkqOyBkO1gQTjp9etbOgOzavJIWV0RSCVXIYZO76devTisiAkx2pPJ8uQ5PrtFbHhID7ZccdZLcH3G0H+dS9whubkUayXFxFtWUNJIHJ4VIwu0HPrxx70lvFje24pPDwX56+p9QRmotJJ+wXByctIcn1+c1YvJHEbMGbcUXnP+yaXS50R0ZcjnYMgSFXZgSrL8oYDrlTwDz268fWljuMscbzwAWHBXpgY9e1U7LmazJ6lgT+Oc/yFXrxQFkwB/rPT/ZNG6NkW7qbakET5dA5VTkf3emfpTIt1xFHJbsFUgokY/h9c/XBqrMS1toqsSVaWQkHoflqVhsufk+X5o+nHak97AloJJIFuI4bdpUcurYUEk/KRxjv15FSK2GjYFViKjezfx9jz1plmzCNmBIZVXaQeR8w6fnS678kabPl+Xtx/wAth/iaDSPxcpL5xhXbHKJGWNUjcMGAHQEHuP5YqANF5fktkMUSZjk8kgYPHXPPt1q4qqJ7UBRj6f7D1S3Etbgkkebtx7bs4+maBS3HXUb3MpUbSm0AA5AYj+QwRUF3yztFhl+UKpyMkjBA9OCD+HvTN7bLf5j9w9/ZqjtudOhz/wA8ifx2vz+g/KpZKXUvQuJLiWSKJdoBIQEAlWwOB3O4qwHXGSKnXOoSBZQJmaQOSgOcnG8e/UHHrS6r+6Fm0XyMzFWK8EjPQ0uqRpFLM0SKjKSqlRggb5OB+Q/Kn5BEsRyrcGNiQ6IrCRS2C4xkj1yAencVZvZwYJwHX93EUyR1THb0IIBpmnIn9s60Nq4GoyKOO3PFQXXF4uP4njJ9yZBmk3oDSuWYCZ7aK2uGcw5DbCcFN2Qyk9dpOcEelKkguZTMi+dFG3k/MuA2BjcvPY8e+BSwsxF8pJIFu5xn0Jx+VLEBHod35Y2/uLd/l4+Y9T9TT8hdLjb3UZp9QuLdYwHjAZ/MIUE5xg4z7++aswKrWuzeiiXAl3HIcjkc+nGB+FUNGAbUtXBGQLrAz2znNSW5INggJ2PHhl7N8r9aFqU4pKyNPe8UsgdcxIoJKr1T72F79sH8ar3Mvmtb+cWVGGCE/iXJyBjuOOvbmn7mEAwSOW7/AO1/9c1LpnzadKG5GX4P0NBKstR58p2bCyMkfzqin5SCO47Hr+NZzu98YfKUbA5jVWOMrg9VPow/l2Nat78ul3rrw/2cvuHXPHOfXk/nWPOB9kLYG4Nwe4+U0mEdWPtYXtsyo4EI+QBydoHXJA5AxyOver26B/madVJ5I+zMce2d3NMlP+jzL/D9nHH0KY/ma55jhiBwB2p7GsI8+p//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient has involvement of the retroauricular area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3301=[""].join("\n");
var outline_f3_14_3301=null;
var title_f3_14_3302="Patient position for laparoscopic or robotic trachelectomy";
var content_f3_14_3302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Patient position for laparoscopic or robotic trachelectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient lies directly on an anti-skid material that is taped securely to the operating table. No straps or blocks are utilized to minimize risk of neuropathies. The arms are tucked on the patient's sides using blankets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rosanne M Kho, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3302=[""].join("\n");
var outline_f3_14_3302=null;
var title_f3_14_3303="Hyperuricemia and gout in renal transplant recipients";
var content_f3_14_3303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperuricemia and gout in renal transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/14/3303/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/14/3303/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/14/3303/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/14/3303/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/14/3303/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/14/3303/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/14/3303/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced uric acid excretion can occur after renal transplantation, leading to hyperuricemia and, in some cases, gouty arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This problem is more common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/1,2,4,5\">",
"     1,2,4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of hyperuricemia in one study of renal transplant recipients was 84 percent in those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      versus 30 percent in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective cohort study, there was an increased relative risk of new onset gout with Neoral, compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (adjusted hazard ratio 1.25, 95% CI 1.07-1.47) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lower GFR induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    probably contributes to uric acid retention [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/1\">",
"     1",
"    </a>",
"    ], but tubular damage may also be important by impairing urate secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/2\">",
"     2",
"    </a>",
"    ]. Concurrent diuretic use and renal insufficiency due to rejection are other risk factors for hyperuricemia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"     \"Diuretic-induced hyperuricemia and gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although renal insufficiency predisposes to hyperuricemia and gout, patients with advanced renal failure may be at lesser risk of symptomatic disease. This hypothesis derives from observations in patients with end-stage renal disease treated with maintenance dialysis. Despite persistent hyperuricemia, patients with previous gouty arthritis note a marked reduction in symptomatic episodes, and de novo gout is a rare event [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/6\">",
"     6",
"    </a>",
"    ]. Why this occurs and whether it is applicable to transplant recipients are not clear; it is possible that the antiinflammatory effect of uremia is an important protective factor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hyperuricemia induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is not restricted to renal transplant recipients but is also frequent in heart or heart-lung transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/8\">",
"     8",
"    </a>",
"    ]. In these patients, hyperuricemia is associated with an increased risk of symptomatic gout. Gouty arthritis has been reported in 7 to 24 percent of cyclosporine-treated transplant recipients but only occasionally in transplant patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]; in severe cases, the gout may be polyarticular and tophi may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/8\">",
"     8",
"    </a>",
"    ]. Gout frequently occurs as a de novo event, although patients with a prior history of gout are at higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/8\">",
"     8",
"    </a>",
"    ]. De novo gout generally begins 17 to 24 months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic treatment and prevention of gout is not without risk in the transplant recipient. Thus, asymptomatic hyperuricemia should not be treated (a recommendation that also applies to the great majority of patients without a transplant). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the following complex and potentially serious drug interactions, gout in organ transplant patients should",
"    <strong>",
"     only",
"    </strong>",
"    be managed by physicians who are experienced with these clinical problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute gouty arthritis and gout flare prophylaxis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred therapy for acute gouty arthritis or for prophylaxis of acute gout in a transplant recipient who has had prior gouty attacks is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    . A dose of 0.15 to 0.6 mg",
"    <strong>",
"     once",
"    </strong>",
"    daily may be given unless the patient has advanced renal insufficiency. However, even these doses can induce the abrupt or insidious onset of a myoneuropathy that is probably due to decreased clearance of colchicine, resulting from the simultaneous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Thus, it is recommended that for acute gout flare treatment in a transplant recipient receiving a p-glycoprotein inhibitor such as cyclosporine for prevention of graft rejection, a single dose of colchicine 0.6 mg should be given; dosing should not repeated for 3 days. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     \"Colchicine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For gout flare prophylaxis in such a patient, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    dose of 0.3 mg daily or every other day (depending on renal functional status) can be given.",
"   </p>",
"   <p>",
"    In this setting, myalgias, paresthesias, or weakness may be the first and only sign of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    toxicity, warranting its discontinuation or dose reduction while the patient is being evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link&amp;anchor=H12#H12\">",
"     \"Drug-induced myopathies\", section on 'Colchicine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Nonsteroidal antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic gout flare prophylaxis with nonsteroidal antiinflammatory drugs is a potential concern in organ transplant recipients, since inhibition of renal prostaglandin synthesis may lead to a further reduction in GFR and worsening",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    nephrotoxicity. Thus, gout flare prophylaxis with these agents is generally avoided. However, use of nonsteroidal antiinflammatory drugs for a few days to treat acute gout flares can usually be done without significant adverse results. The serum creatinine concentration should be closely monitored.",
"   </p>",
"   <p>",
"    The use of nonsteroidal anti-inflammatory agents for gout flare prophylaxis, such as in the first months of urate-lowering treatment, is generally avoided in organ transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Increased glucocorticoid dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary increases in the steroid dose to 20 to 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be effective in acute gouty episodes. However, rebound attacks may occur if the prednisone dose is rapidly reduced to baseline maintenance levels. Progressive reduction of steroid dose to the baseline anti-rejection regimen over 10 days to 2 weeks is less likely to result in a rebound gout flare.",
"   </p>",
"   <p>",
"    In contrast to the case in acute gout flares, there is insufficient evidence to validate the efficacy of glucocorticoids for gout flare prophylaxis whether or not a patient has received a transplanted organ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Urate-lowering therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Xanthine oxidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    (and the recently approved non-purine-analog xanthine oxidase inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29668?source=see_link\">",
"     febuxostat",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]) should generally be avoided in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . This is because the metabolism of 6-mercaptopurine, the active metabolite of azathioprine, in part involves conversion of 6-mercaptopurine to 6-thiouric acid, a reaction catalyzed by xanthine oxidase [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, 6-mercaptopurine accumulation and severe bone marrow toxicity may result from co-administration of azathioprine and a xanthine oxidase inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If, however, the patient has severe gout and a xanthine oxidase inhibitor must be used, we have reduced the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    dose (by at least 50 percent) and carefully monitored the white blood cell count. Despite such monitoring, discontinuation of azathioprine was eventually required in many such patients.",
"   </p>",
"   <p>",
"    An alternative means of management is switching from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , which does not interact with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29668?source=see_link\">",
"     febuxostat",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The commonly accepted goal range for urate reduction and maintenance in patients with gout is &lt;6.0",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    can be used in the treatment of transplant recipients who have had symptomatic gout, are NOT receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and have mild or minimal renal functional impairment. For allopurinol, a starting dose of 50 mg once daily is recommended, with dose adjustments in 50 mg increments at approximately three to four week intervals based upon serum urate and creatinine concentrations. Unfortunately, if the maximum allopurinol dose is limited to published schedules for allopurinol dose reduction in patients with renal functional impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], adequate control of serum urate levels is usually not achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     \"Allopurinol: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no substantial evidence that the incidence of severe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    adverse events has been reduced as a result of following recommended dose reduction schemes. In two reports of small trials of allopurinol dose titration to goal serum urate levels, severe allopurinol toxicity was not observed in subjects with renal impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. One of these trials documented lower serum urate concentrations as a result of allopurinol dose titration [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, coadministration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    can be undertaken, but this approach has a low therapeutic index that requires very close monitoring, particularly of the white blood cell count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H950098\">",
"    <span class=\"h2\">",
"     Modified mammalian recombinant uricase",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H950112\">",
"    <span class=\"h3\">",
"     Pegloticase",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/38/41572?source=see_link\">",
"     Pegloticase",
"    </a>",
"    , a methyl polyethylene glycol-conjugated mammalian recombinant uricase, was approved by the United States Food and Drug Administration in 2010 for treatment of symptomatic gout refractory to conventional therapies. The uricase activity of this biological agent, which is administered every other week by intravenous infusion, converts uric acid to the more soluble and readily excreted purine end product, allantoin. In replicate phase 3 randomized, placebo-controlled clinical trials, more patients treated with pegloticase compared with placebo achieved markedly reduced plasma urate levels for the entire six month study period [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/20\">",
"     20",
"    </a>",
"    ]. This study is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link&amp;anchor=H402899#H402899\">",
"     \"Prevention of recurrent gout\", section on 'Pegloticase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these clinical trials excluded refractory gout patients with prior organ transplantation, it is likely that transplant recipients with progressively severe gout and no other treatment options will be considered for treatment with this new agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Uricosuric agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Probenecid or sulfinpyrazone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uricosuric agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    or sulfinpyrazone, may be used for urate-lowering in transplant patients with gout if renal function is adequate and there is no history of renal calculi. Since sulfinpyrazone lowers trough",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    concentrations, levels of cyclosporine must be closely monitored and the dose adjusted accordingly. Sulfinpyrazone is no longer available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Losartan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angiotensin II receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    , also has uricosuric effects, apparently by diminishing tubular uric acid reabsorption due to the inhibition of",
"    <span class=\"nowrap\">",
"     urate/anion",
"    </span>",
"    exchanger activity in renal tubular brush border membrane vesicles [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind crossover study of 10 hypertensive heart transplant recipients, individuals were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      (50 mg once per day) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      (20 mg once per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/22\">",
"       22",
"      </a>",
"      ]. Significantly lower levels of plasma urate were observed with losartan (p&lt;0.05).",
"     </li>",
"     <li>",
"      Among 23 renal transplant recipients, the effect upon the fractional excretion of uric acid was evaluated in a crossover trial in which a two week period of once daily administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      (50 mg) was compared with a two week control period [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/23\">",
"       23",
"      </a>",
"      ]. Losartan resulted in a 17 percent increase in fractional excretion of uric acid and a significant 8 percent decrease in plasma urate concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study is required to assess the clinical significance of these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Benzbromarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzbromarone, a uricosuric agent that is available in some European countries, reduces serum urate levels in transplant recipients with hyperuricemia and gout. In 25 such patients, the administration of benzbromarone at 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    reduced serum urate levels from a mean of 9.7 to 5.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (577 to 315",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/24\">",
"     24",
"    </a>",
"    ]. Unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    and sulfinpyrazone, benzbromarone is an effective uricosuric, even in patients with creatinine clearances as low as 20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Investigational agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-1 is prominent among the proinflammatory cytokines released as a result of innate immune mechanisms activated by the interaction of monosodium urate crystals and leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. It is suspected to play a prominent role in inducing the symptoms of the acute gout flare.",
"   </p>",
"   <p>",
"    An open label pilot study assessed treatment with the recombinant IL-1 receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    , in acute gouty arthritis in ten (non-transplant recipient) subjects who had either failed or could not tolerate alternative antiinflammatory treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/26\">",
"     26",
"    </a>",
"    ]. In all ten subjects, the acute inflammatory arthritis responded favorably (pain improvement, 50 to 100 percent; clinical evaluation concordant) within 24 to 48 hours. No adverse effects were reported. In other reports, the IL-1 inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=see_link\">",
"     rilonacept",
"    </a>",
"    , was superior to placebo in the prophylaxis of acute gout flares occurring early in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    treatment of non-transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/27\">",
"     27",
"    </a>",
"    ], and the IL-1 beta monoclonal antibody,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"     canakinumab",
"    </a>",
"    , was superior to intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    in the resolution of pain associated with an acute gout flare and in reductions of flare recurrence following the initial flare [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3303/abstract/29\">",
"     29",
"    </a>",
"    ] have stimulated justifiable interest in inhibitors of IL-1 action in the treatment and prophylaxis of acute gout. Until the results of these trials are confirmed and demonstrated to be applicable to organ transplant recipients, these approaches to prevention and treatment of acute gout are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5149503\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced uric acid excretion can occur after renal transplant, particularly in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      to prevent graft rejection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Impaired renal urate excretion frequently leads to hyperuricemia and, not uncommonly to gouty arthritis. Gouty arthritis is often difficult to treat because of chronic kidney disease and the interaction of gout medications (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , NSAIDs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      ) with agents commonly used in transplant recipients (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , diuretics). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic treatment and prevention of gout is not without risk in the transplant recipient and warrants management by physicians experienced with the clinical problems likely to be encountered. Asymptomatic hyperuricemia should not be treated in the organ transplant recipient. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      both inhibit p-glycoprotein action, so for acute gout flare treatment in a transplant recipient receiving cyclosporine or another p-glycoprotein inhibitor, colchicine administration should be limited to a single oral dose of 0.6 mg and not repeated for at least three days. For gout flare prophylaxis, a colchicine dose of 0.3 mg daily or every other day (depending on renal functional status) can be given. In either case, careful monitoring for colchicine-induced myoneuropathy and blood cytopenias should be undertaken to mitigate the potential consequences of excessive colchicine levels. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Colchicine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternative approaches to flare management include short-term NSAID use and supplementation of the baseline corticosteroid dose most transplant recipients receive. Slow (over 10 to 14 days) rather than rapid tapering of corticosteroids to the baseline dose is recommended to avoid rebound gout flares. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nonsteroidal antiinflammatory agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Increased glucocorticoid dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term serum urate-lowering in transplant recipients needs to be undertaken with special care. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Urate-lowering therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The xanthine oxidase inhibitors",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29668?source=see_link\">",
"       febuxostat",
"      </a>",
"      should be avoided in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , because azathioprine metabolism involves conversion of 6-mercaptopurine to 6-thiouric acid in a reaction catalyzed by xanthine oxidase. Accumulation of 6-mercaptopurine can result in severe bone marrow toxicity in the setting of co-administration of azathioprine and a xanthine oxidase inhibitor.",
"     </li>",
"     <li>",
"      Replacement of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      (which does not affect xanthine oxidase activity) for graft protection presents a suitable option if gout management mandates use of a xanthine oxidase inhibitor.",
"     </li>",
"     <li>",
"      Titration of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      dose is strongly recommended, especially given the frequency of renal function impairment and diuretic use among transplant recipients. If published recommendations regarding allopurinol dose restriction according to creatinine clearance are followed, goal range (&lt;6.0",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      serum urate level is often not achieved or maintained, and use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29668?source=see_link\">",
"       febuxostat",
"      </a>",
"      (for which no dose adjustment is needed when creatinine clearance exceeds 30",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      should be considered.",
"     </li>",
"     <li>",
"      In transplant recipients with normal or near normal renal function use of a uricosuric agent may be considered, especially where benzbromarone is available.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       Losartan",
"      </a>",
"      is the only angiotensin II receptor antagonist with uricosuric properties and may serve as a useful adjunctive agent in transplant recipients with gout.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/1\">",
"      Lin HY, Rocher LL, McQuillan MA, et al. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989; 321:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/2\">",
"      Noordzij TC, Leunissen KM, Van Hooff JP. Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use. Transplantation 1991; 52:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/3\">",
"      Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/4\">",
"      Deray G, Benhmida M, Le Hoang P, et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992; 117:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/5\">",
"      Abbott KC, Kimmel PL, Dharnidharka V, et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation 2005; 80:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/6\">",
"      Ifudu O, Tan CC, Dulin AL, et al. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am J Kidney Dis 1994; 23:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/7\">",
"      Schreiner O, Wandel E, Himmelsbach F, et al. Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients? Nephrol Dial Transplant 2000; 15:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/8\">",
"      Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med 1992; 92:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/9\">",
"      Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol 2000; 27:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/10\">",
"      Rana SS, Giuliani MJ, Oddis CV, Lacomis D. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. Clin Neurol Neurosurg 1997; 99:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/11\">",
"      Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450.",
"     </a>",
"    </li>",
"    <li>",
"     Febuxostat [Package Insert]. Deerfield, IL: Takeda Pharmaceuticals North America, Inc. 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/13\">",
"      Elion, GB, Callahan, S, Nathan, H. Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase. Biochem Pharmacol 1963; 12:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/14\">",
"      Ragab AH, Gilkerson E, Myers M. The effect of 6-mercaptopurine and allopurinol on granulopoiesis. Cancer Res 1974; 34:2246.",
"     </a>",
"    </li>",
"    <li>",
"     Fam, AG. Xanthine oxidase inhibitors. In: Crystal-induced arthropathies. Gout, pseudogout and apatite-associated syndromes. Wortmann, RL, Schumacher, HR Jr, Becker, MA, Ryan, LM (Eds), Taylor &amp; Francis, New York, 2006. p 381.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/16\">",
"      Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/17\">",
"      Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/18\">",
"      V&aacute;zquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/19\">",
"      Stamp, L, O'Donnell, JL, Zhang, M, et al. Increasing allopurinol dose above the recommended range is effective and safe in chronic gout, including those with renal impairment. Arthritis Rheum 2009; 60:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/20\">",
"      Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/21\">",
"      Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/22\">",
"      Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998; 66:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/23\">",
"      Kamper AL, Nielsen AH. Uricosuric effect of losartan in patients with renal transplants. Transplantation 2001; 72:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/24\">",
"      Z&uuml;rcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994; 9:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/25\">",
"      Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999; 5:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/26\">",
"      So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/27\">",
"      Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3303/abstract/28\">",
"      So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62:3064.",
"     </a>",
"    </li>",
"    <li>",
"     Schumacher, HR Jr, Sundy, JS, Terkeltaub, RL, et al. Placebo-Controlled Study of Rilonacept for Gout Flare Prophylaxis During Initiation of Urate-Lowering Therapy. Arthritis Rheum 2009; (In Press).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7297 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3303=[""].join("\n");
var outline_f3_14_3303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5149503\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute gouty arthritis and gout flare prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Colchicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Nonsteroidal antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Increased glucocorticoid dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Urate-lowering therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Xanthine oxidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H950098\">",
"      Modified mammalian recombinant uricase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H950112\">",
"      - Pegloticase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Uricosuric agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Probenecid or sulfinpyrazone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Losartan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Benzbromarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Investigational agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5149503\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=related_link\">",
"      Allopurinol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=related_link\">",
"      Colchicine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=related_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=related_link\">",
"      Prevention of recurrent gout",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_14_3304="Mycosis fungoides tumor leg";
var content_f3_14_3304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycosis fungoides - tumor stage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple tumor nodules are present in this patient with tumor stage mycosis fungoides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3304=[""].join("\n");
var outline_f3_14_3304=null;
var title_f3_14_3305="Lansoprazole: Drug information";
var content_f3_14_3305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lansoprazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/57/24469?source=see_link\">",
"    see \"Lansoprazole: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=see_link\">",
"    see \"Lansoprazole: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      First&reg;-Lansoprazole;",
"     </li>",
"     <li>",
"      Prevacid&reg;;",
"     </li>",
"     <li>",
"      Prevacid&reg; 24 HR [OTC];",
"     </li>",
"     <li>",
"      Prevacid&reg; SoluTab&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F186758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lansoprazole&reg;;",
"     </li>",
"     <li>",
"      Mylan-Lansoprazole;",
"     </li>",
"     <li>",
"      Prevacid&reg;;",
"     </li>",
"     <li>",
"      Prevacid&reg; FasTab;",
"     </li>",
"     <li>",
"      Teva-Lansoprazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F186807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Proton Pump Inhibitor;",
"     </li>",
"     <li>",
"      Substituted Benzimidazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F186762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Symptomatic GERD:",
"     </b>",
"     Oral: Short-term treatment: 15 mg once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Erosive esophagitis:",
"     </b>",
"     Oral: Short-term treatment: 30 mg once daily for up to 8 weeks; continued treatment for an additional 8 weeks may be considered for recurrence or for patients who do not heal after the first 8 weeks of therapy; maintenance therapy: 15 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypersecretory conditions:",
"     </b>",
"     Oral: Initial: 60 mg once daily; adjust dose based upon patient response and to reduce acid secretion to &lt;10 mEq/hour (5 mEq/hour in patients with prior gastric surgery); doses of 90 mg twice daily have been used; administer doses &gt;120 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Duodenal ulcer:",
"     </b>",
"     Oral: Short-term treatment: 15 mg once daily for 4 weeks; maintenance therapy: 15 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"     </b>",
"     <b>",
"      eradication:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer labeling: 30 mg 3 times daily administered with amoxicillin 1000 mg 3 times daily for 14 days",
"     <b>",
"      or",
"     </b>",
"     30 mg twice daily administered with amoxicillin 1000 mg",
"     <i>",
"      and",
"     </i>",
"     clarithromycin 500 mg twice daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     American College of Gastroenterology guidelines (Chey, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nonpenicillin allergy: 30 mg twice daily administered with amoxicillin 1000 mg",
"     <i>",
"      and",
"     </i>",
"     clarithromycin 500 mg twice daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Penicillin allergy: 30 mg twice daily administered with clarithromycin 500 mg",
"     <i>",
"      and",
"     </i>",
"     metronidazole 500 mg twice daily for 10-14 days",
"     <b>",
"      or",
"     </b>",
"     30 mg once or twice daily administered with bismuth subsalicylate 525 mg",
"     <i>",
"      and",
"     </i>",
"     metronidazole 250 mg",
"     <i>",
"      plus",
"     </i>",
"     tetracycline 500 mg 4 times daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric ulcer:",
"     </b>",
"     Oral: Short-term treatment: 30 mg once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      NSAID-associated gastric ulcer (healing):",
"     </b>",
"     Oral: 30 mg once daily for 8 weeks; controlled studies did not extend past 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      NSAID-associated gastric ulcer (to reduce risk):",
"     </b>",
"     Oral: 15 mg once daily for up to 12 weeks; controlled studies did not extend past 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heartburn (OTC labeling):",
"     </b>",
"     Oral: 15 mg once daily for 14 days; may repeat 14 days of therapy every 4 months. Do not take for &gt;14 days or more often than every 4 months, unless instructed by healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F186785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=see_link\">",
"      see \"Lansoprazole: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     GERD, erosive esophagitis: Oral: Children 1-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;30 kg: 15 mg once daily for up to 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;30 kg: 30 mg once daily for up to 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses were increased in some pediatric patients if still symptomatic after 2 or more weeks of treatment (maximum dose: 30 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Erosive esophagitis: Children 12-17 years: Oral: 30 mg once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nonerosive GERD: Children 12-17 years: Oral: 15 mg once daily for up to 8 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F186763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F186764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F186765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bioavailability increased in hepatic impairment. Consider dose reduction in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, oral: 15 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevacid&reg;: 15 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevacid&reg; 24 HR: 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral [compounding kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&reg;-Lansoprazole: 3 mg/mL (90 mL, 150 mL, 300 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, orally disintegrating, oral: 15 mg [DSC], 30 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevacid&reg; SoluTab&trade;: 15 mg [contains phenylalanine 2.5 mg/tablet; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevacid&reg; SoluTab&trade;: 30 mg [contains phenylalanine 5.1 mg/tablet; strawberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15241705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Prevacid&reg; capsules, orally disintegrating tablets:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322354.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322354.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F186734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer before food; best if taken before breakfast. The intact granules should not be chewed or crushed; however, several options are available for those patients unable to swallow capsules:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsules may be opened and the intact granules sprinkled on 1 tablespoon of applesauce, Ensure&reg; pudding, cottage cheese, yogurt, or strained pears. The granules should then be swallowed immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsules may be opened and emptied into ~60 mL orange juice, apple juice, or tomato juice; mix and swallow immediately. Rinse the glass with additional juice and swallow to assure complete delivery of the dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orally-disintegrating tablets: Should not be swallowed whole, broken, cut, or chewed. Place tablet on tongue; allow to dissolve (with or without water) until particles can be swallowed. Orally-disintegrating tablets may also be administered via an oral syringe: Place the 15 mg tablet in an oral syringe and draw up ~4 mL water, or place the 30 mg tablet in an oral syringe and draw up ~10 mL water. After tablet has dispersed, administer within 15 minutes. Refill the syringe with water (2 mL for the 15 mg tablet; 5 mL for the 30 mg tablet), shake gently, then administer any remaining contents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nasogastric tube administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: Capsule can be opened, the granules mixed (not crushed) with 40 mL of apple juice and then injected through the NG tube into the stomach, then flush tube with additional apple juice. Do not mix with other liquids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orally-disintegrating tablet: Nasogastric tube &ge;8 French: Place a 15 mg tablet in a syringe and draw up ~4 mL water, or place the 30 mg tablet in a syringe and draw up ~10 mL water. After tablet has dispersed, administer within 15 minutes. Refill the syringe with ~5 mL water, shake gently, and then flush the nasogastric tube.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F186733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Short-term (4 weeks) treatment of active duodenal ulcers; maintenance treatment of healed duodenal ulcers; as part of a multidrug regimen for",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication to reduce the risk of duodenal ulcer recurrence; short-term (up to 8 weeks) treatment of active benign gastric ulcer; treatment of NSAID-associated gastric ulcer; to reduce the risk of NSAID-associated gastric ulcer in patients with a history of gastric ulcer who require an NSAID; short-term treatment of symptomatic GERD; short-term (up to 8 weeks) treatment for all grades of erosive esophagitis; to maintain healing of erosive esophagitis; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     OTC labeling: Relief of frequent heartburn (&ge;2 days/week)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F186815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lansoprazole may be confused with aripiprazole, dexlansoprazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prevacid&reg; may be confused with Pravachol&reg;, Prevpac&reg;, PriLOSEC&reg;, Prinivil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F186805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (children 1-11 years 3%, 12-17 years 7%), dizziness (children 12-17 years 3%; adults &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (1% to 5%; 60 mg/day: 7%), abdominal pain (children 12-17 years 5%; adults 2%), constipation (children 1-11 years 5%; adults 1%), nausea (children 12-17 years 3%; adults 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdomen enlarged, abnormal dreams, abnormal menses, abnormal stools, abnormal vision, agitation, agranulocytosis, albuminuria, allergic reaction, alkaline phosphatase increased, ALT increased, alopecia, amblyopia, amnesia, anaphylactoid reaction, anemia, angina, anorexia, anxiety, aplastic anemia, appetite increased, arrhythmia, AST increased, arthralgia, arthritis, asthma, avitaminosis, bezoar, bilirubinemia, blepharitis, blurred vision, bradycardia, breast enlargement, breast pain, breast tenderness, bronchitis, candidiasis, carcinoma, cardiospasm, cataract, cerebrovascular accident, cerebral infarction, chest pain, chills, cholelithiasis, cholesterol increased/decreased,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), colitis, confusion, conjunctivitis, cough increased, creatinine increased, deafness, dehydration, dementia, depersonalization, depression, diabetes mellitus, diaphoresis, diplopia, dry eyes, dry skin, dyspepsia, dysphagia, dyspnea, dysmenorrhea, dysuria, edema, electrolyte imbalance, emotional lability, enteritis, eosinophilia, epistaxis, eructation, erythema multiforme, esophageal stenosis, esophageal ulcer, esophagitis, fecal discoloration, fever, fixed eruption, flatulence, flu-like syndrome, fracture, fundic gland polyps, gastric nodules, gastrin levels increased, gastritis, gastroenteritis, gastrointestinal anomaly, gastrointestinal hemorrhage, GGTP increased/decreased, glaucoma, glucocorticoid levels increased, glossitis, glycosuria, goiter, gout, gum hemorrhage, gynecomastia, halitosis, hallucinations, hematemesis, hematuria, hemiplegia, hemolysis, hemolytic anemia, hemoptysis, hepatotoxicity, hostility aggravated, hyper-/hypoglycemia, hyperkinesia, hyperlipemia, hypertonia, hypoesthesia, hyper-/hypotension, hypomagnesemia, hypothyroidism, impotence, infection, insomnia, interstitial nephritis, kidney calculus, laryngeal neoplasia, LDH increased, leg cramps, leukopenia, leukorrhea, libido decreased/increased, liver function test abnormal, lung fibrosis, lymphadenopathy, maculopapular rash, malaise, melena, menorrhagia, migraine, moniliasis (oral), mouth ulceration, musculoskeletal pain, myalgia, myasthenia, myositis, MI, nervousness, neurosis, neutropenia, pain, palpitation, pancreatitis, pancytopenia, paresthesia, parosmia, pelvic pain, peripheral edema, pharyngitis, photophobia, platelet abnormalities, pneumonia, polyuria, pruritus, ptosis, rash, rectal hemorrhage, retinal degeneration, rhinitis, salivation increased, seizure, shock, sinusitis, skin carcinoma, sleep disorder, somnolence, speech disorder, Stevens-Johnson syndrome, stomatitis, stridor, syncope, synovitis, tachycardia, taste loss, taste perversion, tenesmus, thirst, thrombocytopenia, thrombotic thrombocytopenic purpura, tinnitus, tremor, tongue disorder, toxic epidermal necrolysis, ulcerative colitis, ulcerative stomatitis, upper respiratory inflammation, upper respiratory infection, urethral pain, urinary frequency/urgency, urination impaired, urinary retention, urinary tract infection, urticaria, vaginitis, vasodilation, vertigo, visual field defect, vomiting, weakness, WBC abnormal, weight gain/loss, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F186738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lansoprazole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F186719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrophic gastritis: Long-term omeprazole therapy has caused atrophic gastritis (by biopsy); this may also occur with lansoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinoma: No reports of enterochromaffin-like (ECL) cell carcinoids, dysplasia, or neoplasia has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter.  Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of lansoprazole may be necessary; magnesium levels typically return to normal within 1 week of stopping.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal infection (eg,",
"     <i>",
"      Salmonella, Campylobacter",
"     </i>",
"     ): Use of proton pump inhibitors may increase risk of these infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Patients with severe liver dysfunction may require dosage reductions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). Although lansoprazole exhibits the most potent CYP2C19 inhibition",
"     <i>",
"      in vitro",
"     </i>",
"     (Li, 2004; Ogilvie, 2011), an",
"     <i>",
"      in vivo",
"     </i>",
"     study of extensive CYP2C19 metabolizers showed less reduction of the active metabolite of clopidogrel by lansoprazole/dexlansoprazole compared to esomeprazole/omeprazole (Frelinger, 2012). The manufacturer of lansoprazole states that no dosage adjustment is necessary for clopidogrel when used concurrently. In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically-significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham, 2010; Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for other interactions: Concomitant use of lansoprazole with some drugs may require cautious use, may not be recommended, or may require dosage adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Lansoprazole has been shown to be ineffective for the treatment of symptomatic GERD in children 1 month to &lt;1 year.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Prevacid&reg; SoluTab&trade; contains phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10-14 days of therapy (triple or quadruple) for eradication of",
"     <i>",
"      H. pylori",
"     </i>",
"     (Chey, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication, patients should be instructed not to use if they have difficulty swallowing, are vomiting blood, or have bloody or black stools. Prior to use, patients should contact healthcare provider if they have liver disease, heartburn for &gt;3 months,  heartburn with dizziness, lightheadedness, or sweating, MI symptoms, frequent chest pain, frequent wheezing (especially with heartburn), unexplained weight loss, nausea/vomiting, stomach pain, or are taking antifungals, atazanavir, digoxin, tacrolimus, theophylline, or warfarin. Patients should stop use and consult a healthcare provider if heartburn continues or worsens, or if they need to take for &gt;14 days or more often than every 4 months. Patients should be informed that it may take 1-4 days for full effect to be seen.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F186800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F186724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Lansoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Lansoprazole may enhance the dermatologic adverse effect of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Lansoprazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Proton Pump Inhibitors.  Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F186754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may cause gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Lansoprazole serum concentrations may be decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease the levels/effect of lansoprazole).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not shown teratogenic effects to the fetus. However, there are no adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F186770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F186742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken before eating; best if taken before breakfast. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F186740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Lansoprazole Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (30): $170.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $566.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Prevacid 24HR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (14): $10.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Prevacid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (30): $249.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $832.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (First-Lansoprazole Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg/mL (150 mL): $62.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Prevacid SoluTab Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $832.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $832.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F186728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with Zollinger-Ellison syndrome should be monitored for gastric acid output, which should be maintained at &le;10 mEq/hour during the last hour before the next lansoprazole dose; lab monitoring should include CBC, liver function, renal function, and serum gastrin levels",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F186743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agopton (AT, CH, DE);",
"     </li>",
"     <li>",
"      Betalans (ID);",
"     </li>",
"     <li>",
"      Dakar (LU);",
"     </li>",
"     <li>",
"      Dapuaa (KP);",
"     </li>",
"     <li>",
"      Daxar (BE);",
"     </li>",
"     <li>",
"      Digest (ID);",
"     </li>",
"     <li>",
"      Emlansa (HK);",
"     </li>",
"     <li>",
"      Estomil (ES);",
"     </li>",
"     <li>",
"      Gastrovex (MY);",
"     </li>",
"     <li>",
"      Imidex (MX);",
"     </li>",
"     <li>",
"      Inhipraz (ID);",
"     </li>",
"     <li>",
"      Julphasole (MY);",
"     </li>",
"     <li>",
"      Lacopen (CO);",
"     </li>",
"     <li>",
"      Lancid (KP);",
"     </li>",
"     <li>",
"      Langaton (KP);",
"     </li>",
"     <li>",
"      Lanodizol (MX);",
"     </li>",
"     <li>",
"      Lanpraz (CO);",
"     </li>",
"     <li>",
"      Lanpro (MY);",
"     </li>",
"     <li>",
"      Lanprol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Lanproton (CO);",
"     </li>",
"     <li>",
"      Lans-OD (MY);",
"     </li>",
"     <li>",
"      Lansal (FI);",
"     </li>",
"     <li>",
"      Lanso (GR, IL, MY);",
"     </li>",
"     <li>",
"      Lansodin (PH);",
"     </li>",
"     <li>",
"      Lansone (HU);",
"     </li>",
"     <li>",
"      Lansopep (CO);",
"     </li>",
"     <li>",
"      Lansor (TR);",
"     </li>",
"     <li>",
"      Lansozole (KP);",
"     </li>",
"     <li>",
"      Lanspro-30 (PH);",
"     </li>",
"     <li>",
"      Lanster (KP);",
"     </li>",
"     <li>",
"      Lanston (KP);",
"     </li>",
"     <li>",
"      Lanton (IL);",
"     </li>",
"     <li>",
"      Lanximed (CO);",
"     </li>",
"     <li>",
"      Lanzap (RU);",
"     </li>",
"     <li>",
"      Lanzep (PH);",
"     </li>",
"     <li>",
"      Lanzo (DK, SE);",
"     </li>",
"     <li>",
"      Lanzo Melt (NO);",
"     </li>",
"     <li>",
"      Lanzol (HK);",
"     </li>",
"     <li>",
"      Lanzol-30 (IN);",
"     </li>",
"     <li>",
"      Lanzole (PH);",
"     </li>",
"     <li>",
"      Lanzopral (AR, PE, PY, UY, VE);",
"     </li>",
"     <li>",
"      Lanzor (DE, FR);",
"     </li>",
"     <li>",
"      Lanzul (CZ, EE, HR, PL);",
"     </li>",
"     <li>",
"      Lapraz (ID);",
"     </li>",
"     <li>",
"      Laproton (ID);",
"     </li>",
"     <li>",
"      Lasgan (ID);",
"     </li>",
"     <li>",
"      Lasoprol (SG);",
"     </li>",
"     <li>",
"      Laz (ID);",
"     </li>",
"     <li>",
"      Monolitum (CR, DO, ES, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Ogast (FR);",
"     </li>",
"     <li>",
"      Ogastro (BB, BM, BR, BS, BZ, CN, CO, CR, EC, FR, GT, GY, HN, JM, MX, NI, PA, PE, PR, SR, SV, TT);",
"     </li>",
"     <li>",
"      Olan (MX);",
"     </li>",
"     <li>",
"      Palatrin (MX);",
"     </li>",
"     <li>",
"      Prevacid (CL, MY, PH, PK, SG, TH);",
"     </li>",
"     <li>",
"      Prezal (NL);",
"     </li>",
"     <li>",
"      Prilosan (MX);",
"     </li>",
"     <li>",
"      Propilan (PH);",
"     </li>",
"     <li>",
"      Prosogan fd (ID);",
"     </li>",
"     <li>",
"      Protonexa (BG);",
"     </li>",
"     <li>",
"      Pysolan (ID);",
"     </li>",
"     <li>",
"      Quitulcer (TW);",
"     </li>",
"     <li>",
"      Safemar (MX);",
"     </li>",
"     <li>",
"      Solox (NZ);",
"     </li>",
"     <li>",
"      Sopralan-30 (ID);",
"     </li>",
"     <li>",
"      Sopranix (SE);",
"     </li>",
"     <li>",
"      Sorifran (MX);",
"     </li>",
"     <li>",
"      Takepron (BF, BJ, CI, CL, ET, GH, GM, GN, JP, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Takepron OD (HK);",
"     </li>",
"     <li>",
"      Taquidine (TW);",
"     </li>",
"     <li>",
"      Uldapril (MX);",
"     </li>",
"     <li>",
"      Ulpax (MX);",
"     </li>",
"     <li>",
"      Xizhixin (CL);",
"     </li>",
"     <li>",
"      Zopral (AU);",
"     </li>",
"     <li>",
"      Zopraz (PE);",
"     </li>",
"     <li>",
"      Zoton (AU, GB, IE, IL, IT);",
"     </li>",
"     <li>",
"      Zoton Fastab (GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F186718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases acid secretion in gastric parietal cells through inhibition of (H+, K+)-ATPase enzyme system, blocking the final step in gastric acid production.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F186737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Gastric acid suppression: Oral: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Gastric acid suppression: Oral: &gt;1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 14-18 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C19 and 3A4, and in parietal cells to two active metabolites that are not present in systemic circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &ge;80%; decreased 50% to 70% if given 30 minutes after food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.5 &plusmn; 1 hours; Elderly: 2-3 hours; Hepatic impairment: 3-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (67%); urine (33%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(24):2619-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/21060077/pubmed\" id=\"21060077\" target=\"_blank\">",
"        21060077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brunner G, Luna P, Hartmann M, et al, &ldquo;Optimizing the Intragastric pH as a Supportive Therapy in Upper GI Bleeding,&rdquo;",
"      <i>",
"       Yale J Biol Med",
"      </i>",
"      , 1996, 69(3):225-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/9165691/pubmed\" id=\"9165691\" target=\"_blank\">",
"        9165691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD, Wong BC, and Practice Parameters Committee of the American College of Gastroenterology, &ldquo;American College of Gastroenterology, Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007, 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chun AH, Eason CJ, Shi HH, et al, &ldquo;Lansoprazole: An Alternative Method of Administration of a Capsule Dosage Formulation,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 1995, 17(3):441-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/7585848/pubmed\" id=\"7585848\" target=\"_blank\">",
"        7585848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cockayne SE, Glet RJ, Gawkrodger DJ, et al, &ldquo;Severe Erythrodermic Reactions to the Proton Pump Inhibitors Omeprazole and Lansoprazole,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      ,1999, 141(1):173-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/10417548/pubmed\" id=\"10417548\" target=\"_blank\">",
"        10417548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jager CP, Wever PC, Gemen EF, et al, &ldquo;Proton Pump Inhibitor Therapy Predisposes to Community-Acquired",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2012, 36(10):941-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/23034135/pubmed\" id=\"23034135\" target=\"_blank\">",
"        23034135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo; [published correction appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6],",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeVault KR and Castell DO, &ldquo;Practice Guidelines. Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease&rdquo;,",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2005,100(1):190-200.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/15654800/pubmed\" id=\"15654800\" target=\"_blank\">",
"        15654800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frazzoni M, De Micheli E, Grisendi A, et al, &ldquo;Effective Intra-Oesophageal Acid Suppression in Patients With Gastro-Oesophageal Reflux Disease: Lansoprazole vs. Pantoprazole,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2003, 17(2):235-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/12534408/pubmed\" id=\"12534408\" target=\"_blank\">",
"        12534408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frelinger AL 3rd, Lee RD, Mulford DJ, et al, &ldquo;A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2012, 59(14):1304-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/22464259/pubmed\" id=\"22464259\" target=\"_blank\">",
"        22464259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huang JQ, Goldwater DR, Thomson AB, et al, &ldquo;Acid Suppression in Healthy Subjects Following Lansoprazole or Pantoprazole,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2002, 16(3):425-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/11876695/pubmed\" id=\"11876695\" target=\"_blank\">",
"        11876695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jung R and MacLaren R, &ldquo;Proton-Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(12):1929-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/12452757/pubmed\" id=\"12452757\" target=\"_blank\">",
"        12452757",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2008, 135(4):1383-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/18789939/pubmed\" id=\"18789939\" target=\"_blank\">",
"        18789939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lanza FL, Chan FK, and Quigley EM, &ldquo;Guidelines for Prevention of NSAID-Related Ulcer Complications,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 140(3):728-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/19240698/pubmed\" id=\"19240698\" target=\"_blank\">",
"        19240698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li XQ, Andersson TB, Ahalstr&ouml;m M, et al, \"Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole and Rabeprazole on Human Cytochrome P450 Activities,\"",
"      <i>",
"       Drug Metab Dispo",
"      </i>",
"      , 2004, 32(8):821-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/15258107/pubmed\" id=\"15258107\" target=\"_blank\">",
"        15258107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Natsch S, Vinks MH, Voogt AK, et al, &ldquo;Anaphylactic Reactions to Proton-Pump Inhibitors,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(4):474-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/10772433/pubmed\" id=\"10772433\" target=\"_blank\">",
"        10772433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ogilvie BW, Yerino P, Kazmi F, et al, &ldquo;The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration With Clopidogrel,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2011, 39(11):2020-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/21795468/pubmed\" id=\"21795468\" target=\"_blank\">",
"        21795468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paoluzi P, Iacopini F, Crispino P, et al, &ldquo;2-Week Triple Therapy for",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study,&rdquo;",
"      <i>",
"       Helicobacter",
"      </i>",
"      , 2006, 11(6):562-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/17083378/pubmed\" id=\"17083378\" target=\"_blank\">",
"        17083378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2005, 100(10):2324-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/14/3305/abstract-text/16181387/pubmed\" id=\"16181387\" target=\"_blank\">",
"        16181387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolfe MM and Sachs G, &ldquo;Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2000,118(2 Suppl 1):9-31.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9546 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3305=[""].join("\n");
var outline_f3_14_3305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572473\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186757\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186758\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186807\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186762\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186785\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186763\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186764\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186765\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186730\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186715\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15241705\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186734\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186733\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186815\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186805\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186738\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186719\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186800\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186724\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186754\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186726\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186741\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186770\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186742\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186740\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186728\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186743\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186718\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186737\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9546|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/57/24469?source=related_link\">",
"      Lansoprazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=related_link\">",
"      Lansoprazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_14_3306="Placement of jugular venous catheters";
var content_f3_14_3306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Placement of jugular venous catheters",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/14/3306/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/14/3306/contributors\">",
"     Mark P Androes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/14/3306/contributors\">",
"     Alan C Heffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/14/3306/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/14/3306/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/14/3306/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/14/3306/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/14/3306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/14/3306/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/14/3306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H86781061\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central catheters provide dependable intravenous access and enable hemodynamic monitoring and blood sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The jugular veins are one of the most popular sites for central venous access due to accessibility and overall low complication rates, and are the preferred site for temporary hemodialysis.",
"   </p>",
"   <p>",
"    Jugular venous cannulation and catheter placement will be reviewed here. General considerations for venous access and issues related to other access sites are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=see_link\">",
"     \"Placement of femoral venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1466?source=see_link\">",
"     \"Placement of subclavian venous catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86781076\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The jugular veins (internal, external) are reliable access sites for temporary and permanent (",
"    <a class=\"graphic graphic_table graphicRef71716 \" href=\"UTD.htm?1/53/1885\">",
"     table 1",
"    </a>",
"    ) (eg, tunneled central catheters and subcutaneous ports) venous cannulation to support hemodynamic monitoring, fluid and medication administration, and parenteral nutrition. Jugular venous access can also be used for the placement of inferior vena cava filters and other venous devices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Internal jugular venous access (especially right-sided) is associated with a low rate of catheter malposition [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/4\">",
"     4",
"    </a>",
"    ], and is commonly used in situations that require reliable tip positioning for immediate use, such as drug administration or transvenous pacing. Similarly, the direct route from the right internal jugular vein to the superior vena cava facilitates hemodialysis access and pulmonary artery catheter placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25221?source=see_link\">",
"     \"Insertion of pulmonary artery catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86781613\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative contraindications to jugular venous catheterization, in general, include coagulopathy, prior access, the presence of another device at the site, and altered local anatomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of central venous access\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the jugular site, local anatomy may be altered due to prior clavicular fracture, median sternotomy, neck surgery, or neck irradiation. Following neck surgery (eg, carotid endarterectomy), the internal jugular vein generally maintains its patency, course, and anatomic relationships, but scar tissue may impede access to it [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Internal jugular access in patients with coagulopathy places the patient at risk for neck hematoma, which can be life-threatening due to airway compromise if inadvertent carotid artery puncture occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, when arterial puncture is recognized, direct pressure can be applied to the neck to control bleeding, which is not the case for inadvertent subclavian artery puncture. A femoral site may be more appropriate for urgent or emergent venous access when ultrasound is not available to guide internal jugular access, in uncooperative patients who cannot lay still, and for less experienced operators. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=see_link\">",
"     \"Placement of femoral venous catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H437920391\">",
"    <span class=\"h1\">",
"     JUGULAR VEIN ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal jugular vein is a continuation of the sigmoid sinus as it emerges from the jugular foramen at the skull base. The vein is contained within the carotid sheath traveling with the carotid artery and vagus nerve throughout its length (",
"    <a class=\"graphic graphic_figure graphicRef74801 graphicRef79232 \" href=\"UTD.htm?34/28/35273\">",
"     figure 1A-B",
"    </a>",
"    ). The internal jugular vein on the right is larger than the left in the majority of patients, with significant diameter discrepancy present in over one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The internal jugular vein exits the skull posterior to the internal carotid artery, but assumes a position anterolateral to the common carotid artery as it courses beneath the sternocleidomastoid muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. At the level of the cricoid cartilage, the internal jugular vein lies beneath the sternocleidomastoid muscle and more caudally, it is located between the two heads of the sternocleidomastoid muscle at the base of the neck. In this region, the vein is superficially located approximately 1 to 1.5 cm from the surface of the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The internal jugular vein joins the subclavian vein to form the brachiocephalic (innominate) vein behind the medial clavicle [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The external jugular vein is a superficial vein of the neck amenable to visual identification. The vessel takes an oblique course across the sternocleidomastoid muscle (",
"    <a class=\"graphic graphic_figure graphicRef69353 \" href=\"UTD.htm?32/9/32917\">",
"     figure 2",
"    </a>",
"    ). It joins the subclavian vein anterior or just lateral to the anterior scalene muscle. External jugular veins are commonly greater than 10 mm in diameter; their diameter varies inversely with the diameter of the internal jugular vein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85541889\">",
"    <span class=\"h2\">",
"     Landmarks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary surface landmarks for internal jugular cannulation relate to the borders of the sternocleidomastoid muscle (",
"    <a class=\"graphic graphic_figure graphicRef79232 \" href=\"UTD.htm?42/52/43845\">",
"     figure 1B",
"    </a>",
"    ), which are accentuated by muscle flexion (asking the patient to raise the head off the bed), or turning the head away from the access vein. Palpation of the two origins of the sternocleidomastoid muscle (ie, sternal and clavicular heads) defines a triangular gap just above the medial clavicle. The medial sternal head is more easily palpated than the broad, flat clavicular head. The vein normally courses deep to the muscle and emerges along the medial border of the clavicular head.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85542001\">",
"    <span class=\"h1\">",
"     JUGULAR SITE SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal jugular vein is more often chosen for the placement of central venous catheters; however, the external jugular vein is an excellent choice for rapid intravenous access, or as an alternative site following internal jugular vein occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. External jugular vein access is performed in a manner that is similar to other superficial peripheral vein access, typically using an angiocatheter rather than a needle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6361?source=see_link\">",
"     \"Peripheral venous access in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Right internal jugular vein cannulation is generally preferred over the left due to the larger diameter of the right-sided vein, its more direct path to the superior vena cava, lower dome of the right pleura, absence of the thoracic duct, and the relative ease-of-access for a right-handed operator [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/9\">",
"     9",
"    </a>",
"    ]. Two single-center randomized trials found that cannulation of the left jugular vein is more time-consuming and associated with a higher incidence of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, a left-sided approach may be necessary for those with prior right-sided access, excessive scarring, vein thrombosis, or those with other indwelling central venous devices.",
"   </p>",
"   <p>",
"    The risk of pneumothorax is low when an ultrasound-guided technique is used to access the internal jugular vein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/18\">",
"     18",
"    </a>",
"    ]. However, when ultrasound is not available to guide needle placement, we avoid access ipsilateral to the compromised lung in patients with significant unilateral lung disease. (See",
"    <a class=\"local\" href=\"#H86781613\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with prior indwelling catheter placement in the subclavian veins or internal jugular veins, or a history of upper extremity deep venous thrombosis, we obtain Duplex ultrasound to assess venous patency prior to attempting jugular access. This assessment can often be performed concurrent with vein localization for the operator experienced with ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link&amp;anchor=H20#H20\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Duplex ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85542008\">",
"    <span class=\"h2\">",
"     Static ultrasound guidance for vein localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to preparing the patient, we localize the internal or external jugular vein and mark its position using the following steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Locate the jugular vein using care to distinguish it from the carotid artery (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72691 \" href=\"UTD.htm?14/5/14418\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link&amp;anchor=H10#H10\">",
"       \"Principles of ultrasound-guided venous access\", section on 'Ultrasound anatomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mark the position of the vein on the skin surface with an indelible pen.",
"     </li>",
"     <li>",
"      Remove the ultrasound transducer and gel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the vein is localized, jugular catheterization can be performed using the markings as a guide. (See",
"    <a class=\"local\" href=\"#H437918651\">",
"     'Internal jugular vein cannulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1316646382\">",
"    <span class=\"h1\">",
"     GENERAL PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;General considerations for patient preparation including catheter and access site selection, monitoring and sedation, measures to control infection, and consent are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=see_link&amp;anchor=H3104738#H3104738\">",
"     \"Overview of central venous access\", section on 'Preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232389802\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jugular venous catheters and other jugular devices are usually placed using a modified Seldinger technique in a series of defined steps usually using a kit that contains all the materials needed for their placement (",
"    <a class=\"graphic graphic_table graphicRef54646 \" href=\"UTD.htm?26/30/27115\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/19\">",
"     19",
"    </a>",
"    ]. For non-tunneled catheters, the steps for central venous catheterization are given in the table (",
"    <a class=\"graphic graphic_table graphicRef68138 \" href=\"UTD.htm?43/26/44459\">",
"     table 3",
"    </a>",
"    ). For tunneled catheters and other devices, the steps are similar except that a sheath is placed over the guidewire, and the catheter (or other device such as pacemaker leads, filter) is placed through the sheath, which is then removed.",
"   </p>",
"   <p>",
"    Prior to the placement of jugular venous catheters, assemble the following equipment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ultrasound machine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link&amp;anchor=H16#H16\">",
"       \"Principles of ultrasound-guided venous access\", section on 'Ultrasound machine preparation'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Sterile ultrasound transducer gel",
"     </li>",
"     <li>",
"      Central line kit with intravenous catheter (size and length based upon diameter and depth of vein)",
"     </li>",
"     <li>",
"      Sterile drapes, gloves, gown, surgical mask, and cap",
"     </li>",
"     <li>",
"      Topical antiseptic (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=see_link\">",
"       \"Controversies in control measures to prevent surgical site infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Local anesthetic (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link\">",
"       \"Topical anesthetics in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"       \"Infiltration of local anesthetics\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Isotonic saline",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      for flushing the catheter",
"     </li>",
"     <li>",
"      Transparent adhesive dressing, tape",
"     </li>",
"     <li>",
"      Intravenous tubing and connectors (eg, needleless Luer connector, three-way stopcock)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The proper functioning of any fluoroscopic equipment that will be used should be verified. Although fluoroscopy is rarely needed for jugular access, it may be useful when altered venous anatomy is encountered. When placing implanted catheters or devices (eg, pacemaker, defibrillator, pulmonary artery catheter, vena cava filter), fluoroscopy is routinely employed to measure the length of the catheter needed and to image the sheath or device as it is introduced into the vein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H437920630\">",
"    <span class=\"h2\">",
"     Skin preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For jugular venous access, a wide skin preparation that includes the neck and chest above the nipple line allows the operator to attempt cannulation at an alternative ipsilateral target (eg, supraclavicular or infraclavicular subclavian approach) if the initial plan fails. If difficult access is anticipated, we prepare the neck and chest bilaterally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105076091\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient positioning that maximizes the diameter of the jugular vein is associated with increased cannulation success [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/8,20,21\">",
"     8,20,21",
"    </a>",
"    ]. This is accomplished primarily with Trendelenburg position, when tolerated, and proper neck positioning. The Trendelenburg position (head down) of 10 to 15 degrees significantly increases jugular diameter compared with flat positioning [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/8,11,20-23\">",
"     8,11,20-23",
"    </a>",
"    ]. Placing the patient in Trendelenburg position may also reduce the potential for venous air embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients can be safely positioned supine or in Trendelenburg position [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, critically ill and obese patients may develop respiratory compromise in the supine position and require close monitoring. Some patients may require anesthesia with a controlled airway for safe placement of central venous catheters and devices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35482?source=see_link&amp;anchor=H708418#H708418\">",
"     \"Anesthesia for the obese patient undergoing non-cardiac surgery\", section on 'Positioning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diameter of the compliant jugular vein varies with the respiratory cycle. Inspiration generates a negative intrathoracic pressure, which collapses the vein, while exhalation accentuates distention. To increase the diameter of the jugular vein, cooperative patients can be asked to hum or perform a Valsalva maneuver. If the patient is not awake or is unable to cooperate, slight abdominal compression can increase venous dimension [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/11,21,23\">",
"     11,21,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The position of the patient&rsquo;s head also influences jugular vein diameter and its relationship to the carotid artery. Vein diameter is increased with slight head elevation while the use of a shoulder bolster or head rotation past 45 degrees both decrease vein diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The position of the head also influences the location of the jugular vein relative to the carotid artery. Some degree of overlap of the jugular vein and carotid artery is common [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/26\">",
"     26",
"    </a>",
"    ]. The overlap progressively increases with rotation of the head laterally from a neutral position [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/5,27,28\">",
"     5,27,28",
"    </a>",
"    ]. Limiting head rotation minimizes superimposition of the vessels and decreases the risk of arterial puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/16,27-29\">",
"     16,27-29",
"    </a>",
"    ]. Although a neutral head position provides the maximal distance between the artery and vein, some head rotation may be needed to adequately expose the anterior neck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H437918651\">",
"    <span class=\"h1\">",
"     INTERNAL JUGULAR VEIN CANNULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal jugular vein is generally cannulated with ultrasound guidance using one of three anatomic approaches. Following cannulation, internal jugular catheters are placed using an orderly sequence of steps (",
"    <a class=\"graphic graphic_table graphicRef68138 \" href=\"UTD.htm?43/26/44459\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232390400\">",
"    <span class=\"h2\">",
"     Needle access",
"    </span>",
"    &nbsp;&mdash;&nbsp;When equipment and expertise are available, children and adults undergoing cannulation of the internal jugular vein (regardless of approach or type of needle used) should have the procedure guided by ultrasound rather than using anatomic landmarks alone. Ultrasound increases success rates and reduces the rate of inadvertent arterial puncture. The basic principles of ultrasound for guiding venous access are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link&amp;anchor=H1232393281#H1232393281\">",
"     \"Principles of ultrasound-guided venous access\", section on 'Internal jugular vein'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1232390100\">",
"     'Dynamic ultrasound-guided internal jugular access'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85542813\">",
"    <span class=\"h3\">",
"     General techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal jugular vein can be cannulated using an access needle with or without the aid of a seeker needle or by using an angiocatheter (catheter over needle combination). The general technique for each of these is described below. Isolated arterial needle puncture is one of the most common complications of venous access, but is typically uneventful if recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/30\">",
"     30",
"    </a>",
"    ]. Confirmation that the tip of the needle or angiocatheter is within the vein is essential prior to dilating the subcutaneous tissue and vein. (See",
"    <a class=\"local\" href=\"#H1232387736\">",
"     'Venous confirmation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is a learning curve for central venous access procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/2\">",
"     2",
"    </a>",
"    ]. Experienced operators enjoy greater success rates with fewer complications, among both experienced and inexperienced operators, an increased number of introducer needle passes correlates with increased complication rates, which are significantly higher after two to three unsuccessful passes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/1\">",
"     1",
"    </a>",
"    ]. If two attempts have been made, the needle should be completely removed and the landmarks reassessed, a new access site chosen, or assistance obtained from a more experienced clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/1,31,32\">",
"     1,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85542874\">",
"    <span class=\"h4\">",
"     Access with introducer needle",
"    </span>",
"    &nbsp;&mdash;&nbsp;To access the jugular vein with the introducer needle:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the introducer needle into the skin and apply continuous negative pressure by pulling back on the plunger of the syringe. Penetration into the vein will go unrecognized unless negative pressure is applied, but only a small amount of continuous negative pressure is needed (about 1 cc of a 10 cc syringe) during forward advancement of the needle.",
"     </li>",
"     <li>",
"      Always advance and withdraw the needle in the same vector. Lateral movement of an inserted needle can lacerate vessels and should",
"      <strong>",
"       not",
"      </strong>",
"      be done. Prior to any redirection of the needle, it should be withdrawn to the skin surface.",
"     </li>",
"     <li>",
"      Anticipate that venous backflow into the introducer needle will be sudden, and steady the position of your hand to avoid losing access when it occurs.",
"     </li>",
"     <li>",
"      The introducer needle may compress the anterior wall, puncturing both walls simultaneously without entering the lumen. Failure to aspirate blood during needle advancement is common. In this circumstance, withdraw the needle slowly while maintaining continuous negative pressure. Up to half of jugular punctures are recognized during needle withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Once access is achieved, stabilize the hub of the needle and carefully remove the syringe to avoid dislodging the introducer needle from the vessel.",
"     </li>",
"     <li>",
"      Cover the hub of the needle between manipulations and coordinate hub exposure with the patient&rsquo;s exhalation to avoid air entry during jugular access. Encourage the patient to hum or perform Valsalva maneuvers to augment central venous pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85542881\">",
"    <span class=\"h4\">",
"     Using a seeker needle",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small caliber (21 to 22 gauge) exploratory seeker needle, 3.5 cm in length, is often useful for initially locating the internal jugular vein (",
"    <a class=\"graphic graphic_picture graphicRef55560 \" href=\"UTD.htm?6/60/7105\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/31,34\">",
"     31,34",
"    </a>",
"    ]. This technique minimizes injury in the event of inadvertent arterial puncture. When using landmarks to guide access, we use the seeker needle for all internal jugular access; however, with ultrasound-guidance to aid vein localization, a seeker needle may not be needed.",
"   </p>",
"   <p>",
"    To use a seeker needle to aid introducer needle placement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As described above for large-bore needle access, insert the seeker needle while applying negative suction on the plunger of the syringe; more suction will be required (about 2 to 3 cc of a 10 cc syringe). Steady, unimpeded blood return confirms intraluminal venous placement.",
"     </li>",
"     <li>",
"      Once the needle enters the jugular vein, withdraw the seeker needle, noting the angle and depth needed to reach the vein. Alternatively, remove the syringe, leaving the seeker needle in place to anchor the vessel and provide a guide for venous access by the introducer needle [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/35\">",
"       35",
"      </a>",
"      ]. While applying negative pressure to the syringe, advance the introducer needle in the same vector, or alongside the preceding seeker needle, into the vein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85542888\">",
"    <span class=\"h4\">",
"     Using an angiocatheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;An angiocatheter, which consists of an 18 gauge plastic catheter mounted on a 20 gauge needle, can also be used for initial jugular access. The needle tip is exposed and extends 2 mm distal to the catheter tip. The angiocatheter (not the needle) accommodates a standard 0.035&rdquo; guidewire.",
"   </p>",
"   <p>",
"    To use an angiocatheter for jugular venous access:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attach the catheter-over-needle unit to the syringe and advance it into the target vessel as described above.",
"     </li>",
"     <li>",
"      Once blood is aspirated, advance the needle another 2 to 3 mm to ensure intraluminal positioning of the tip of the catheter, then advance the catheter over the needle and into the vessel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85542669\">",
"    <span class=\"h3\">",
"     Approaches to the internal jugular vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three approaches to the internal jugular vein are widely recognized and include central, posterior, and anterior approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/36\">",
"     36",
"    </a>",
"    ]. The landmarks and needle placement for each of these approaches are presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85542676\">",
"    <span class=\"h4\">",
"     Central",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central approach to the internal jugular vein is commonly used (",
"    <a class=\"graphic graphic_figure graphicRef77907 \" href=\"UTD.htm?24/25/24978\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79232 \" href=\"UTD.htm?42/52/43845\">",
"     figure 1B",
"    </a>",
"    ). The apex of the triangle formed by the heads of the sternocleidomastoid is approximately 5 cm superior to the clavicle and marks the needle insertion site. To access the internal jugular vein with a central approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Introduce the needle lateral to the carotid pulsation at an angle 30 to 45 degrees to the skin.",
"     </li>",
"     <li>",
"      Direct the needle lateral to the sagittal plane toward the ipsilateral nipple. This path typically traverses alongside or beneath the lateral head of the sternocleidomastoid.",
"     </li>",
"     <li>",
"      If blood is not aspirated within 2.5 cm, withdraw the needle slowly while maintaining continuous negative pressure and watching for blood return.",
"     </li>",
"     <li>",
"      If the first needle pass fails, promptly withdraw the needle to the skin surface and redirect the needle 10 degrees medially.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85542683\">",
"    <span class=\"h4\">",
"     Posterior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Turning the head to the contralateral side accentuates muscular landmarks and may improve access for the posterior approach (",
"    <a class=\"graphic graphic_figure graphicRef69353 \" href=\"UTD.htm?32/9/32917\">",
"     figure 2",
"    </a>",
"    ). To access the internal jugular vein with a posterior approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the needle along the posterior edge of the sternocleidomastoid at the junction of the middle and lower third of the muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/36\">",
"       36",
"      </a>",
"      ]. This point is approximately 5 cm above the clavicle and is commonly marked by presence of the external jugular vein.",
"     </li>",
"     <li>",
"      Introduce the needle beneath the posterior sternocleidomastoid and advance anteromedially toward the sternal notch.",
"     </li>",
"     <li>",
"      Any subsequent changes in needle orientation should follow a systematic approach of lateral to medial needle passes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85542690\">",
"    <span class=\"h4\">",
"     Anterior",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the name implies, the anterior technique accesses the internal jugular vein from an insertion point anterior to the sternal head of the sternocleidomastoid. To access the internal jugular vein with an anterior approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpate the course of the carotid artery",
"     </li>",
"     <li>",
"      Introduce the needle 5 cm above the sternum, at the midpoint of the anterior border of the sternocleidomastoid.",
"     </li>",
"     <li>",
"      Direct the needle lateral to the carotid pulsation along a plane aimed at the ipsilateral nipple.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232390100\">",
"    <span class=\"h3\">",
"     Dynamic ultrasound-guided internal jugular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic principles of ultrasound-guided venous access, including ultrasound modes, types of probes, and equipment preparation, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link\">",
"     \"Principles of ultrasound-guided venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When using ultrasound to guide jugular venous access, the following steps should be performed (",
"    <a class=\"graphic graphic_table graphicRef68138 \" href=\"UTD.htm?43/26/44459\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prepare the site with antiseptic cleansing and a sterile drape (central line). (See",
"      <a class=\"local\" href=\"#H1316646382\">",
"       'General preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Place the ultrasound gel and probe into a sterile sheath.",
"     </li>",
"     <li>",
"      Apply sterile ultrasound conduction medium (eg, water soluble lubricant) to the external probe cover.",
"     </li>",
"     <li>",
"      Identify the jugular vein and center the image on the ultrasound screen (transverse view) or obtain a longitudinal view using care to distinguish veins from arteries (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72691 \" href=\"UTD.htm?14/5/14418\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link&amp;anchor=H10#H10\">",
"       \"Principles of ultrasound-guided venous access\", section on 'Ultrasound anatomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infiltrate the skin at the intended puncture site with 1%",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Insert the needle (preferably echogenic needle), which has been placed onto a syringe, into the skin and advance it slowly toward the vein. (See",
"      <a class=\"local\" href=\"#H85542813\">",
"       'General techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If visualization of the needle tip is difficult using the transverse view, gently jiggle the needle up and down in the tissues to help identify the needle.",
"     </li>",
"     <li>",
"      If using the longitudinal view, directly observe the needle penetrate the vein on the ultrasound monitor (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50251 \" href=\"UTD.htm?11/34/11811\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      While maintaining negative pressure on the syringe, advance the needle slowly until a free flow of blood return occurs. Although the tip of the needle may not be visualized, the depth of the vessel is shown on the US monitor and should guide the depth of needle placement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remove the transducer and complete cannulation in standard fashion as described below (",
"      <a class=\"graphic graphic_table graphicRef68138 \" href=\"UTD.htm?43/26/44459\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232387736\">",
"    <span class=\"h2\">",
"     Venous confirmation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intraluminal position of the needle can be confirmed by observation of the needle entering the vein with ultrasound-guided access coupled with a steady flow of dark blood into the syringe. Bright red and high-pressure pulsatile bleeding are important but imperfect clues to arterial puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/37\">",
"     37",
"    </a>",
"    ], which can occur, although less frequently, with ultrasound-guided access. Moreover, the absence of these signs is not perfectly reliable for excluding inadvertent arterial puncture. Dark, nonpulsatile backflow of blood may be seen with arterial puncture in the face of oxygen desaturation, hypotension, or needle malposition. If there is any doubt, the needle&rsquo;s location can be confirmed by pressure transduction. As an alternative, a blood gas can be drawn from the accessed venous site and compared with an arterial sample; however, blood gas analysis is more time consuming.",
"   </p>",
"   <p>",
"    To transduce the blood pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attach the needle directly to the pressure tubing system",
"     </li>",
"     <li>",
"      Alternatively, replace the needle over a guidewire with a 6 cm, 18-gauge single-lumen transduction catheter (without any intervening dilation). Connect the transduction catheter to a pressure line and transducer, and evaluate the pressure and waveform tracings on the monitor. Typical venous waveforms should be seen (",
"      <a class=\"graphic graphic_figure graphicRef58343 \" href=\"UTD.htm?35/53/36701\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If a pressure transduction system is not available, attach a short length of saline-filled intravenous tubing to the needle and extended it vertically to measure the pressure, which should be &lt;10 cm in height, and should demonstrate respiratory variation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the carotid artery has inadvertently been punctured, withdraw the needle and apply pressure over the site for 5 to 10 minutes. Jugular venous access can be re-attempted provided anatomic landmarks have not become distorted from hematoma. Inadvertent dilation and cannulation of the carotid artery with a standard catheter does not usually pose a significant problem. However, larger bore catheters, such as dialysis catheters, may be associated with bleeding or vascular complications such as arterial thrombosis and embolization. If carotid catheterization is confirmed, the catheter should be left in place and a vascular consultation obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86783685\">",
"    <span class=\"h1\">",
"     CATHETER PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most catheters and other central venous devices are placed using the Seldinger method, which refers to the use of a guidewire placed into a vessel to provide a conduit for intravascular device placement [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/19\">",
"     19",
"    </a>",
"    ]. Seldinger first described the guidewire technique for arterial cannulation in 1953 and it was subsequently adopted for venous access procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232391005\">",
"    <span class=\"h2\">",
"     Guidewire handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the jugular vein has been successfully accessed, a guidewire should be advanced through the needle or angiocatheter. Multiple types of wires are available to assist with venous access procedures. The most commonly used wire for initial jugular venous access is a flexible J-tip guidewire, favored because it negotiates curvatures and minimizes vessel trauma during passage (",
"    <a class=\"graphic graphic_picture graphicRef82419 \" href=\"UTD.htm?39/24/40320\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Orientation of the needle bevel and J-tip medially facilitates guidewire passage from the jugular vein into the superior vena cava rather than into the ipsilateral subclavian vein.",
"   </p>",
"   <p>",
"    The guidewire should always pass smoothly and easily thorough the needle, dilator, or catheter without resistance. Methods to address resistance to guidewire advancement or withdrawal are discussed below.",
"   </p>",
"   <p>",
"    To place the guidewire:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Position the tapered plastic introducer to straighten the distal J-tip (",
"      <a class=\"graphic graphic_picture graphicRef72306 \" href=\"UTD.htm?42/22/43360\">",
"       picture 3",
"      </a>",
"      ). The orientation of the bevel tip of the introducer needle and the J-tip of the wire can help facilitate the direction of wire placement.",
"     </li>",
"     <li>",
"      Maintain the residual length of guidewire (50 cm standard length) under constant manual control to maintain sterility and avoid its loss off the operating field.",
"     </li>",
"     <li>",
"      Advance the guidewire only as far as needed to allow passage of the catheter over the wire. The atriocaval junction averages about 18 cm from most upper body access sites and positioning guidewires and catheters any deeper is rarely needed [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/4,38\">",
"       4,38",
"      </a>",
"      ]. These average values vary depending upon stature. In an Asian study, average distances were slightly shorter at 15 cm for the right internal jugular vein and 18 cm for left internal jugular vein [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/39\">",
"       39",
"      </a>",
"      ]. Advancing the guidewire deeper risks intracardiac or inferior vena cava (IVC) wire placement with the potential for cardiac arrhythmia, perforation, and snaring of other intravascular devices [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Never forcefully advance the guidewire, as this can kink and permanently deform the wire and risk vessel injury. The guidewire should always pass smoothly and easily thorough the needle, dilator, or catheter without resistance. Resistance to guidewire passage can be due to needle dislodgement, compression of the guidewire against the vessel wall, or anatomic obstruction. Rotating the needle",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      guidewire to reorient the bevel or J-tip may relieve impingement of the guidewire on the posterior vessel wall.",
"     </li>",
"     <li>",
"      If resistance persists, remove the guidewire and aspirate blood to confirm intraluminal needle position. Reducing the angle of the needle against the skin may facilitate guidewire passage. Once the guidewire is positioned, hold it firmly in place, and remove the needle.",
"     </li>",
"     <li>",
"      Resistance during guidewire withdrawal can be managed by simultaneous removal of the needle and indwelling wire. Continued resistance may indicate entrapment and warrants diagnostic radiography to evaluate the wire appearance and position. Withdrawing a kinked guidewire through the needle can shear off the wire, allowing it to embolize [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232391012\">",
"    <span class=\"h2\">",
"     Tract dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous catheters are substantially larger caliber than the needle and guidewire used for venous access. Dilation of the subcutaneous tissue tract is required for catheter insertion and is accomplished by threading a single stiff tapered dilator or series of dilators over the wire to expand the subcutaneous tissue and vein. The skin and fascia catheter tract should be dilated carefully with gentle pressure. Only the soft tissue and vein wall need to be dilated. Overzealous efforts and guidewire kinking (especially with stiff dilators) risk traumatic vein injury.",
"   </p>",
"   <p>",
"    Many indwelling tunneled jugular catheters are placed through a peel-away sheath. To place these devices, a dilator-sheath combination is placed over the wire after the tract has been dilated. The dilator is removed and the catheter is placed through the sheath. Once the catheter is in place, the sheath is peeled away from the catheter and discarded. &nbsp;",
"   </p>",
"   <p>",
"    The dilator-sheath combination for large-bore tunneled catheters is stiff, and placement is facilitated with fluoroscopy, which allows imaging of the tip of the dilator and sheath, ensuring that it is placed no further into the vein than is necessary. (See",
"    <a class=\"local\" href=\"#H1232389802\">",
"     'Equipment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    To place the dilator:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the guidewire is in place, make a controlled 3 mm stab incision made in the skin at the entry site with a #11 blade to prevent the dilator from catching.",
"     </li>",
"     <li>",
"      Thread the stiff tapered dilator over the wire, making certain the guidewire does not advance and is not pulled out at the skin exit site. The guidewire and dilator should",
"      <strong>",
"       never",
"      </strong>",
"      be advanced as a single unit, to avoid venous injury. The wire should serve as an immobile monorail over which the dilator (or catheter) is passed. Cephalad retraction of the skin may be needed to smooth out redundant neck skin to avoid kinking the wire.",
"     </li>",
"     <li>",
"      Hold the wire just above the dilator hub, grasp the dilator just above its tip and push it over the guidewire with a firm corkscrew motion (",
"      <a class=\"graphic graphic_picture graphicRef77656 \" href=\"UTD.htm?35/50/36640\">",
"       picture 4",
"      </a>",
"      ). Mild resistance is normal. Excessive resistance may represent an inadequate skin incision, a malpositioned guidewire, or guidewire or dilator deformation. Kinking of the guidewire against the dilator is associated with vessel trauma and puncture [",
"      <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As described above with needle placement, the opening of the dilator (or",
"      <span class=\"nowrap\">",
"       dilator/sheath",
"      </span>",
"      combination) should be covered and the patient encouraged to Valsalva to prevent entry of air.",
"     </li>",
"     <li>",
"      Advance the dilator only to the anticipated depth of the jugular vein,",
"      <strong>",
"       not",
"      </strong>",
"      the entire length of the dilator. For the jugular site, the dilator need only be advanced 3 to 5 cm into the vein depending upon the thickness of the patient&rsquo;s neck.",
"     </li>",
"     <li>",
"      Withdraw the dilator while maintaining the guidewire position within the vessel. Apply direct pressure to the exit site to maintain hemostasis prior to catheter insertion.",
"     </li>",
"     <li>",
"      Steady traction on the wire during soft-tissue dilatation helps prevent wire kinking. Rotating the dilator during advancement often facilitates tract dilatation (round dilators only). If resistance is met, it may be related to a kink in the wire, which can be remedied by advancing the wire deeper or withdrawing the kink into the dilator. Overzealous efforts and guidewire kinking (especially with stiff dilators) risks traumatic vein injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662981911\">",
"    <span class=\"h2\">",
"     Positioning the catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the subcutaneous tissues and vein have been dilated, the catheter is placed over the wire and positioned (",
"    <a class=\"graphic graphic_picture graphicRef70002 \" href=\"UTD.htm?27/56/28559\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    To place and position the catheter, thread the guidewire back through the end-hole of the catheter until it emerges from the distal port, and advance the catheter over the wire into the vessel (",
"    <a class=\"graphic graphic_picture graphicRef51314 \" href=\"UTD.htm?33/50/34593\">",
"     picture 6",
"    </a>",
"    ). If any resistance is met with forward advancement, withdraw the catheter and re-dilate the tract.",
"   </p>",
"   <p>",
"    The initial catheter insertion depth for most adults should be 16 to 18 cm for right-sided and 20 cm for left-sided jugular catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/31\">",
"     31",
"    </a>",
"    ]. Height-based formulas to determine insertion depth exist, but there are no well-controlled studies supporting their use [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Placing a jugular venous catheter too deeply can result in serious sequelae including cardiac tamponade and central vein perforation. Rare case reports implicate intracardiac catheter tip placement as a possible cause of cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H437921236\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast to right-sided catheters, catheters inserted from the left negotiate the angulation of the brachiocephalic vein to enter the superior vena cava. For large bore catheters used for hemodialysis or oncology, advancement under fluoroscopic guidance helps minimize the risk of central venous laceration. The risk of complications is related to the angle of catheter impingement on the superior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/31\">",
"     31",
"    </a>",
"    ]. From the left, catheters positioned above the pericardial reflection can abut the weak lateral wall of the superior vena cava and risk erosion and perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. As such, left-sided catheters should be inserted to an appropriate length to lie parallel in the long axis of the superior vena cava. This typically requires catheter tip placement in the upper right atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. It is also important to realize that catheter tips are not fixed, and migrate 2 to 3 cm with head and arm movement and change in body position [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232388451\">",
"    <span class=\"h2\">",
"     Catheter flushing and fixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the catheter is in place, the proper function of the catheter should be confirmed by aspirating blood and subsequently flushing each port with saline (",
"    <a class=\"graphic graphic_picture graphicRef56646 \" href=\"UTD.htm?9/12/9409\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/31,55\">",
"     31,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The catheter should then be sutured into place. The short cutaneous tract (often less than 2 cm) of jugular central venous catheters requires secure catheter fixation at the skin insertion site to avoid catheter movement along the skin tract which carries the potential for movement of the contaminated external portion of the catheter insertion into the vessel during head movement.",
"   </p>",
"   <p>",
"    The catheter can be secured using 2-0 or 3-0 nylon or silk sutures (",
"    <a class=\"graphic graphic_picture graphicRef58552 \" href=\"UTD.htm?21/30/21984\">",
"     picture 8",
"    </a>",
"    ). If more than 2 cm of catheter remains exposed, it can be sutured to the skin or to a separate catheter anchor that is often included in the catheter kit. A transparent dressing should be placed over the catheter exit site to protect it from contamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232391295\">",
"    <span class=\"h1\">",
"     CONFIRMATION OF JUGULAR CATHETER POSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of jugular catheter tip location can use one or more of the following methods: chest radiography, ultrasound, fluoroscopy, and transesophageal echocardiography (typically intraoperative setting) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/56-64\">",
"     56-64",
"    </a>",
"    ]. Chest radiography and fluoroscopy are the most commonly used methods. In general, catheters function well with the tip situated in any major vein. However, suboptimal tip position may be related to delayed complications.",
"   </p>",
"   <p>",
"    Following jugular catheter placement, a post-procedure chest radiograph is commonly performed to confirm catheter position and exclude pneumothorax. However, investigators have questioned the need for routine radiography for uncomplicated right internal jugular catheters placed on the first needle pass [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/62,65,66\">",
"     62,65,66",
"    </a>",
"    ]. When using fluoroscopy for placement, a routine chest radiograph is unnecessary unless clinical suspicion of",
"    <span class=\"nowrap\">",
"     pneumothorax/hemothorax",
"    </span>",
"    is high. If fluoroscopy has not been used, we obtain a post-procedure chest radiograph to confirm catheter course and tip position prior to using jugular catheters in non-life-threatening situations. If immediate catheter use is needed, venous positioning (but not tip position) can also be confirmed with transduction of the central venous pressure, display of the central venous waveform, or with ultrasound. Bedside ultrasound is under investigation as an alternative modality to confirm catheter placement and detect pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/67\">",
"     67",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The optimal catheter tip position is controversial, and controlled studies are lacking. The distal tip of jugular catheters should lie in the lower superior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. To minimize the likelihood of cardiac complications, some guidelines recommend catheter tip position outside the right atrium and above the pericardial reflection. The right superior heart border on chest radiography is not a reliable determinant of right atrial position [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/68\">",
"     68",
"    </a>",
"    ]. The carina and right tracheobronchial angle represent reliable landmarks for the pericardial reflection and right-sided catheters should generally be positioned above this point [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malposition occurs in up to one-third of jugular catheter insertions, but varies depending upon the definition of malposition. If a catheter is malpositioned within the venous system, it can be used for fluid administration under emergency circumstances but should be repositioned as soon as feasible. In contrast, inadvertent placement of a catheter into the carotid artery mandates surgical consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/14/3306/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a jugular catheter tip is positioned too deeply, it can be repositioned at the bedside using sterile technique. Remove the sutures, withdraw the catheter, and re-suture the catheter into place.",
"     </li>",
"     <li>",
"      If a catheter is not in far enough or is misplaced into the contralateral subclavian or internal jugular vein, it will need to be replaced over a guidewire under sterile conditions. The portion of a catheter left out of the body is unsterile and should never be advanced into the patient, not even if it is under a sterile dressing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662983777\">",
"    <span class=\"h1\">",
"     CATHETER MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of central catheters is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Site care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link&amp;anchor=H25#H25\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Catheter care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H437921236\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications related to jugular venous access are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86787843\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central catheters provide dependable intravenous access and enable hemodynamic monitoring and blood sampling. The jugular veins are a commonly used site for central venous access. The internal jugular vein should be cannulated with ultrasound guidance using one of three anatomic approaches. Following cannulation, jugular catheters are placed using an orderly sequence of steps (",
"      <a class=\"graphic graphic_table graphicRef68138 \" href=\"UTD.htm?43/26/44459\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H86781061\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient positioning that maximizes the diameter of the internal jugular vein is associated with increased cannulation success. For jugular venous cannulation, these include Trendelenburg position, slight head elevation, and the use of Valsalva. These maneuvers may also reduce the risk of venous air embolism. (See",
"      <a class=\"local\" href=\"#H105076091\">",
"       'Positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When equipment and expertise are available, children and adults undergoing jugular vein cannulation should have the procedure guided by ultrasound rather than using landmark techniques alone. Ultrasound-guidance improves initial cannulation success. (See",
"      <a class=\"local\" href=\"#H105076091\">",
"       'Positioning'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=see_link\">",
"       \"Principles of ultrasound-guided venous access\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carotid artery puncture during attempted internal jugular vein cannulation is not uncommon and can be managed by withdrawing the needle and applying pressure over the site for 5 to 10 minutes. Venous access can be re-attempted, provided there is no distortion of surface landmarks from hematoma. Inadvertent dilation and cannulation of the carotid artery is associated with severe complications such as carotid thrombosis and acute stroke. If arterial catheterization is confirmed, the catheter should be left in place and a vascular surgery consult obtained. (See",
"      <a class=\"local\" href=\"#H1232387736\">",
"       'Venous confirmation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following placement of central catheters using a jugular approach, we obtain a post-procedure chest radiograph to confirm correct catheter position and assess for pneumothorax. The distal tip of jugular catheters should lie in the lower superior vena cava. The need to confirm placement in all patients undergoing jugular venous access procedures is controversial. Completion radiograph can likely be omitted following procedures performed with ultrasound or fluoroscopy guidance, particularly if access was achieved in a single needle pass. (See",
"      <a class=\"local\" href=\"#H1232391295\">",
"       'Confirmation of jugular catheter position'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If an internal jugular catheter is placed too deeply, it can be withdrawn at the bedside using sterile techniques. If the catheter is not placed deeply enough or is malpositioned, the catheter should be replaced over a guidewire under sterile conditions. The portion of a catheter left out of the body is unsterile and should never be advanced into the patient. (See",
"      <a class=\"local\" href=\"#H86783685\">",
"       'Catheter placement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/1\">",
"      McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003; 348:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/2\">",
"      Sznajder JI, Zveibil FR, Bitterman H, et al. Central vein catheterization. Failure and complication rates by three percutaneous approaches. Arch Intern Med 1986; 146:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/3\">",
"      Baskin JL, Pui CH, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 2009; 374:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/4\">",
"      McGee WT, Moriarty KP. Accurate placement of central venous catheters using a 16-cm catheter. J Intensive Care Med 1996; 11:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/5\">",
"      Khatri VP, Wagner-Sevy S, Espinosa MH, Fisher JB. The internal jugular vein maintains its regional anatomy and patency after carotid endarterectomy: a prospective study. Ann Surg 2001; 233:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/6\">",
"      Digby S. Fatal respiratory obstruction following insertion of a central venous line. Anaesthesia 1994; 49:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/7\">",
"      Wu PJ, Chau SW, Lu IC, et al. Delayed airway obstruction after internal jugular venous catheterization in a patient with anticoagulant therapy. Case Rep Anesthesiol 2011; 2011:359867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/8\">",
"      Lobato EB, Florete OG Jr, Paige GB, Morey TE. Cross-sectional area and intravascular pressure of the right internal jugular vein during anesthesia: effects of Trendelenburg position, positive intrathoracic pressure, and hepatic compression. J Clin Anesth 1998; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/9\">",
"      Botha R, van Schoor AN, Boon JM, et al. Anatomical considerations of the anterior approach for central venous catheter placement. Clin Anat 2006; 19:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/10\">",
"      Turba UC, Uflacker R, Hannegan C, Selby JB. Anatomic relationship of the internal jugular vein and the common carotid artery applied to percutaneous transjugular procedures. Cardiovasc Intervent Radiol 2005; 28:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/11\">",
"      Denys BG, Uretsky BF. Anatomical variations of internal jugular vein location: impact on central venous access. Crit Care Med 1991; 19:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/12\">",
"      The clinical anatomy of several invasive procedures. American Association of Clinical Anatomists, Educational Affairs Committee. Clin Anat 1999; 12:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/13\">",
"      Stickle BR, McFarlane H. Prediction of a small internal jugular vein by external jugular vein diameter. Anaesthesia 1997; 52:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/14\">",
"      Cho SK, Shin SW, Do YS, et al. Use of the right external jugular vein as the preferred access site when the right internal jugular vein is not usable. J Vasc Interv Radiol 2006; 17:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/15\">",
"      Blitt CD, Wright WA, Petty WC, Webster TA. Central venous catheterization via the external jugular vein. A technique employing the J-WIRE. JAMA 1974; 229:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/16\">",
"      Sulek CA, Blas ML, Lobato EB. A randomized study of left versus right internal jugular vein cannulation in adults. J Clin Anesth 2000; 12:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/17\">",
"      Muralidhar K. Left internal versus right internal jugular vein access to central venous circulation using the Seldinger technique. J Cardiothorac Vasc Anesth 1995; 9:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/18\">",
"      Oner B, Karam AR, Surapaneni P, Phillips DA. Pneumothorax following ultrasound-guided jugular vein puncture for central venous access in interventional radiology: 4 years of experience. J Intensive Care Med 2012; 27:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/19\">",
"      SELDINGER SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta radiol 1953; 39:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/20\">",
"      Mallory DL, Shawker T, Evans RG, et al. Effects of clinical maneuvers on sonographically determined internal jugular vein size during venous cannulation. Crit Care Med 1990; 18:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/21\">",
"      Beddy P, Geoghegan T, Ramesh N, et al. Valsalva and gravitational variability of the internal jugular vein and common femoral vein: ultrasound assessment. Eur J Radiol 2006; 58:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/22\">",
"      Parry G. Trendelenburg position, head elevation and a midline position optimize right internal jugular vein diameter. Can J Anaesth 2004; 51:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/23\">",
"      Armstrong PJ, Sutherland R, Scott DH. The effect of position and different manoeuvres on internal jugular vein diameter size. Acta Anaesthesiol Scand 1994; 38:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/24\">",
"      Ely EW, Hite RD, Baker AM, et al. Venous air embolism from central venous catheterization: a need for increased physician awareness. Crit Care Med 1999; 27:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/25\">",
"      Mirski MA, Lele AV, Fitzsimmons L, Toung TJ. Diagnosis and treatment of vascular air embolism. Anesthesiology 2007; 106:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/26\">",
"      Troianos CA, Kuwik RJ, Pasqual JR, et al. Internal jugular vein and carotid artery anatomic relation as determined by ultrasonography. Anesthesiology 1996; 85:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/27\">",
"      Wang R, Snoey ER, Clements RC, et al. Effect of head rotation on vascular anatomy of the neck: an ultrasound study. J Emerg Med 2006; 31:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/28\">",
"      Sulek CA, Gravenstein N, Blackshear RH, Weiss L. Head rotation during internal jugular vein cannulation and the risk of carotid artery puncture. Anesth Analg 1996; 82:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/29\">",
"      Lieberman JA, Williams KA, Rosenberg AL. Optimal head rotation for internal jugular vein cannulation when relying on external landmarks. Anesth Analg 2004; 99:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/30\">",
"      Guilbert MC, Elkouri S, Bracco D, et al. Arterial trauma during central venous catheter insertion: Case series, review and proposed algorithm. J Vasc Surg 2008; 48:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/31\">",
"      Polderman KH, Girbes AJ. Central venous catheter use. Part 1: mechanical complications. Intensive Care Med 2002; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/32\">",
"      Boyd R, Saxe A, Phillips E. Effect of patient position upon success in placing central venous catheters. Am J Surg 1996; 172:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/33\">",
"      Mangar D, Turnage WS, Mohamed SA. Is the internal jugular vein cannulated during insertion or withdrawal of the needle during central venous cannulation? Anesth Analg 1993; 76:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/34\">",
"      Albuquerque J&uacute;nior FC, Vasconcelos PR. Technical aspects of central venous catheterization. Curr Opin Clin Nutr Metab Care 1998; 1:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/35\">",
"      Tripathi M, Pandey M. Anchoring of the internal jugular vein with a pilot needle to facilitate its puncture with a wide bore needle: a randomised, prospective, clinical study. Anaesthesia 2006; 61:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/36\">",
"      Defalque RJ. Percutaneous catheterization of the internal jugular vein. Anesth Analg 1974; 53:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/37\">",
"      Ezaru CS, Mangione MP, Oravitz TM, et al. Eliminating arterial injury during central venous catheterization using manometry. Anesth Analg 2009; 109:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/38\">",
"      Andrews RT, Bova DA, Venbrux AC. How much guidewire is too much? Direct measurement of the distance from subclavian and internal jugular vein access sites to the superior vena cava-atrial junction during central venous catheter placement. Crit Care Med 2000; 28:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/39\">",
"      Kim WY, Lee CW, Sohn CH, et al. Optimal insertion depth of central venous catheters--is a formula required? A prospective cohort study. Injury 2012; 43:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/40\">",
"      Stuart RK, Shikora SA, Akerman P, et al. Incidence of arrhythmia with central venous catheter insertion and exchange. JPEN J Parenter Enteral Nutr 1990; 14:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/41\">",
"      Propp DA, Cline D, Hennenfent BR. Catheter embolism. J Emerg Med 1988; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/42\">",
"      Robinson JF, Robinson WA, Cohn A, et al. Perforation of the great vessels during central venous line placement. Arch Intern Med 1995; 155:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/43\">",
"      Czepizak CA, O'Callaghan JM, Venus B. Evaluation of formulas for optimal positioning of central venous catheters. Chest 1995; 107:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/44\">",
"      Peres PW. Positioning central venous catheters--a prospective survey. Anaesth Intensive Care 1990; 18:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/45\">",
"      Booth SA, Norton B, Mulvey DA. Central venous catheterization and fatal cardiac tamponade. Br J Anaesth 2001; 87:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/46\">",
"      Collier PE, Blocker SH, Graff DM, Doyle P. Cardiac tamponade from central venous catheters. Am J Surg 1998; 176:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/47\">",
"      Tocino IM, Watanabe A. Impending catheter perforation of superior vena cava: radiographic recognition. AJR Am J Roentgenol 1986; 146:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/48\">",
"      Dailey RH. Late vascular perforations by CVP catheter tips. J Emerg Med 1988; 6:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/49\">",
"      Duntley P, Siever J, Korwes ML, et al. Vascular erosion by central venous catheters. Clinical features and outcome. Chest 1992; 101:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/50\">",
"      Mukau L, Talamini MA, Sitzmann JV. Risk factors for central venous catheter-related vascular erosions. JPEN J Parenter Enteral Nutr 1991; 15:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/51\">",
"      Fletcher SJ, Bodenham AR. Safe placement of central venous catheters: where should the tip of the catheter lie? Br J Anaesth 2000; 85:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/52\">",
"      Vesely TM. Central venous catheter tip position: a continuing controversy. J Vasc Interv Radiol 2003; 14:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/53\">",
"      Stonelake PA, Bodenham AR. The carina as a radiological landmark for central venous catheter tip position. Br J Anaesth 2006; 96:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/54\">",
"      Kowalski CM, Kaufman JA, Rivitz SM, et al. Migration of central venous catheters: implications for initial catheter tip positioning. J Vasc Interv Radiol 1997; 8:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/55\">",
"      Chalkiadis GA, Goucke CR. Depth of central venous catheter insertion in adults: an audit and assessment of a technique to improve tip position. Anaesth Intensive Care 1998; 26:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/56\">",
"      Gillman LM, Blaivas M, Lord J, et al. Ultrasound confirmation of guidewire position may eliminate accidental arterial dilatation during central venous cannulation. Scand J Trauma Resusc Emerg Med 2010; 18:39.",
"     </a>",
"    </li>",
"    <li>",
"     Gu X, Paulsen W, Tisnado J, He Y, Li Z, Nixon JV: Malposition of a central venous catheter in the right main pulmonary artery detected by transesophageal echocardiography. J Am Soc Echocardiogr 2009; 22:1420",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/58\">",
"      Sawchuk C, Fayad A. Confirmation of internal jugular guide wire position utilizing transesophageal echocardiography. Can J Anaesth 2001; 48:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/59\">",
"      Lucey B, Varghese JC, Haslam P, Lee MJ. Routine chest radiographs after central line insertion: mandatory postprocedural evaluation or unnecessary waste of resources? Cardiovasc Intervent Radiol 1999; 22:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/60\">",
"      Gebhard RE, Szmuk P, Pivalizza EG, et al. The accuracy of electrocardiogram-controlled central line placement. Anesth Analg 2007; 104:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/61\">",
"      Abood GJ, Davis KA, Esposito TJ, et al. Comparison of routine chest radiograph versus clinician judgment to determine adequate central line placement in critically ill patients. J Trauma 2007; 63:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/62\">",
"      Lessnau KD. Is chest radiography necessary after uncomplicated insertion of a triple-lumen catheter in the right internal jugular vein, using the anterior approach? Chest 2005; 127:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/63\">",
"      Wirsing M, Schummer C, Neumann R, et al. Is traditional reading of the bedside chest radiograph appropriate to detect intraatrial central venous catheter position? Chest 2008; 134:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/64\">",
"      Francis KR, Picard DL, Fajardo MA, Pizzi WF. Avoiding complications and decreasing costs of central venous catheter placement utilizing electrocardiographic guidance. Surg Gynecol Obstet 1992; 175:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/65\">",
"      Ammirati C, Maizel J, Slama M. Is chest X-ray still necessary after central venous catheter insertion? Crit Care Med 2010; 38:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/66\">",
"      Gladwin MT, Slonim A, Landucci DL, et al. Cannulation of the internal jugular vein: is postprocedural chest radiography always necessary? Crit Care Med 1999; 27:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/67\">",
"      Vezzani A, Brusasco C, Palermo S, et al. Ultrasound localization of central vein catheter and detection of postprocedural pneumothorax: an alternative to chest radiography. Crit Care Med 2010; 38:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/68\">",
"      Aslamy Z, Dewald CL, Heffner JE. MRI of central venous anatomy: implications for central venous catheter insertion. Chest 1998; 114:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/69\">",
"      Schuster M, Nave H, Piepenbrock S, et al. The carina as a landmark in central venous catheter placement. Br J Anaesth 2000; 85:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/14/3306/abstract/70\">",
"      Albrecht K, Nave H, Breitmeier D, et al. Applied anatomy of the superior vena cava-the carina as a landmark to guide central venous catheter placement. Br J Anaesth 2004; 92:75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15672 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3306=[""].join("\n");
var outline_f3_14_3306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H86787843\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86781061\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86781076\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86781613\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H437920391\">",
"      JUGULAR VEIN ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85541889\">",
"      Landmarks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85542001\">",
"      JUGULAR SITE SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85542008\">",
"      Static ultrasound guidance for vein localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1316646382\">",
"      GENERAL PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232389802\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H437920630\">",
"      Skin preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105076091\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H437918651\">",
"      INTERNAL JUGULAR VEIN CANNULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232390400\">",
"      Needle access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85542813\">",
"      - General techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85542874\">",
"      Access with introducer needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85542881\">",
"      Using a seeker needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85542888\">",
"      Using an angiocatheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85542669\">",
"      - Approaches to the internal jugular vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85542676\">",
"      Central",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85542683\">",
"      Posterior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85542690\">",
"      Anterior",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1232390100\">",
"      - Dynamic ultrasound-guided internal jugular access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232387736\">",
"      Venous confirmation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86783685\">",
"      CATHETER PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232391005\">",
"      Guidewire handling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232391012\">",
"      Tract dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H662981911\">",
"      Positioning the catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232388451\">",
"      Catheter flushing and fixation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1232391295\">",
"      CONFIRMATION OF JUGULAR CATHETER POSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H662983777\">",
"      CATHETER MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H437921236\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86787843\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15672|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/5/14418\" title=\"diagnostic image 1\">",
"      Ultrasound neck vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/34/11811\" title=\"diagnostic image 2\">",
"      Ultrasound view needle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15672|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/21/42324\" title=\"figure 1A\">",
"      Anatomy SC IJ central line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/52/43845\" title=\"figure 1B\">",
"      Central line IJ anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/9/32917\" title=\"figure 2\">",
"      Central line IJ post anat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/25/24978\" title=\"figure 3\">",
"      IJ central line mid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/53/36701\" title=\"figure 4\">",
"      Right atrial pressure tracing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15672|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/60/7105\" title=\"picture 1\">",
"      Central line IJ finder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/24/40320\" title=\"picture 2\">",
"      Central line J wire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/22/43360\" title=\"picture 3\">",
"      Central line wire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/50/36640\" title=\"picture 4\">",
"      Central line dilator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/56/28559\" title=\"picture 5\">",
"      Central line catheter wire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/50/34593\" title=\"picture 6\">",
"      Central line catheter insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/12/9409\" title=\"picture 7\">",
"      Aspiration following central venous catheter placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/30/21984\" title=\"picture 8\">",
"      Central line suture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15672|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/53/1885\" title=\"table 1\">",
"      Advantages and disadvantages of central vein approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/30/27115\" title=\"table 2\">",
"      Central line equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/26/44459\" title=\"table 3\">",
"      Technique of central venous catheterization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35482?source=related_link\">",
"      Anesthesia for the obese patient undergoing non-cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25221?source=related_link\">",
"      Insertion of pulmonary artery catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6361?source=related_link\">",
"      Peripheral venous access in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=related_link\">",
"      Placement of femoral venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1466?source=related_link\">",
"      Placement of subclavian venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3833?source=related_link\">",
"      Principles of ultrasound-guided venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_14_3307="CSF concentrations penicillins";
var content_f3_14_3307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Peak CSF concentrations of penicillins in bacterial meningitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Penicillin G",
"       </td>",
"       <td>",
"        1.0-2.5&micro;g/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nafcillin",
"       </td>",
"       <td>",
"        9.5&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin",
"       </td>",
"       <td>",
"        9.9&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ticarcillin",
"       </td>",
"       <td>",
"        26-33&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piperacillin",
"       </td>",
"       <td>",
"        13-35&nbsp;&micro;g/mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The doses used varied from study to study, making comparisons between drugs unreliable.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3307=[""].join("\n");
var outline_f3_14_3307=null;
var title_f3_14_3308="Neutrophilic dermatoses I";
var content_f3_14_3308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The non-infectious neutrophilic dermatoses without vasculitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Involving predominantly the epidermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pustular psoriasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-induced/acute generalized exanthematous pustulosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratoderma blennorrhagicum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sneddon-Wilkinson disease (subcorneal pustulosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgA pemphigus (subcorneal pustular dermatosis type, intraepidermal neutrophilic IgA dermatosis type)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antimicrobial pustulosis of the folds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infantile acropustulosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient neonatal pustulosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Involving predominantly the dermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweet's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyoderma gangrenosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beh&ccedil;et's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel-associated dermatosis-arthritis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel disease (may also have small vessel vasculitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutrophilic eccrine hidradenitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid neutrophilic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutrophilic urticaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Still's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema marginatum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary periodic fever syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Moschella, SL, Davis, MDP. Neutrophilic dermatoses. In: Dermatology, 2nd ed, Bolognia, JL, Jorizzo, JL, Rapini, RP (Eds), Mosby Elsevier, Spain 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3308=[""].join("\n");
var outline_f3_14_3308=null;
var title_f3_14_3309="Parent report screens";
var content_f3_14_3309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected developmental screens relying on information from parents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test/age range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purchasing information",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time frame*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Ages and Stages Questionnaire-3 (ASQ) (2009)",
"         </strong>",
"        </p>",
"        <p>",
"         1 to 66 months",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Paul H. Brookes Publishing, Inc.",
"        </p>",
"        <p>",
"         P.O. Box 10624",
"        </p>",
"        <p>",
"         Baltimore, MD 21285",
"        </p>",
"        <p>",
"         Phone: 800.638.3775",
"        </p>",
"        <p>",
"         <a href=\"file://www.agesandstages.com\" target=\"_blank\">",
"          www.agesandstages.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $249.95 (forms can be photocopied).",
"        </p>",
"       </td>",
"       <td>",
"        About 12 minutes (if interview needed)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Infant-Toddler Checklist for Language and Communication (ITC)",
"          <sup>",
"           &bull;",
"          </sup>",
"          (1998)",
"         </strong>",
"        </p>",
"        <p>",
"         6 to 24 months",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Paul H. Brookes Publishing, Inc.",
"        </p>",
"        <p>",
"         P.O. Box 10624",
"        </p>",
"        <p>",
"         Baltimiore, MD 21285",
"        </p>",
"        <p>",
"         Phone: 800.638.3775",
"        </p>",
"        <p>",
"         <a href=\"file://www.pbrookes.com\" target=\"_blank\">",
"          www.pbrookes.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $109:95 w/CD-ROM that includes printable forms and scoring software.",
"        </p>",
"       </td>",
"       <td>",
"        About 8 minutes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Parents' Evaluations of Developmental Status (PEDS) (2010)",
"         </strong>",
"        </p>",
"        <p>",
"         Birth to 8 years",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         PEDS",
"         <em>",
"          Test",
"         </em>",
"         .com, LLC",
"        </p>",
"        <p>",
"         1013 Austin Court",
"        </p>",
"        <p>",
"         Nolensville, NT 37135",
"        </p>",
"        <p>",
"         Phone: 615.776.4121",
"        </p>",
"        <p>",
"         Fax: 615.776.4119",
"        </p>",
"        <p>",
"         <a href=\"file://www.pedstest.com\" target=\"_blank\">",
"          www.pedstest.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $30 (set includes 50 response forms, 50 score and interpretation forms, and one brief administration and scoring guide).",
"        </p>",
"       </td>",
"       <td>",
"        About 2 minutes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          PEDS: Developmental Milestones (PEDS:DM)",
"         </strong>",
"        </p>",
"        <p>",
"         Birth to 8 years",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         PEDS",
"         <em>",
"          Test",
"         </em>",
"         .com, LLC",
"        </p>",
"        <p>",
"         1013 Austin Court",
"        </p>",
"        <p>",
"         Nolensville, TN 37135",
"        </p>",
"        <p>",
"         Phone: 615.776.4121",
"        </p>",
"        <p>",
"         Fax: 615.776.4119",
"        </p>",
"        <p>",
"         <a href=\"file://www.pedstest.com\" target=\"_blank\">",
"          www.pedstest.com",
"         </a>",
"        </p>",
"        <p>",
"         The PEDS:DM costs $275 and consists of a book of laminated forms that parents (and older children) write on with dry erase markers, and 100 longitudinal recording forms (after purchase a single form per child is the only ongoing material cost).",
"        </p>",
"       </td>",
"       <td>",
"        3 to 4 minutes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Does not include score time.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Part of Communication and Symbolic Behavior Scales-Developmental Profile.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Frances Page Glascoe, 2011, Nolensville, TN: PEDSTest.com, LLC, www.pedstest.com. Adapted with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3309=[""].join("\n");
var outline_f3_14_3309=null;
var title_f3_14_3310="Thermophilic actinomycetes HP";
var content_f3_14_3310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypersensitivity to thermophilic actinomycetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 300px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical clinical and two stage physiologic response to inhalation challenge with an extract of thermophilic actinomycetes.",
"    <div class=\"footnotes\">",
"     FVC: forced vital capacity; FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second; D",
"     <sub>",
"      L",
"     </sub>",
"     CO: diffusing capacity, mL/min/mmHg.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Schlueter DP, Am J Med 1974; 57:476.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3310=[""].join("\n");
var outline_f3_14_3310=null;
var title_f3_14_3311="Physical activity and weight loss in children";
var content_f3_14_3311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Comparison of reducing inactivity and increasing physical activity on weight loss in adolescents",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Epstein LH, Valoski AM, Vara LS, et al. Effects of decreasing sedentary behavior and increasing activity on weight change in obese children. Health Psychol 1995; 14:109. Copyright &copy; 1995 by the American Psychological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_14_3311=[""].join("\n");
var outline_f3_14_3311=null;
